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Zinc is an essential micronutrient that regulates many cellular processes. Deficits or 
excessive abundance in zinc concentration have catastrophic consequences for organisms and 
have been linked to many human diseases. Consequently, intracellular zinc levels are kept within 
narrow limits by an orchestrated network of zinc binding proteins and transporters. Within the 
cell, zinc accumulates in virtually all organelles, including lysosomes, which break down cellular 
waste materials. Lysosomes have recently become the focus of zinc regulation, as they have been 
shown to absorb zinc from the cytoplasm and contribute to zinc-induced toxicity. Additionally, 
recent evidence of zinc permeability of the lysosomal ion channel TRPML1, and the evidence of 
abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc 
transport. Mutations in TRPML1 in humans result in a neurodegenerative lysosomal storage 
disorder called Mucolipidosis type IV (MLIV) characterized by psychomotor and mental 
retardation.  
I have found that an siRNA-driven TRPML1 knockdown in HeLa cells leads to the 
buildup of enlarged cytoplasmic and lysosomal vesicles filled with zinc via live cell confocal 
imaging. Also, lysosomal enlargement and zinc buildup in TRPML1-deficient cells exposed to 
zinc are ameliorated by knocking down the lysosomal zinc importer ZnT4. This data provides 
important insights into the function of TRPML1 and the role of zinc in MLIV and other 
neurodegenerative diseases. Moreover, I have found that lysosomes, generally, play a 
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 v 
cytoprotective role during exposure to extracellular zinc, which requires lysosomal acidification 
and exocytosis. Specifically, inhibition of lysosomal function with bafilomycin redistributed zinc 
pools to other organelles and increased cell death. Furthermore, inhibition of lysosomal 
exocytosis through knockdown of lysosomal SNARE proteins VAMP7 and SYT7 suppressed 
zinc secretion. VAMP7 knockdown increased apoptosis. Interestingly however, the 
overexpression of the lysosomal biogenesis transcription factor TFEB increased zinc secretion, 
suggesting that zinc secretion correlates with lysosomal function. Overall, these data underscore 
a role for TRPML1 and lysosomes in zinc metabolism and suggest that lysosomes form a “zinc 
sink” to dynamically buffer and counteract high zinc levels. This is a novel paradigm that 
implicates lysosomes in an entirely new function and identifies a completely new zinc 
detoxification pathway. 
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1.0  INTRODUCTION 
1.1 OVERVIEW 
Zinc is an essential nutrient for all organisms and is required for almost all aspects of cell 
physiology. Deficits in zinc content or excessive abundance in zinc concentration have 
catastrophic consequences for organisms and have been linked to many human diseases. Thus, 
cells maintain zinc concentrations within very narrow limits through a precise and highly 
regulated system that controls zinc abundance and distribution. The vast number of zinc-binding 
proteins reflects the complexity of zinc homeostasis and transporters found in every cell 
compartment. However, given its physiological importance, it is surprising that many aspects of 
zinc function and regulation are still not very well understood. For example, it is still not known 
why or how zinc enters and leaves certain cell compartments such as the mitochondria or 
lysosomes, and whether this transport is physiologically important. Moreover, the lysosome is 
generally depicted as the degradative compartment of the cell, and yet there are a large number 
of metal transporters found on the lysosomal membrane, suggesting that they also regulate metal 
homeostasis. What remains puzzling is why lysosomes have been shown to take up large 
quantities of zinc. My thesis research investigates the role of lysosomes, and specifically, the 
lysosomal protein TRPML1, in regulating cellular zinc levels. As such, this chapter focuses on 
the current knowledge of zinc homeostasis, lysosomal functions, and TRPML1 function. 
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1.2 ZINC REGULATION AND PHYSIOLOGICAL REQUIREMENTS 
Zinc (Zn2+) is an essential micronutrient and the most abundant trace element in cells. It is 
required for many different processes including transcription, enzymatic activity, and cell 
signaling. However, excess Zn2+ is also toxic and has been associated with many pathological 
conditions, thus necessitating careful regulation of Zn2+ levels for proper cell function. 
Additionally, a growing body of evidence indicates that just like Ca2+, Zn2+ pools are 
redistributed for cellular needs, identifying Zn2+ as “the Ca2+ of the twenty-first century” [1]. 
Here I will briefly describe the orchestrated network responsible for regulating Zn2+ homeostasis 
as well as why this is important.  
1.2.1 Cellular zinc levels.   
A bioinformatics study on the human genome showed that roughly 10% of proteins (about 2800 
gene products) bind Zn2+ [2]. Zn2+ binds to and is required for the function of many proteins 
including enzymes, transcription factors, receptors, growth factors and cytokines, emphasizing 
its broad physiological relevance [3]. For example, Zn2+ is required in the nucleus for gene 
transcription, where it forms a “zinc finger” DNA binding motif in TFIIIA, by arranging in a 
tetrahedral coordination complex with the conserved cysteine and histidine residues  [4]. Zn2+ is 
also required in the mitochondria for ATP production [5], in the Golgi for enzyme activation [6], 
and in the lysosome for enzyme maturation [7]. Interestingly, free or labile Zn2+ is also critical 
for cellular response and acts as modulator of synaptic transmission [1] and as a signaling 
molecule, much like Ca2+, that  mediates intracellular communication [8]. So, since many 
proteins can interact with it, control of Zn2+ concentration and localization is critical for 
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physiological responses and because of this, compartmentalized cells need Zn2+ transport 
mechanisms to accumulate and dissipate Zn2+ in various organelles such as the nucleus, ER, 
Golgi, mitochondria and lysosome. These transport mechanisms are discussed in section 1.2.2. 
Although it varies from cell type to cell type, mammalian cells need a total cellular Zn2+ 
concentration of 0.1 – 0.5 mM to maintain proper functions. This concentration represents the 
total calculated Zn2+ cellular concentration, which is much higher than the one calculated for 
extracellular physiological content [9] (blood plasma has a free Zn2+  concentration of 20 pM 
[10]), further supporting the role and need for intracellular Zn2+.  Inside cells, the majority of this 
Zn2+ is bound to proteins, keeping free intracellular Zn2+ levels within the pM range [11]. Thus, 
optimal cell health and function are possible only within a very narrow range of intracellular 
Zn2+ free concentrations. More importantly, even though Zn2+ is the only essential transition 
metal to not have redox activity [12], more Zn2+ is prevalent in cells than any other transition 
metal. This poses a problem for cells since metal binding to proteins follows the Irving-Williams 
series for metal ion complex stability and, except for Cu2+, Zn2+ is highly preferred over other 
metals [13]. This means that if intracellular Zn2+ concentrations are not tightly regulated, then 
unspecific Zn2+ binding would permanently take place. Not surprisingly, uncontrolled Zn2+ 
access to metalloproteins is deleterious and likely results in cell death. In sum, cytosolic free 
Zn2+ concentrations are kept within a narrow range that is optimal for proper Zn2+ functions, but 
below a threshold that would result in unspecific interactions with metalloproteins. To achieve 
this, cells use a combination of cytosolic Zn2+–binding proteins called metallothioneins and Zn2+ 
transporters that sequester Zn2+ in organelles. Perturbations in this delicate balance are associated 
with many pathologic conditions. For example, Zn2+ deficiency has been associated with 
hormonal imbalance, immune deficiency, impaired synaptogenesis, impaired vision, learning and 
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memory, and seizure susceptibility, while Zn2+ overload has been associated with ischemic cell 
death, immune deficiency, oxidative stress, excitotoxicity, apoptosis and amyloid plaque 
formation (Alzheimer’s disease) [14]. Thus, a careful Zn2+ balance must be achieved to maintain 
homeostasis. 
1.2.2 Zinc transporters and metallothioneins.   
Zn2+ uptake into cells as well as its transport into and out of intracellular organelles is 
orchestrated by a network of transmembrane proteins that facilitate its movement. The first Zn2+ 
transporter was identified in 1995 [15]. Since then, 24 such proteins have been described in 
mammalian cells, and they can be divided into two distinct families: the Zn2+ Transporter (ZnT, 
SLC30A) family and Zrt-, irt-like protein (ZIP or SLC39A) family named after the yeast Zrt1 
and Arabidopsis Irt1 proteins. The 14 identified ZIPs control Zn2+ influx by importing Zn2+ into 
the cell across the plasma membrane, or by transporting it out of organelles and into the 
cytoplasm. The 10 identified ZnTs, on the other hand, control Zn2+ efflux by either transporting 
Zn2+ into organelles or exporting it out of the cell across the plasma membrane.  
Most ZIPs are predicted to have eight transmembrane domains with N- and C-termini 
within the noncytoplasmic face of the membrane (Figure 1). ZnTs, on the other hand, are 
predicted to have six transmembrane domains (with the exception of ZnT5 which has nine) and 
N- and C- termini within the cytoplasm. Both families have a long cytoplasmic loop with a 
histidine-rich domain thought to facilitate Zn2+ binding, which is present between transmembrane 
domains 3-4 in ZIPs and 4-5 in ZnTs [16, 17]. A recent crystal structure of the Escherichia coli 
ZnT homologue, YiiP, confirmed these topological predictions for ZnTs and shed light on the 
transport mechanisms (Figure 2) [18, 19]. YiiP was found to be a Y-shaped homodimer held  
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Figure 1. Predicted structures and transport mechanisms of ZIP and ZnT transporters.  
Predicted topologies of ZIP (left) and ZnT (right) are shown. The histidine –rich cluster of ZIPs and the histidine-
rich loop of ZnTs are indicated by the bold lines. ZIPs transport zinc from the extracellular space or intracellular 
compartments into the cytoplasm through an unknown mechanism. ZnTs, on the other hand, transport zinc from the 
cytoplasm into intracellular compartments or into the extracellular space through a Zn2+ / H+ exchange mechanism. 
Figure adapted from [17]. 
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Figure 2. YiiP structure and helix packing in the TMD.  
(a) Ribbon representation of the YiiP homodimer (yellow and cyan for each protomer) viewed from the membrane 
plane. Magenta spheres represent bound zinc ions in zinc-binding sites, which are marked by red circles. Grey lines 
indicate the possible membrane boundaries. Red arrows indicate the directions of Zn(II) exit from the two active 
sites. Conserved hydrophobic residues involved in the TMD-TMD contacts are shown as sticks. (b) The YiiP 
homodimer viewed from the periplasm with the extracellular loops. The red oval marks hydrophobic interactions at 
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the TMD-TMD interface, and red diamonds highlight the four-helix bundles. (c) Packing of the TM3-TM6 pairs in 
the membrane. TMDs are viewed from the membrane plane and are related to a with a 40° rotation about the dimer 
two-fold axis. TM3-TM6 pairs are shown in cylinder representation, whereas the four-helix bundle is shown in 
solvent-accessible surface. (d) The charge interlock at the dimer interface is highlighted with a red circle and viewed 
from the cytoplasm. (e) Regulation of coordination geometry. A close-up view of site A situated between TM2 and 
TM5 (cyan cylinders) with four coordinating residues (cyan sticks) in a tetrahedral arrangement (shown as a 
tetrahedron). The black arrow indicates a hypothesized TM5 movement (shown as a gray cylinder) with respect to 
TM2. (f) Schematic model for autoregulation. TM3-TM6 pairs and four-helix bundles are colored in yellow and 
cyan, respectively. Open boxes represent the charge interlock located at the pivotal point of the hinge-like motions. 
Figure adapted from [19]. 
 
together through the tetrahedral binding of four Zn2+ ions at the interface of the cytoplasmic 
domains (Figure 2) [18, 19]. Dax Fu and colleagues found that Zn2+ binding triggers hinge 
movements of two electrically repulsive cytoplasmic domains pivoting around four salt bridges 
located at the intersection of the cytoplasmic and transmembrane domains (TMDs) [19]. These 
salt bridges then interlock transmembrane helices so that they can coordinate the active site of 
Zn2+ transport [19]. Also, the cytoplasmic domain of YiiP was found to mimic the metal-binding 
domains of the metal-transporting P-type ATPases, which might be a modular regulatory 
element for transport activity [19]. Similarly, even though the exact function of the histidine-rich 
loop has not yet been determined, mutagenesis of the histidine residues has been shown to 
abolish Zn2+ transport activity [20, 21]. It has also been shown that the histidine residues confer 
metal ion selectivity [22], such as selectively transporting Zn2+ over cadmium (Cd2+) 
(mammalian ZnTs have been shown to mobilize iron (Fe2+), manganese (Zn2+), and Cd2+ [16]). 
Nonetheless, both ZIPs and ZnTs have a histidine-rich domain that allows them pump Zn2+ either 
out of (in the case of ZIPs) or into (in the case of ZnTs) organelles. Not surprisingly then, 
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because of their function, most ZIPs are found on the plasma membrane while most ZnTs are 
found in intracellular compartments [23]. Subsequently, ZnTs are known to function as Zn2+/ H+ 
exchangers, and when reconstituted into proteoliposomes, the bacterial ZnT homologue, ZitB, 
confirms this mechanism [24]. Additionally, many ZnTs localize to acidic vesicular 
compartments [16] and there is some evidence that the low pH is necessary for Zn2+ binding and 
transport activity [24, 25]. At the same time, while the transport mechanism for ZIPs has not yet 
been clarified and structural data are lacking, it has been proposed that they function either as 
electrodiffusion channels, or HCO3- symporters [16]. One recent study using the Bordatella 
bronchiseptica ZIP homologue, ZIPB, showed that ZIPB is a selective electrodiffusion channel 
with an unsaturable Zn2+ flux (no evidence of saturation up to an extracellular Zn2+ concentration 
of 2mM) [26], but whether this applies to other ZIPs remains to be seen. 
In addition to Zn2+ transporters, intracellular and specifically, cytoplasmic Zn2 levels are 
also controlled by metallothioneins (MTs). MTs are small, cysteine rich proteins that bind Zn2+ 
with high affinity. They were first discovered in 1957 as cadmium (Cd2+)-binding proteins from 
horse kidney samples that were high in metal and sulfur content [27]. Since then, MTs have been 
shown to be instrumental in metal ion homeostasis, detoxification of toxic metals, and protection 
against allergic inflammation and oxidative stress [11]. Mammalian MTs are encoded by a 
multigene family that consists of 10 functional genes including 7 MT-1 genes (MT-1A, -B, -E, -
F, -G, -H, and –X) in addition to the MT-2A, MT-3 and MT-4 genes [28-31]. MT-1 and MT-2 
are ubiquitously expressed [32, 33], MT-3 is primarily expressed in the central nervous tissue [1, 
34], and MT-4 is expressed in stratified squamous epithelial tissues [30]. In addition to Cd2+ and 
Zn2+, MTs have binding affinities for other metals as follows: Hg2+ > Cu2+ > Cd2+ > Zn2+ [35, 
36]. Mammalian MTs have a dumbbell-shaped conformation consisting of two structural 
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domains: an α–domain that has 11 cysteine residues and can bind 4 Cd2+ or Zn2+, or 6 Cu2+ ions, 
and a β–domain that has 9 cysteine residues and can bind 3 Cd2+ or Zn2+, or 6 Cu2+ ions [11]. Of 
the 61-68 amino acids that make up MTs, 20 are highly conserved cysteines that allow them to 
bind up to 7 Zn2+ atoms per molecule, with an overall binding affinity of up to 10-13 M [11, 37]. 
It has also been shown that MTs assume a donor/ acceptor role for other Zn2+ binding proteins in 
order to influence key cellular processes such as transcription, proliferation, differentiation, 
signal transduction and apoptosis [38, 39].  
Mouse knockout studies have demonstrated the importance of MTs in Zn2+ homeostasis. 
For example, MT-null mice lacking the MT-1 and MT-2 genes fed Zn2+ deficient diets had 
delayed kidney development compared to their wild-type littermates, likely due to a decreased 
hepatic reservoir of Zn2+ needed for development [40]. At the same time, MT-null adult mice 
exposed to increased Zn2+ were predisposed to pancreatic acinar cell degeneration [40]. These 
data demonstrate that MTs are critical for protecting organisms against both Zn2+ deficiency and 
excess, and necessary for accommodating Zn2+ influx. These results are not entirely surprising 
since the expression of MT-1 and MT-2 is ubiquitous, but exceptionally high in the intestine, 
pancreas, kidney and liver [40]. However, the most widely studied role of MTs is their ability to 
protect in vitro and in vivo against reactive oxygen species (ROS) due to their high thiol content. 
For example, in mouse models where MT is overexpressed in cardiac tissue, MT inhibits 
ischemia-reperfusion induced myocardial injury and apoptosis [41, 42]. It has also been shown 
that MT expression is upregulated by ROS through antioxidant response elements (AREs) within 
their promoter region [43]. Additionally, MTs have been shown to act as reducing agents and 
antioxidants. It is proposed that ROS oxidizes the normally Zn2+–bound MT, causing it to release 
Zn2+ [44, 45]. Evidence from this comes from nitric oxide studies. Nitric oxide increases 
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intracellular Zn2+ levels through the oxidation of Zn2+–MT in mouse lung fibroblasts [46]. 
Further supporting this idea, H202 exposure has also been shown to release Zn2+ in cell free and 
cell culture studies [47-49]. The released Zn2+ then binds to MTF-1, which will upregulate MTs 
and ZnTs, and restart the cycle (see below).  Lastly, through their antioxidant activity, MTs may 
also protect cells against allergic inflammation by suppressing inflammatory cytokines [50], 
which, if impaired, cause severe inflammatory responses in multiple sclerosis and Helicobacter-
induced gastritis [51-53]. Together, these data highlight the importance of MT function in many 
different biological processes and disorders.  
1.2.3 Transcriptional regulation of ZnTs and ZIPs.   
The expression of many ZnT and ZIP transporters is regulated transcriptionally as well as 
postranscriptionally. In higher eukaryotes ranging from insects to mammals, some transporters 
and MTs are transcriptional targets of the Zn2+–sensing, metal-response-element-binding 
transcription factor-1 (MTF-1). MTF-1 regulates the metal-dependent induction of gene 
expression in response to heavy metal toxicity, ionizing radiation and oxidative stress [54-58]. 
Often times, MTF-1 is referred as a Zn2+ sensor because of its nanomolar affinity for Zn2+ [59]. 
The reason behind this high affinity is that MTF-1 has a metalloregulatory DNA-binding domain 
that has 6 Cys2His2 zinc fingers that allow it to bind to Zn2+ with very high affinity [60, 61]. 
Under basal conditions, MTF-1 is localized within the cytoplasm, however, upon a transient 
increase in cytoplasmic Zn2+, MTF-1 binds to Zn2+ and translocates to the nucleus to activate the 
expression of Zn2+–responsive genes [62-65]. For example, in mammals, MTF-1 protects against 
Zn2+ toxicity by increasing the expression of MT-1 and MT-2 [66] as well as lowering 
cytoplasmic Zn2+ levels by upregulating the expression of ZnT1, the Zn2+ efflux transporter 
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localized to the plasma membrane [57]. Thus far, MTF-1 inducible targets include MT genes, 
ZnT1, and the glutamate-cysteine ligase heavy chain (γGCShc) that codes for an oxidative stress 
protein [67], but MT induction is the best studied. Some of the stimuli that induce MT gene 
induction include: metal ions Zn2+, Cd2+, and Cu2+, and chemical agents diethylmaleate, 
paraquat, nitric oxide, hydrogen peroxide and cytokines [68-75]. The transcriptional induction of 
MT and other MTF-1 target genes depends on the highly conserved metal response element 
(MRE) consensus sequence (5’-TGCRCnCGGCCC-3’) found within the promoters of such 
genes [76-80]. Interestingly, although MTF-1 knockout in mice is lethal, it has not been shown 
that MTF-1 regulates the expression of other ZnTs or ZIPs, potentially due to a redundant 
pathway. Multiple levels of MTF-1 functional regulation have been found; including nuclear 
translocation, DNA-binding, posttranslational modification through phosphorylation, and 
interactions with other factors. Additionally, a recent report showed that a single-nucleotide 
within the MRE consensus sequence can affect MTF-1 transcriptional activation. For example, 
given that the core (Zn2+) MRE is TGCRCNC, the Cu2+ MRE is TGCACRCG, while the Cd2+ 
MRE is TGCACYCG [81], indicating that the cells can sense the specific challenge they are 
exposed to and can respond accordingly.  
 To date, the transcription factor regulating ZIP expression, that responds to Zn2+ 
deficiency, has not yet been identified in mammals. However, it has been identified in S. 
cerevisiae, as Zn2+ -responsive activator protein-1 (Zap1) [82-84]. Under Zn2+ deficient 
conditions, Zap1 upregulates the expression of 3 ZIPs: ZRT1, ZRT2, and FET4 [82-84]. Zap1 
also induces Zn2+ release from vacuolar stores by activating the expression of the vacuolar ZIP, 
ZRT3 [85]. Lastly, Zap1 has also been shown have some features in common with MTF-1 (such 
as transactivating domains, and DNA-binding domains with Cys2His2 zinc finger motifs) as well 
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as to induce the expression of 43 other genes, some of which also participate in Zn2+ homeostasis 
[86]. While a homologue for Zap1 has not yet been identified for multi-cellular organisms, some 
Zn2+ transporters, such as ZIP6 and ZnT2, have been shown to be regulated by signal transducers 
and activators of transcription 3 (STAT3) [87] and STAT5 [88], respectively, suggesting that 
different signaling cascades converge on the transcriptional control of Zn2+ transporters.  These 
transcriptional control mechanisms likely reflect cell type-specific functions and signaling 
events. 
1.2.4 Subcellular localization of zinc transporters.   
To understand metal ion homeostasis, one first has to understand how the subcellular localization 
of the transport machinery.  The first Zn2+ transporter identified was ZnT1. It was cloned in 1995 
and identified in baby hamster kidney (BHK) cells that were growing in very high (300 µM) 
extracellular Zn2+ concentrations [15]. When normal BHK cells were transfected with ZnT1 
cDNA, they grew in high Zn2+ concentrations, all the while keeping intracellular Zn2+ 
concentrations low [15]. Another study found that the mRNA expression of ZnT1 was 
upregulated in response to high Zn2+ exposure in rat hippocampal neurons that this upregulation  
is often associated with neuronal death [89] (discussed further in section 1.3). From these and 
other studies, ZnT1 was identified as a Zn2+ efflux transporter that localizes to the plasma 
membrane and mediates Zn2+ efflux from the cytoplasm to prevent toxic accumulation of Zn2+ 
(Figure 3). Similarly, the primary uptake system for cellular Zn2+ is the ZIP family of 
transporters. Of the 14 ZIPs identified, ZIP1 is ubiquitously expressed and upregulated by Zn2+ 
deficiency [90]. In basal conditions, ZIP1 has been shown to localize to intracellular 
compartments, but in Zn2+-deficient conditions, ZIP1 has been shown to migrate to the plasma 
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Figure 3. Subcellular localization of ZIP and ZnT transporters.  
The localization and direction of zinc mobilization by ZIPs (blue arrows) and ZnTs (black arrows) are shown 
according to current information available. Extracellular zinc is taken up by ZIP transporters localized at the plasma 
membrane, while cytoplasmic zinc is transported by ZnTs into the secretory compartments such as the ER and the 
Golgi, endosomes/ lysosomes, synaptic vesicles in the brain or insulin granules of pancreatic β-cells. This diagram 
depicts a static view of ZIP and ZnT localization, as they have been shown to change their subcellular localization in 
a cell-specific, developmentally regulated, and zinc-dependent manner. Additionally, in polarized epithelial cells, 
ZIP4, ZIP8, and ZIP14 localize to the plasma membrane, while ZIP5 has been shown to localize to the basolateral 
membrane. TGN, trans-Golgi network. To this date, the subcellular localization of ZnT9, ZIP11 and ZIP12 has not 
been identified. Figure adapted from [91]. 
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membrane to mediate Zn2+ uptake [92]. Since then, other ZIPs were also found to be important 
for Zn2+ uptake. ZIP3 has been shown to be important for Zn2+ uptake in mammary epithelial 
cells [93]. ZIP4 has been found to regulate dietary Zn2+ absorption and is mutated in 
acrodermatitis enteropathica (AE) [94], a recessive disorder characterized by dermatitis, hair loss 
and diarrhea. Additionally, ZIP5 has been implicated in Zn2+ transport from the bloodstream into 
enterocytes [95], and ZIP14 has been associated with Zn2+ uptake in the liver in response to acute 
inflammation and infection [96]. Notably, most knock out models of ZIPs have abnormal 
embryonic development [16].  
 The Zn2+ transporters mediating Zn2+ transport into and out of organelles vary from cell 
type to cell type, but I will briefly present the most notable cases, which are summarized in 
Figure 3. Many organelle specific functions depend on Zn2+. For example, processing of the 
Alzheimer’s Aβ protein depends on a Zn2+ metalloprotease in the Golgi [97], and the packaging 
of insulin into secretory vesicles also depends on Zn2+ in the Golgi [98]. Similarly, in the ER, 
glycosylphosphatidylinositol phosphoethanolamine transferase (GPI-PET) depends on Zn2+ for 
its function in the biosynthesis of GPI anchors [99]. In vertebrates, ZnT5 and ZnT6 form a 
complex and localize to the Golgi to transport Zn2+ into the Golgi [100]. ZnT7 homoligomers 
and ZIP7 also localize to the Golgi and regulate Zn2+ trafficking [101, 102]. Finally, mutations in 
or knock out of the Golgi ZIP13 protein show delayed growth and abnormalities in hard and 
connective tissue development, characteristic of the Ehlers-Danlos syndrome in humans [103]. 
Other transporters involved in packaging Zn2+ into vesicles include ZnT3 in synaptic vesicles 
[104] (discussed further in section 1.3), ZnT8 in pancreatic β-cells [105], and ZnT4 and ZnT2 in 
endosomes and lysosomes. Notably, mutations in ZnT4 result in the lethal milk (lm) syndrome 
where mouse pups do not survive when nursed by lactating dams harboring mutations in ZnT4 
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[106]. When nursed by wild-type dams or given oral Zn2+ supplements, these pups do survive 
[107], suggesting that ZnT4 is important for Zn2+ secretion into milk. In sum, the complement of 
Zn2+ transporters expressed within each cell type reflects its specific function.  
 It is likely that these 24 Zn2+ transporters do not represent a complete list, since some 
organelles such as the mitochondria have not yet been associated with specific transporters. It is 
known that Zn2+ is required in the matrix of the mitochondria for proper function, and that labile 
Zn2+  can be detect in the mitochondria of neurons by the Zn2+–responsive fluorophore, RhodZin-
3 [108]. How Zn2+ gets in the mitochondria is not known. It was previously thought that Zn2+ 
enters the mitochondria through the Ca2+ uniporter system. However, recent studies in rat brain 
samples have shown mitochondrial Zn2+ accumulation that is both Ca2+ uniporter-dependent and 
Ca2+ uniporter-independent [109]. This suggests that there are other unidentified Zn2+ 
transporters, and/ or mechanisms for Zn2+ trafficking in cells.  
1.3 ZINC HOMEOSTASIS AND NEURODEGENERATIVE DISORDERS 
In 1955, Maske discovered Zn2+ -dithizonate staining in rat hippocampal slices [110]. Since then, 
it has been well established that Zn2+ is selectively stored in and released from presynaptic 
vesicles within neurons of the cerebral cortex [1]. The concentration of Zn2+ within these 
vesicles can reach millimolar levels [111-113]. The term “gluzinergic” has been used to describe 
these neurons because in addition to Zn2+, they also release glutamate [114]. Since 1955, our 
knowledge of the neurobiology of Zn2+ has vastly expanded. Overall, through its effects on 
glutamate and γ–aminobutyric acid (GABA) receptors, Zn2+ has been found to modulate the 
excitability of neurons and to play a key role in synaptic plasticity [14, 115]. Here I will briefly 
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describe Zn2+ signaling in normal function as well as in pathophysiology of acute brain damage 
and neurodegenerative diseases.  
1.3.1 Gluzinergic neurons and synaptic zinc release.   
Due to the prevalence of gluzinergic neurons, synaptically released Zn2+ has been implicated in 
neurogenesis, neuronal migration, synatogenesis, motor coordination, memory formation, and 
olfactory and vision processing [14]. Consistent with its essential role, Zn2+ deficiency, 
chelation, or genetic Zn2+ absorption disorders have been associated with pain, impaired vision 
and spatial learning, memory deficits and loss of taste and smell [14]. These studies emphasize 
the necessary levels of Zn2+ that are needed for normal brain function.  
 Zn2+ entry into neuronal somata and dendrites occurs through the Zn2+–permeable, gated 
channels such as the N-methyl-D-aspartate (NMDA) channels and the voltage-gated, Ca2+-
permeable α–amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) channels [116, 
117]. In the presynaptc terminal, Zn2+ is packaged into synaptic vesicles through ZnT3 along 
with glutamate and is released into the synaptic cleft through exocytosis. Once at the 
postsynaptic terminal, Zn2+ can enter cells through Zn2+–permeable glutamate transporters and 
channels. Zn2+ has been shown to inhibit both the NMDA-type glutamate ionophore [118] and 
the GABA type A (GABAA) receptor [119]. Not surprisingly then, this high amount of Zn2+ 
translocation has been associated with excitotoxic, Zn2+–induced cell injury [120]. One of the 
major reasons for this cell injury is the Zn2+ released from MT-3 due to nitrosylation of oxidation 
of the thiol ligands [121, 122]. In fact, MT-3 knockout mice have significantly reduced cell 
injury in the thalamus and hippocampal field CA1 [120]. However, at the same time, lack of 
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MT-3 in hippocampal field CA3, increased cell death after excitotoxic injury, suggesting that 
postsynaptic MT-3 functions as a both a cytoprotective Zn2+ sink and a source of toxic free Zn2+.  
 Although Zn2+ lacks redox activity, it has been shown that free ionic Zn2+ is toxic. 
Neuronal injury and death have been observed after a 15-minute exposure to 300 – 600 µM Zn2+ 
in cortical cell culture [123], as well as after a 5-minute exposure to 100 µM Zn2+ following 
depolarization with high potassium [124]. This neurotoxicity likely results from Zn2+ and Ca2+ 
influx through L-type, NMDA and AMPA/kainite channels. Subsequently, Zn2+ toxicity has also 
been observed in vivo following seizures or transient cerebral ischemia [125], focal ischemia 
[126], and traumatic brain injury [127]. Nevertheless, the source of the toxic Zn2+ in 
degenerating neurons is still debated. Even neurons from ZnT3 knockout mice had extensive 
Zn2+ accumulation [128], indicating that other sources beside presynaptic Zn2+ affect toxicity. 
For example, other sources of Zn2+ contributing to toxicity could come from Zn2+ mobilized 
from MT-3, or from the mitochondria [129].   
Several lines of evidence indicate that Zn2+ toxicity is largely due to oxidative stress. 
Zn2+-induced cell death is often associated with the production of superoxides and lipoperoxides 
[130], and attenuated with antioxidants [131]. The exact mechanism of Zn2+–induced cell death 
is not entirely clear and varies depending on Zn2+ concentration and cell type used, but a few 
pathways have been identified. When cells are treated with lower Zn2+ concentrations, DNA 
fragmentation and caspase activation, indicative of apoptosis, have been observed [131, 132]. 
However, when cells are treated with higher Zn2+ concentrations, cell body swelling, and 
organelle destruction have been observed, indicative of necrosis [130]. Apoptotic cell death 
seems to involve induction of the neutrophin receptor p75NTR and p75NTR-associated death 
executor (NADE), as well as the release of cytochrome C and apoptosis-inducing factor (AIF) 
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from the mitochondria [133, 134]. While necrotic cell death involves the activation of the poly-
ADP-ribose polymerase-1 (PARP-1) pathway [135]. 
1.3.2 Zinc and neurodegenerative disorders.   
Zn2+ has been both directly and indirectly implicated in many neurological diseases including 
Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), depression, epilepsy, ischemia and 
schizophrenia [14]. Here I will briefly review Zn2+ dysregulation in Alzheimer’s and ALS, as 
well as discuss therapeutic strategies.  
Aberrant homeostasis has been linked to β–amyloid aggregation, characteristic of 
Alzheimer’s disease (AD). Presenilin, the enzyme responsible for cleaving β–amyloid precursor 
protein (APP), and the enzyme mutated in Alzheimer’s has been implicated in Zn2+ clearance 
[136]. Other AD-associated enzymes such as APP, tau and BACE have metal-binding properties, 
suggesting that metal homeostasis might be the key mechanism driving AD [137]. Moreover, 
neuritic plaques and cerebrovascular amyloid deposits from AD patients were found to have high 
Zn2+ concentrations [138] and Zn2+ co-purifies with β–amyloid from post-mortem brains [139]. 
Interestingly, Zn2+ and Cu2+ chelators reversed synthetic Aβ aggregation in vitro [140] and 
reduced amyloid deposits in post-mortem brain tissue from patients [141]. Furthermore, evidence 
from ZnT3 knock down in a mouse model of Alzheimer’s disease showed that synaptic Zn2+ 
release is one of the major insults leading to pathology. Specifically, mice lacking ZnT3 and 
therefore synaptic vesicle Zn2+, had fewer β–amyloid plaques [142].  
Mutations in the Cu2+/ Zn2+ superoxide dismutase (SOD1) enzyme are associated with 
familial amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). SOD1 is a 
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ubiquitously expressed enzyme that binds Zn2+ [143]. Gain of function mutations in SOD1 have 
been associated with motor neuron injury due to increased peroxidase activity and aberrant free 
radical handling, leading to excitotoxicity [144, 145]. Additionally, some SOD1 mutant proteins 
have decreased Zn2+, but increased Cu2+ affinity, leading to the generation of peroxynitrate and 
toxicity-induced neuronal death [146, 147]. Furthermore, metallothionein expression is 
upregulated in brain and liver tissue of ALS patients. Specifically, MT-1, MT-2 and MT-3 
expression is increased in astrocytes, and MT-3 in neurons [148]. Lack of MT-1, MT-2 or MT-3 
has been shown to accelerate the onset of symptoms and to shorten life time, consistent with 
MTs’ protective role in preventing the buildup to toxic levels [149].   
Clearly then, Zn2+ homeostasis is an integral part of normal brain function. The 
therapeutic strategies employed in treating excess free Zn2+, such as in Alzheimer’s or ALS, have 
to maintain physiological Zn2+ concentrations in order to maintain proper function. Any 
therapies leading to too much or not enough intracellular Zn2+, will likely result in devastating 
cell death. As such, metal chelating drugs have been used, but more knowledge on Zn2+ 
homeostasis is needed to fully develop therapeutic approaches. For example, the quinoline 
compound, clioquinol has been shown to bind Zn2+ in the mid-nanomloar range and has been 
used to reduce amyloid plaques and slow cognitive decline in Alzheimer’s patients [150]. 
Another therapeutic agent used was pyruvate. Pyruvate has been shown to protect against Zn2+–
induced cell death in cortical and oligodendrocyte progenitor cultures, in addition to preventing 
Zn2+ accumulation in the brain [89, 151]. It is likely that studying Zn2+ release, channels and 
transport will prove important in designing new drug targets for treating many neurological 
disorders.  
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1.4 LYSOSOMAL BIOGENESIS AND FUNCTION 
With the exception of erythrocytes, lysosomes are found in all eukaryotic cells and are the major 
digestive compartment within cells. Lysosomes are intracellular organelles with an acidic 
interior, which contains roughly 25 specific membrane proteins [152] and 60 resident hydrolases 
[153]. Christian de Duve first described lysosomes in a series of centrifugal fractionation 
experiments in the 1950s [154-156] that resulted in a Nobel Prize. Since then, lysosomes have 
been recognized as advanced organelles that are involved in many cellular processes and crucial 
regulators of cell homeostasis.  
Insides cells, lysosomes appear as dense bodies in the cytoplasm [157], most often in a 
perinuclear pattern that constitutes up to 5% of the intracellular volume. Lysosomal size and 
number can vary drastically due to undigested material, for example, lysosomes are typically 1 
µm in diameter [157, 158]. They are enclosed by a single 7-10 nm phospholipid-bilayer [159], 
high in carbohydrate content due to the heavily glycosylated lysosomal membrane proteins 
[160], lysosomes have a pH of 4.5-5.0 [161]. Although this provides an optimal condition for the 
multitude of resident hydrolases and the degradation of all types of macromolecules, it also 
creates a challenge for lysosomal membrane proteins to not be degraded. To protect the 
membrane from the lytic enzymes found within, lysosomal membrane proteins are heavily 
glycosylated at their luminal domains to form a glycocalyx [160], and the inner membrane is rich 
in phospholipid bis(monacylglycero)-phosphate (BMP), also known as lyso-bis-phosphatidic 
acid (LBPA) [162]. This regulation and maintenance of this special lysosomal environment is 
necessary for cell survival. Yet, when this environment is perturbed, it results in several diseases 
called lysosomal storage disorders. The following sections will discuss the transcriptional control 
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of lysosomal genes, biosynthesis and delivery of lysosomal proteins, and how lysosomes attain, 
degrade and expel material. 
1.4.1 Regulation of lysosomal biogenesis. 
Until recently, the molecular machinery regulating lysosomal biogenesis remained unknown. 
However, in 2009, Sardiello et al. discovered that genes encoding lysosomal proteins had a 
GTCACGTGAC sequence within their promoters that they called the coordinated lysosomal 
expression and regulation (CLEAR) sequence [163]. They showed that transcription factor EB 
(TFEB), a member of the microphatalmia and basic helix-loop-helix leucine-zipper family of 
transcription factors, directly binds to CLEAR elements in lysosomal genes, thereby promoting 
their expression [164, 165]. Cells overexpressing TFEB showed that TFEB translocates to the 
nucleus after lysosomal stress, binds to CLEAR sequences, and leads to the generation of more 
lysosomes which can more effectively degrade lysosomal and autophagy substrates [163, 166]. 
Furthermore, TFEB regulates the biogenesis of autophagosomes, the fusion of autophagososmes 
with lysosomes, and autophagic flux. More recently, Palmieri et al, were able to combine 
microarray, deep sequencing of TFEB chromatin immunoprecipitate, genomic and expression 
data to identify over 500 TFEB target genes, solidifying TFEB’s role as a master regulator of 
lysosomal function [164, 165]. More recently, Martina et al., discovered that another 
transcription factor, transcription factor E3 (TFE3), also induces the expression of genes 
involved in autophagy and lysosomal biogenesis, but in response to nutrient status [167], 
indicating that cells are able to actively monitor lysosomal function and respond to degradative 
as well as environmental needs.  
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Once lysosomal genes are transcribed, the sorting of lysosomal proteins requires the 
integration of the biosynthetic and endocytic pathways. Newly translated lysosomal proteins are 
synthesized as N-glycosylated precursors and most soluble acid hydrolases obtain a mannose-6-
phosphate (M6P) recognition marker in the cis-Golgi which is recognized by the mannose-6-
phosphate receptor (M6PR) in the trans-Golgi network (TGN) [168, 169]. The M6PR-bound 
hydrolases are first delivered to endosomes [170, 171] where due to the slightly acidic luminal 
pH, they dissociate from the receptors, allowing the receptors to recycle back to the TGN [172, 
173] and the hydrolases to continue on to be delivered to lysosomes. Newly synthesized 
lysosomal membrane proteins (unlike soluble hydrolases) can either be directly transported to 
lysosomes through the TGN and clathrin-dependent transport of lysosomal hydrolases [174, 
175], or indirectly by following the constitutive secretory pathway where they are first 
transported to the plasma membrane and then, through endocytosis, delivered to lysosomes.  
Endocytosis starts at the plasma membrane and ends in lysosomes, with many 
intermediate “stations” distinguished by their molecular content, morphology and pH (Figure 4). 
Early endosomes (EEs) receive endogenous proteins such as M6PRs carrying lysosomal 
hydrolases from the TGN [170, 171], which they then sort for either recycling or degradation. 
Cargo without a specific targeting signal enters tubular sorting endosomes (TSEs) for recycling, 
while lysosomal cargo remains in the EEs [176, 177]. Cargo receptors and lysosomal 
transmembrane proteins require sorting signals in their cytosolic domains. As a result, lysosomal 
proteins have dileucine-based motifs DXXLL or [DE]XXXL[LI] [178, 179] and tyrosine-based 
motifs YXX∅ [180, 181] that interact with the clathrin machinery and adaptor protein 
complexes. For example, the adaptor protein complex protein AP3 is required for transport of 
lysosomal proteins from TSEs to lysosomes [176, 182]. This complex combination of luminal 
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and cytosolic signals with recognition proteins ensures specific and proper transport of lysosomal 
proteins. The intricate and critical nature of these pathways are evident in many human diseases. 
For example, mutations affecting the function of AP3 in humans result in a pigmentation and 
bleeding disorder called Hermansky-Pudlak syndrome [183-185] where patients have an 
inappropriate redistribution of lysosomal membrane proteins to the plasma membrane. These 
patients have impaired formation of lysosomes and lysosomal related organelles (LROs) such as 
melanosomes and platelet-dense granules. Similarly, M6PR knockout mice and human patients 
with I-cell disease (also known as Mucolipidosis type II), lack the M6P recognition tag because 
of a deficiency in N-acetylglucosamine (GlcNAc) phosphotransferase activity and as a result, 
secrete lysosomal enzymes from cells [186-188].  This is an oversimplification of the trafficking 
and regulated transport of lysosomal proteins (for a more detailed review, please see [189]). 
1.4.2 Lysosomal function.  
The lysosome gets its name from the Greek words lysis, meaning digestion, and soma, meaning 
body. The major function of lysosomes is degradation of intra- and extracellular 
macromolecules. While extracellular material is ingested by cells through endocytosis and 
delivered to the lysosomes through many different compartments, intracellular material reaches 
the lysosome through different forms of autophagy. After digestion, certain products can either 
be reused by the cell as building blocks for anabolic processes, or be expelled into the 
extracellular environment through lysosomal exocytosis (Figure 4). In this section, I will briefly 
discuss lysosomal function and its role in endocytosis, autophagy, and exocytosis. 
The unique and highly acidic (pH 4.5 -5.0) environment of the lysosomal lumen is 
maintained by the action of the vacuolar H+-ATPase; a transmembrane multimeric protein 
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complex that pumps protons from the cytosol against the electrochemical gradient into the 
lysosomal lumen through ATP hydrolysis [190, 191]. Lysosomal transporters such as the Cl-/H+ 
antiporter, anion transporter chloride channel 7 (CIC-7), have been shown to regulate the activity 
of this pump [191-194]. Additionally, lyosomal function depends on proper lysosomal ion 
concentrations facilitated by channels such as the cation transporter mucolipin 1 (TRPML1), two 
pore calcium channel 1 (TPC) [191, 195-197], solute carrier family 11, member 2 (Slc11a2) 
(also known as divalent metal transporter 1 (DMT1) or natural resistance-associated macrophage 
protein 2 (NRAMP2)) [198], and the zinc transporter ZnT4 (Figure 5).  
The low pH of the lysosomal lumen facilitates both the action of over 50 resident 
proteolytic enzymes (proteases, nucleases, lipases, phosphatases, peptidases, glycosidases and 
sulfatases) and the degradation process by loosening the structures of macromolecules [199, 
200]. This combination ensures lysosomal degradation of all kinds of cellular macromolecules.  
Of the lysosomal hydrolases, the cathepsin family of proteases is the best characterized 
and is categorized into three groups based on the amino acid within the active site: aspartic 
cathepsins (D and E), cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, and X) and serine 
cathepsins (A and G) [201]. Interestingly, while the activity of most lysosomal hydrolases 
depends on the lysosomal environment, some hydrolases, such as Cathepsin B, can function in a 
wider pH range and play a critical role in cell death mechanism, discussed later in this chapter, 
by cleaving cytosolic proapoptotic substrates [202-204]. 
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Figure 4. Lysosomal function in endocytosis, autophagy and exocytosis.  
Lysosomes are responsible for the degradation of macromolecules in cells and have distinct morphology and 
function. Endocytosis (right side) is a process where cells absorb extracellular material (black dots) by engulfing 
them. Often, this material travels through several intermediate compartments, with decreasing pH environments, 
before reaching the lysosome for degradation. In the opposite process, lysosomes can expel material outside of the 
cell through docking and fusion of lysosomes with the plasma membrane in a process called lysosomal exocytosis 
(bottom). Another function of lysosomes involves autophagy (left side). During autophagy, sequestration of proteins 
or damaged organelles begins with the formation of the phagophore, a double membrane autophagosome that can 
engulf parts of the cytoplasm as well. The autophagosome can then fuse with a lysosome to obtain acid hydrolases, 
or to form an autolysosome in order to degrade cargo.  
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Figure 5. Lysosomal metal transporters.  
Model illustrating the transport direction of the identified lysosomal metal transporters. Lysosomal function depends 
on the correct ion concentration regulated by these transporters. 
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Extracellular material is internalized from the plasma membrane as endocytic cargo in 
early endosomes (EEs) and then to late endosomes (LEs), which eventually fuse with lysosomes 
to degrade the cargo. This transfer from EE to lysosomes usually takes less than an hour. During 
this time, the various compartments undergo many changes including exchanging material and 
membrane components, decreasing luminal pH, forming intraluminal vesicles (ILVs), changing 
morphology (losing EE tubular extensions), and gathering lysosomal components [205]. 
However, how this cargo is exactly delivered from LEs to lysosomes is still not entirely 
understood and multiple models have been proposed. In the maturation model, LEs gradually 
mature into lysosomes by gradually obtaining lysosomal components and shedding endosomal 
components [206]. In contrast, the vesicular model proposes that the mode of delivery is through 
vesicles that form and bud from LEs and then fuse with lysosomes [207]. Alternatively, the 
“Kiss and run” model postulates that the membranes of LEs and lysosomes transiently fuse 
(kiss), exchanging contents, before separating (run). Lastly, the hybrid model suggests that LEs 
and lysosomes permanently fuse to form a hybrid organelle containing both endosomal and 
lysosomal components, where LE components are later selectively retrieved and lysosomes re-
formed. Because of this continuous exchange of contents between the intermediate 
compartments of the endocytic pathway, the use of terms such as EE, LE and lysosomes is an 
oversimplification of the complexity found within the system. Nonetheless, markers used to 
distinguish between these different compartments are widely used. For example, the early 
endosomal antigen 1 (EEA1) and Rab5 GTPase are used to identify EE [208], while lysosomes 
can be distinguished from LE because they lack M6PR receptors [209]. Current evidence 
suggests that LE directly fuse with lysosomes, requiring N-ethylmaleimide sensitive factor 
(NSF), soluble NSF attachment proteins (SNAPs) and small GTPases such as Rab7 [210]. 
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Similar to other membrane trafficking events, this process has three sequential steps: tethering, 
the formation of a trans-SNAP receptor (SNARE) complex, and the fusion of membranes from 
two different organelles. Tethering appears to be regulated by the homotypic fusion and vacuole 
protein sorting (HOPS) complex (VPS18 and VPS39, in particular), that is recruited by Rab7 
[211, 212]. While membrane fusion requires syntaxin-7, VTI1B, syntaxin-8 [213-215], and the 
release of lumenal calcium (Ca2+) necessary for phospholipid bilayer fusion [216]. At the end of 
this process, lysosomes are reformed from the hybrid organelle through the loss of M6PRs, 
endosomal SNAREs and the condensation of luminal content [217]. Defects in lysosomal 
reformation have been linked to lysosomal storage disorders such as Mucolipidosis type IV [218] 
(discussed further in section 1.5.2). 
Similarly, during autophagy, intracellular components such as damaged proteins, or 
entire organelles are degraded and recycled. In mammalian cells, autophagy begins with 
autophagosomes forming double membranes around cytosolic proteins or effete organelles such 
as dysfunctional mitochondria, and then either fusing with the lysosome to either create an 
autolysosome or briefly interacting with the lysosome to transfter the autophagic content for 
degradation. Moreover, autophagy can be classified into three categories: chaperone-mediated 
autophagy, microautophagy and macroautophagy. In chaperone-mediated autophagy, cytosolic 
proteins with specific motifs are delivered to lysosomes via LAMP-2A and Hcs70 [219]. Very 
little is known about microautophagy where macromolecules are directly translocated to the 
lysosomal lumen for degradation [220]. Macroautophagy, on the other hand, engulfs cytoplasm, 
along with soluble materials and organelles within a double membrane called the phagophore to 
form the autophagosome, which subsequently fuses with lysosomes to degrade and recycle 
material [221]. Mammalian target of rapamycin complex 1 (mTORC1) is a kinase that is central 
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for regulating autophagy and detecting the cell’s energy status by responding to signals from 
amino acids, growth factors and glucose [222]. A basal rate of autophagy is necessary for 
homeostasis, but can be strongly upregulated to various physiological stresses such as the 
presence of aggregated proteins or during starvation [223]. Under basal conditions, mTORC1 
associates with the lysosomal membrane and interacts with and phosphorylates TFEB to prevent 
TFEB nuclear translocation [224]. Upon starvation, mTORC1 is inhibited, allowing 
unphosphorylated TFEB to upregulate the expression of genes coding for lysosomes and 
autophagosomes. Nutrient stress also changes lysosomal localization from peripheral to 
perinuclear clustering [225]. Thus, lysosomal localization regulates mTORC1 signaling. 
Curiously, the reverse is not true. mTORC1 activity does not influence lysosomal localization. 
This implicates lysosomes as key players in the control of the cellular response to nutrient stress.  
For many years, it was thought that only specialized secretory cells undergo a process 
called lysosomal exocytosis where lysosomes fuse with the plasma membrane in order to secrete 
material. However, over the last decade or so, it has been recognized that all cell types are 
capable of lysosomal exocytosis [226]. Lysosomal exocytosis is a Ca2+-regulated mechanism that 
leads to the release of lysosomal contents into the extracellular matrix. This mechanism is 
important for many physiological processes such as plasma membrane wound repair [227, 228], 
platelet function in coagulation [229], melanocyte derived pigmentation [230], degranulation in 
cytotoxic T lymphocytes [231], bone resorption by osteoclasts [232], bacterial defense by mast 
cells [233], and parasitophorous vacuole formation by Trypanosoma cruzi [234]. Lysosomal 
exocytosis is a two-part process where lysosomes first relocate from their perinuclear 
localization closer to the plasma membrane [235], and then fuse with the plasma membrane in 
response to a transient increase in intracellular Ca2+ [226]. In cytotoxic T lymphocytes, for 
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example, once a foreign antigen is detected, lytic granules (LROs) are delivered to the 
immunological synapse via microtubules [236] between the lymphocyte and the target cell to 
induce apoptosis of the foreign cell. Fusion of the lytic granule to the plasma membrane depends 
on priming by Munc-13-4 [237] while docking is Rab27a dependent [238]. Although cell-type 
specific SNARE proteins for this process have not been identified, evidence suggests that 
VAMP7 is required in eosinophils and neutrophils [239, 240] and VAMP8 is required in 
platelets [241]. Defects in the biogenesis, movement and exocytosis of these LROs cause 
albinism, bleeding disorders and immunodeficiency in several syndromes including; Griscelli, 
Chediak Higashi and Hermansky-Pudlak syndromes [242-244].  
In addition to lysosomal exocytosis, autophagy also plays an important role in the host 
defense mechanism against intracellular pathogens [245]. In animals, macroautophagy facilitates 
the recognition of infected cells by innate immune effectors, initiating an elaborate inflammatory 
or immune response [246, 247]. Not surprisingly then, bacteria and viruses have developed 
strategies for either subverting or manipulating autophagic pathways [248, 249]. Beyond 
influencing cell-intrinsic immune responses, autophagy has also been shown to be important for 
the antigenic profile of antigen-donor cells and their ability to release immunogenic signals [250, 
251], as well as the survival, differentiation and function of antigen-presenting cells and T 
lymphocytes [252-255]. Specifically, recent evidence indicates that in antigen-donor cells, 
autophagy affects the release of cytokines [256-259]. Moreover, mutations in autophagy-related 
genes have been associated with immune diseases [245, 260], and an increase in tumor 
development due to depressed immunosurveillance [261, 262]. Thus, autophagy and thereby 
lysosomes have a critical role in cellular immune responses. 
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Lysosomal exocytosis is not only important for secreting lysosomal content, but also has 
an essential role in plasma membrane repair. Injury of the plasma membrane occurs frequently in 
cells infected with pathogens [263], or in muscle and skin cells exposed to mechanical stress 
[264]. Lysosomal exocytosis is thought to be the primary source of membrane for resealing 
[265]. Restoring plasma membrane integrity is essential for cell survival and occurs within 
seconds to a minute timeframe [266, 267]. Soon after plasma membrane disruption, lysosomal 
markers such as LAMP1 appear at the cell surface due to the elevation in cytosolic Ca2+ [228]. 
Ca2+-regulated exocytosis is modulated by the vesicle SNARE (v-SNARE) TI-VAMP/VAMP7, 
the Ca2+ sensor synaptotagmin VII (SYT7) on lysosomes, the target SNAREs (t-SNAREs) 
SNAP23 and syntaxin 4 on the plasma membrane [268], along with many Rab proteins on the 
lysosomal membrane [269-271]. TRPML1, a Ca2+ lysosomal channel has also been shown to 
mediate lysosomal exocytosis [272, 273] (discussed further in section 1.5.2). Defects in resealing 
the plasma membrane lead to bacterial infection [274] and muscular dystrophy [275], which is 
characterized by impaired muscle fiber repair. Intriguingly, TFEB overexpression has been 
shown to increase lysosomal exocytosis through TRPML1 upregulation [273], and play an 
important role in osteoclast differentiation and bone resorption [276]. Additionally, once 
lysosomes fuse with the plasma membrane and plasma membrane integrity has been restored, the 
lesion is removed through endocytosis to promote wound resealing [277]. One of the lysosomal 
enzymes released extracellularly through lysosomal exocytosis, acid sphingomyelinase (aSMase) 
[278], promotes endocytosis by making ceramide. High ceramide content in the plasma 
membrane induces inward bending of the membrane and facilitates endocytosis [279]. Finally, 
lysosomes contain an abundance of ATP that is released with lysosomal exocytosis [280] that 
can be used for cell communication by binding to ATP binding receptors [281]. 
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1.4.3 Signaling from lysosomes.   
Given the abundance of their hydrolytic enzymes, lysosomes were coined “suicide bags” by 
Christian de Duve [155], since they could be quite harmful to cells if not controlled. Damage or 
compromise of the lysosomal membrane results in the release of lysosomal content into the 
cytoplasm, which indiscriminately degrades cellular material. While partial and selective 
lysosomal membrane permeabilization (LMP) induces apoptosis, a complete rupture induces 
cytosolic acidification and necrosis [282]. Specifically, LMP induces the translocation of 
lysosomal proteases such as cathepsin B, CD, and L into the cytoplasm, where they remain 
active even at neutral pH [283]. Cytoplasmic cathepsins trigger signaling cascades that either 
activate proapoptotic effectors such as caspases and mitochondria, or amplify the cell death 
signal [283, 284]. Depending on LMP activation and the cell type, post LMP signaling often 
activates either the caspase cascade through the intrinsic pathway, or the caspase-independent 
pathway of cell death [285, 286]. For example, the leak of cathepsin B into the cytoplasm has 
been shown to induce apoptosis through chromatin condensation, DNA fragmentation, plasma 
membrane blebbing, and phosphatidylserine exposure to the outer plasma membrane [287, 288]. 
In addition to the cathepsin leak, LMP also releases Ca2+. Lysosomes have a Ca2+ content that is 
similar to the endoplasmic reticulum (ER), of up to 600 µM [289, 290]. Lysosomal Ca2+ is 
released through the TPC via nicotinic acid adenine dinucleotide phosphate (NAADP) [291].  
LMP induced increases in Ca2+ cause the externalization of phosphatidylserine [292], effectively 
marking that cell for cell death via phagocytosis. There is a growing list of events that trigger 
LMP. Most of the agents that induce LMP affect the integrity of the lysosomal membrane such 
as lysomotropic agents like Leu-Leu-O-Me and hydixychloroquine. But other apoptotic stimuli 
such as photodamage, p53 activation, and the generation of reactive oxygen species (ROS) also 
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induce LMP [293-295]. Lysosomal cell death pathways are also important physiologically in 
mammary gland regression [296] (discussed further below) and embryonic development [297].  
 It is not clear how cathepsins translocate from the lysosome into the cytosol. Current 
paradigms propose either pore formation or simple membrane damage. One study suggests that 
there is a size-selectivity in the content released from lysosomes of up to 40 kDa [202]. Yet, 
another study showed the release of β–N-acetylglucosaminidase, a 150 kDa lysosomal hydrolase 
[298, 299]. Also unclear are the signaling pathways that induce LMP. One recent study dissected 
the signaling pathway involved in the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) induced LMP. TRAIL is normally expressed in immune effector cells, and induces 
apoptosis in target cells by binding to the death receptor 5 (DR5) [300]. This ligand-receptor 
complex is then internalized through endocytosis and recruits the phosphofurin acidic cluster 
sorting protein (PACS2), which then forms a complex with Bim and Bax to induce LMP [301]. 
Regardless of the exact signaling cascade, maintenance of lysosomal membrane integrity is 
essential for cell survival and evidence suggests that LMP susceptibility is related to the stability 
of lysosomal membranes. Susceptibility to LMP varies depending on cholesterol content [302], 
lysosomal size or lysosomal ion content such as iron [303] or zinc [304], which make lysosomes 
more prone to LMP. Other factors that determine the extent of LMP are endogenous inhibitors. 
For example, the Hsp70 family of chaperones, cannot only protect lysosomal membranes against 
permeabilization, but can also reverse Niemann-Pick disease A phenotypes, where lysosomal 
stability is chronically decreased [305]. Furthermore, endogenous cysteine cathepsin inhibitors, 
such as stefin, in the cytosol inhibit the activity of accidentally released cathepsins [306]. 
Another interesting regulatory step is that, except for cathepsin B, C, D, and L that remain active 
even at neutral pH [283, 307], most cathepsins are inactivated by the neutral pH in the 
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cytoplasm. This inactivation has been linked to either unfolding or deprotonation [308, 309], but 
the proteolytic activity of cathepsins can be stabilized through either substrate binding [307], or 
LMP induced cytosolic acidification. Once in the cytoplasm, cathepsins cleave several known 
substrates that induce the mitochondrial cell death pathways. For example, cathepsins B, D, H, 
K, L and S have been shown to activate the pro-apoptotic Bcl-2 family member, Bid [310, 311], 
and a recent study suggests that cathepsins also target XIAP and anti-apoptotic Bcl-2 proteins 
[312]. Moreover, LMP induced cell death requires Bax/Bak [313], and cytochrome C release 
[314]. Other cathepsin substrates include sphingosine kinase-1 [315], and membrane-associated 
guanylate kinases [316], implicating LMP control in cell-cell contacts, proliferation and tumor 
necrosis factor (TNFα) signaling. 
 LMP-induced cell death has been implicated in post-lactation mammary gland involution. 
Decreased suckling triggers a weaning signaling cascade that involves the controlled elimination 
of the milk secreting mammary gland epithelial cells through necrosis and glandular involution. 
In the first phase of postlactation, the expression of lysosomal membrane proteins LAMP1 and 
LAMP2 decreases, making the lysosomes more leaky, leading to the translocation of cathepsins 
B and L into the cytoplasm and activating caspase-independent cell death [296]. At the same 
time, the expression of cathepsin B and L increases, but the expression of the intracellular 
cysteine peptidase inhibitor serpin Spi2A decreases. Accompanying these events are calpain 
activation and increased intracellular Ca2+ levels. These events lead to increased plasma 
membrane permeability and lysosomal-mediated necrotic cell death. Kreuzaler et al. recently 
showed that the transcription factor STAT3 controls the expression of these proteins and when 
deleted, delays mammary gland cell death and involution [296]. These data link STAT3 and 
LMP in a physiologically relevant cell death model that could potentially be used for mammary 
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tumor therapies or drug targets. On the other hand, studies in bovine mammary gland remodeling 
have implicated autophagic cell death and the formation of autophagosomes as a cell death 
mechanism [317]. Thus, it is unclear whether autophagy also contributes to remodeling of the 
mammary gland during involution, as it could either be activated as a cytoprotective measure to 
prevent cell death, or as a consequence of cell starvation.  
Lysosomes are no longer regarded as “waste” or “suicide” bags, but are now recognized 
as advanced organelles that are involved in many cellular processes and are crucial for regulating 
cell homeostasis. Consequently, it has also become increasingly evident that lysosomes are 
pivotal in nutrient sensing and integrating signaling pathways important for metabolism and 
growth. In fact, mTORC1 localizes to the lysosome and is activated upon nutrient starvation. 
Under basal conditions when nutrients are present, mTORC1 phosphorylates the kinase complex 
ULK1-ATG13-FIP200 (unc-51-like kinase 1-autophagy-related 13-focal adhesion kinase family-
interacting protein of 200 kDa) [318], which suppresses its activity and prevents autophagosome 
formation [319-321]. Under starvation, or pharmacologically induced mTORC1 inhibition, 
ULK1-ATG13-FIP200 is activated, and autophagy takes place, suggesting that lysosomes act as 
sensors, rather than just effectors of these cellular pathways. Moreover, amino acids must build 
up inside the lysosomal lumen for mTORC1 activation [322], and under starvation conditions, 
mTORC1 has been shown to interact with lysoNaATP, an endolysosomal ATP-sensitive Na+-
permeable channel, to regulate lysosomal pH stability and amino acid homeostasis. During 
starvation, mTORC1 dissociates from the lysosomes, allowing lysoNaATP to open and control 
lyosomal membrane potential in response to ATP levels [323]. Intriguingly, prolonged starvation 
leads to lysosomal reformation that requires the kinase activity of phosphatidylinositol 4-kinase 
IIIβ (PI4KIIIβ) [324] and mTORC1 reactivation [325, 326]. 
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1.5 LYSOSOMAL DYSFUNCTION IN HUMAN DISEASES 
Given the vast range of cellular functions that converge on the lysosomal compartment, it is not 
surprising that disruptions of this compartment have a profound impact on cell homeostasis. 
Lysosomal dysfunction has been associated with several human diseases, in addition to the 
process of aging. Over time, lysosomal function decreases and a progressive accumulation of 
undigested material occurs [327]. In fact, one of the main reasons why caloric restriction 
prolongs life spans is by enhancing the autophagic-lysosomal pathways [328]. Unfortunately, 1 
in 5000 births worldwide are affected by lysosomal storage disorders (LSDs) in which a 
lysosomal defect creates intra-lysosomal accumulations of undigested material [329, 330]. Even 
though lysosomes are centrally implicated in LSDs, they have also been shown to be involved in 
many more widespread diseases such as cancer, Alzheimer’s disease, amyotrophic lateral 
sclerosis and Parkinson’s disease. In this section, I will discuss many of the LSD pathologies as 
well as the neurodegenerative diseases associated with lysosomal and autophagic dysfunction.  
1.5.1 Lysosomal storage disorders.   
Lysosomal storage disorders (LSDs) are a class of genetic pathologies characterized by the 
accumulation of material inside lysosomes. To date, over 50 human diseases associated with 
lysosomal dysfunction have been identified. The majority of these diseases are autosomal 
recessive and monogenic, although multiple mutations have been found in the same gene for 
each disorder. Unfortunately, identifying the genetic mutation has not led to new therapies as the 
underlying molecular and cellular events are highly complex and remain elusive [331]. The key 
question within the field is to address how endosomal-lysosomal storage leads to pathogenesis. 
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Nonetheless, LSDs provide a wealth of information about the normal functions of lysosomal 
proteins. The most common mutations causing LSDs occur in lysosomal enzymes, nonenzymatic 
lysosomal proteins, and nonlysosomal proteins that regulate lysosomal functions [331]. The 
degree of penetrance depends on the severity of the mutation; null mutations develop symptoms 
in utero or early on in childhood, while milder mutations can develop later in adulthood [331].  
 Some of the first LSDs to be clinically characterized were Gaucher disease and Tay-
Sachs disease in the 1880s [332]. Both Gaucher disease and Tay-Sachs disease are now 
classified as sphingolipidoses. In general, LSDs have distinct clinical and biochemical features, 
but are often classified based on the storage material that accumulates; mucopolysaccharidoses 
(MPS) accumulate mucopolysaccharides, sphingolipidoses accumulate sphingolipids, and 
oligosaccharidoses accumulate oligosaccharides. It is important to note that some LSDs have an 
accumulation of multiple substrates due to a deficiency in a single enzyme, largely due to the 
dysfunction in some of the common substrates. Additionally, LSDs are identified at a cellular 
level by the primary defect in the clearance of autophagic and endocytic substrates that lead to 
the formation of dense cellular inclusions filled with undigested material [333-335]. This 
undigested material seems to also lead to many secondary defects shared by many LSDs such as 
reduced autophagic flux, insufficient metabolic function, perturbed Ca2+ homeostasis in the ER 
and the mitochondria, increased reactive oxygen species, and impaired inflammatory and 
apoptotic signaling [336-339]. These secondary defects complicate matters for researchers trying 
to identify the root cause of each LSD and make it difficult to interpret the causative and 
underlying insults from the genetic mutation. These secondary defects also make it difficult to 
study LSDs in patient fibroblasts since they already have developed inclusions and secondary 
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defects, thereby obscuring the model system. Even with these chronic complications, the patient 
fibroblasts cells are nonetheless, indispensable for finding treatments.  
Strikingly, most LSDs are characteristically neurodegenerative in nature (except for 
Gaucher and Pompe diseases), resulting in mental retardation, progressive motor degeneration, 
retinopathies and shortened life spans. Lysosomal dysfunctions could arise from genetic 
mutations, lack of or mislocalized protein delivery, or misfolding. In some LSDs, a genetic 
mutation directly affects the activity of one lysosomal enzyme, such as glucocerebrosidase/ β-
glucosidase in Gaucher disease [340],  β-hexosaminidase A in GM2 gangliosidosis (Tay-Sachs), 
α-glucosidase in Pompe disease, or α–galactosidase A in Fabry disease [332]. While in other 
LSDs, a defect in a critical processing step can affect multiple enzymes, such as in multiple 
sulphatase deficiency (MSD), where a defect in the sulphatase-modifying factor- 1 gene 
(SUMF1) results in a defective enzyme responsible for generating the Cα-formylglycine residue 
that is the critical catalytic center of all sulphatases [341, 342].  In the same way, improper 
trafficking of lysosomal enzymes causes other LSDs. For example, in Mucolipidosis II and III, a 
mutation in the GNPTA (MGC4170) gene coding for the GlcNAc-1-phosphotransferase results 
in a defect in the M6P tag from the Golgi, and instead of lysosomal localization, the hydrolases 
are secreted out of the cell [343, 344]. LSDs are not exclusively due to defects in lysosomal 
enzymes, but can also arise from defects in lysosomal membrane proteins, such as in 
Mucolipidosis type IV (discussed in section 1.5.2), neuronal ceroid lipofuscinosis (NCLs, also 
known as Batten disease), cystinosis and Niemann-Pick C (NPC). NPC, for example, is caused 
by a defect in the cholesterol transporter NPC1, or by defects in the soluble lysosomal 
cholesterol binding protein NPC2 and is characterized by impaired sphingolipid and cholesterol 
levels [345]. Cystinosis, on the other hand, results due to a mutation in cystinon, a cystine 
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transporter, which subsequently leads to the buildup of the amino acid cystine inside lysosomes 
[346]. In these diseases, mutations in lysosomal membrane proteins have demonstrated the 
importance of maintaining the lysosomal environment, and have added complexity to the 
dynamics of how we look at lysosomes and LSDs.  
1.5.2 Mucolipidosis type IV.   
Unlike most other LSDs that arise from lysosomal enzyme deficiencies, Mucolipidosis type IV 
(MLIV) occurs from loss-of-function mutations in MCOLN1, a gene encoding the lysosomal ion 
channel transient receptor potential mucolipin 1 (TRPML1). MLIV was first described in 1974 
[347]. It was subsequently found to be autosomal recessive, and to predominantly occur among 
the Ashkenazi Jewish population with a carrier frequency of 1 in 100 [348, 349], but it has also 
been reported in non-Jewish populations [350, 351]. As of 2014, over 20 different TRPML1 
mutations have been identified, but the two founder mutations account for over 95% of MLIV 
cases [352, 353]. Most of the mutations result in loss of TRPML1 channel, but a few affect 
channel localization or function [354, 355]. Some splice variants have been reported, but their 
function or regulation is uncharacterized [356, 357]. MLIV is a developmental and degenerative 
disorder with the onset beginning within a year of birth and patients presenting with severe 
motor and mental impairment, corneal clouding and progressive retinal degeneration, 
achlorhydria (low production of gastric acid, but elevated plasma gastrin levels), anemia, and a 
thin corpus collosum [355]. Most MLIV patients are unable to walk by their early teens, have 
limited or no ability to speak, and have severe vision loss or blindness.  
Electron microscopy of patient fibroblasts showed enlarged vacuolar structures, or 
inclusions, that accumulate mucopolysaccharides, sphingolipids and phospholipids in 
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multiconcentric lamellae [347, 358, 359]. This suggests that the loss of TRPML1 affects many 
different lysosomal hydrolases and likely affects the lysosomal environment. It is difficult to 
reach conclusions about the pathology from these inclusions since it has been reported that they 
vary from tissue to tissue [360, 361]. This variation could be due to cell type specific 
transcriptional profiles, and/ or to cell type specific reactions to TRPML1 loss. The presence of 
these inclusions or vacuoles in parietal cells, for example, could explain the achlorhydria seen in 
MLIV patients. Parietal cells normally produce gastric acid in the stomach epithelium, but 
TRPML1 loss could result in defects in the endocytic pathway or exocytosis, and lead to 
decreased gastric acid secretion [362]. Similarly, in retinal epithelial cells these vacuoles or 
inclusions could be causing the vision loss or be a factor in neurodegeneration in neurons. 
However, no correlation between the number of inclusions and the severity of the MLIV 
symptoms has been observed. Thus, it is unclear whether the formation of these inclusions and 
vacuoles is the primary insult as a result of TRPML1 loss, or a secondary defect. Delineating cell 
type specific responses and understanding TRPML1 function will provide insights into TRPML1 
cell type-specific roles and an understanding of how cells respond to different endocytic loads 
and insults.  
The MCOLN1 gene, coding for the TRPML1 channel, was cloned by three labs in 2000 
[363-366]. Since then, several orthologues have been discovered in Drosophila (trpml), C. 
elegans (cup-5) and mice. In humans, TRPML1 is predicted to roughly be 65 kDa. Although no 
crystal structure of TRPML1 exists, it is predicted to have 6 transmembrane domains, a putative 
transient receptor potential (TRP) channel pore domain between the fifth and sixth 
transmembrane domains, an N- and C- terminus orientated towards the cytosol [355], and a 
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large, highly N-glycosylated loop between the first and second transmembrane domains in the 
lysosomal lumen that gets cleaved by Cathepsin B (Figure 6) [367].  
 The TRP family of ion channels includes TRPA, TRPC, TRPM, TRPML, TRPV and 
TRPP [368]. Most TRP channels respond to extracellular stimuli such as temperature, light, 
mechanical stress, and osmolarity, but a few respond to intracellular stimuli such as pH or ion 
concentrations [369]. Several TRP channels localize to endosomal compartments, but TRPML1 
is the first member of the TRP superfamily to localize to late endosomes and lysosomes [367, 
370]. Trafficking of TRPML1 requires two acidic di-leucine motifs at the N- and C- terminus of 
the protein. The E11TERLL motif at the N-terminus interacts with the clathrin adaptors AP1 and 
AP3 to sort TRPML1 directly from the TGN to the lysosomes. However, TRPML1 is also sorted 
indirectly from the TGN to the plasma membrane, and then to the lysosome through endocytosis 
and AP2 binding to the E573EHSLL motif within the C-terminus [371]. TRPML1 also has two 
proline-rich regions (aa 28-36, and 197-205), and a lipase serine active site domain (aa 104-114). 
Additionally, TRPML1 does not seem to have ankyrin repeats like other TRP channels, but it has 
been shown to be phosphorylated by PKA-domains [372]. Lastly, TRPML1 has been reported to 
homo- and hetero-multimerize with its two homologues TRPML2 and TRPML3 [373, 374]. 
TRPML2 and TRPML3 also localize to endosomes and lysosomes. It is not known whether any 
of the MLIV symptoms might be due a mislocalization of TRPML3, for example, instead of just 
TRPML1 loss. There is very little evidence from co-localization studies of the native protein, 
possibly due to a short-half life in the lysosome, or a lack of good antibodies. Further work on 
the structural determinants of TRPML1 will fully explain TRPML1 function. 
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Figure 6. TRPML1 predicted structure.  
Model illustrating TRPML1 topology and some of the identified structural features. TRPML1 localizes to late 
endosomes and lysosomes and has been shown to be permeable to Na+, K+, Ca2+, Fe2+ /Mn2+, and potentially Zn2+. 
Mutations in TRPML1 cause MLIV.  
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Even with the severe pathology of MLIV, TRPML1 functions remain unclear. The first 
study on the cation-selective channel activity by TRPML1 was published in 2002 and examined 
the activity of a MCON1 cDNA transfected into either Xenopus oocytes or HEK-293 cells [375]. 
In both cases, the study confirmed permeability to Na+, K+, and Ca2+ [375]. Two years later, 
another group showed that in a lipid bilayer system, TRPML1 is a pH-dependent cation channel 
and postulated that TRPML1 regulates the vesicular membrane potential by switching off at low 
pH and thus, it was concluded that mutated TRPML1 cannot shut off at low pH [354]. Since 
then, TRPML1 channel activity has been recorded on native endolysosomal membranes by direct 
lysosomal patch-clamp studies of enlarged (vacuolin-treated) lysosomes. These studies made use 
of a constitutive active TRPML1 mutant (V432P) to show that TRPML1 is an inwardly 
rectifying (from the lysosomal lumen to the cytoplasm) channel permeable to Na+, K+, Ca2+, Fe2+ 
/Mn2+, and potentially Zn2+ [376]. This 2008 study identified TRPML1 as an endolysosomal iron 
release channel, whose activity may be potentiated by low pH.  
Since TRPML1 function is so poorly understood. At first, the main physiological 
function of TRPML1 was thought to facilitate Ca2+ efflux necessary for SNARE-mediated endo-
lysosomal membrane fusion. This “traffic-,” or “biogenesis” model for TRPML1 function 
proposes that TRPML1 directly regulates membrane traffic and in the absence of TRPML1, 
endocytic material (lipids and proteins) targeted for degradation accumulate. Several studies 
have shown delays in lipid trafficking in MLIV models ranging from MLIV fibroblasts [370, 
377] to C. elegans [218, 378]. Support for this model is based on the observation that TRPML1-
deficient cells delay trafficking of a fluorescent BODIPY conjugate, C5-lactosylceramide 
(LacCer) [370, 379, 380], as well as defects in lysosomal biogenesis, increased colocalization of 
endosomal and lysosomal markers, and the accumulation of vacuolar structures in CUP-5 
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knockout C. elegans [378, 381]. TRPML1 loss has been also associated with lipofuscin 
accumulation [382, 383], decreased lysosomal exocytosis [272], and deficient autophagy [372]. 
Additionally, MLIV fibroblasts, mouse neurons, and Drosophila knockouts have defective 
chaperone-mediated as well as macro-autophagy and accumulate autophagososmes, effete 
mitochondria, ubiquitinated aggregates, and p62 protein inclusions [372, 382-385]. It is not clear 
whether these defects in membrane trafficking and lipid metabolism are the primary cause of 
MLIV, or an added complexity due to secondary effects of undigested material. It is likely that 
the buildup of undigested material prevents the delivery of trafficking markers into lysosomal 
compartments by “clogging” membrane traffic and appears as defects in membrane traffic, 
clouding the possible primary cause of MLIV pathogenesis. An example of this occurred in 
sphingolipidoses where a metabolic defect had multiple membrane traffic delays similar to the 
ones observed in MLIV [386]. Thus, to fully understand MLIV pathogenesis and TRPML1 
function, it is imperative to distinguish the acute primary deficits from the more chronic, 
secondary compensatory side effects. To directly address this problem, two labs at the University 
of Pittsburgh, led by Drs. Ora Weisz and Kirill Kiselyov, utilized an siRNA-driven TRPML1 
knockdown system in HeLa cells in 2008 to determine the immediate effects of TRPML1 loss 
[387]. Interestingly, they confirmed the accumulation of inclusions and decreased lysosomal pH 
in this system, but found no trafficking delays [387]. 
Thus the second “metabolic,” model prevailed. This model suggests that TRPML1 
regulates ion homeostasis and directly impacts the activity of lysosomal enzymes. Under this 
paradigm, loss of TRPML1 decreases lysosomal digestive function by affecting lysosomal ion 
concentrations. Support for this model comes from several key observations made over the last 
couple of years. To begin with, Dong et al. recently showed that TRPML1 directly binds and is 
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activated by PI(3,5)P2 [388, 389], an endolysosomal specific phosphoinositide. This suggested 
that TRPML1 is active in the lysosome and provided insight into the spatial and mechanistic 
regulation of endolysosomal dynamics as well as of TRPML1 Ca2+ release. Additiomal details 
were revealed when the penta-EH-hand protein ALG-2 has been found to bind both PI(3,5)P2 
and TRPML1 only when Ca2+ is present [390]. The current hypothesis is that ALG-2 acts as a 
Ca2+ sensor to modulate trafficking events through TRPML1. Moreover, TRPML1 might 
regulate the activity of other lysosomal transporters such as the two-pore family of ion channels 
(TPC). TPCs are Na+ channels in endosomes and lysosomes. Pharmacological inhibition of TPC 
activity has been shown to rescue enlarged lysososmes in TRPML1-deficient cells, further 
implicating TRPML1 as a regulator of TPCs [197, 290, 391, 392]. More support for the 
“metabolic” model of TRPML1 function comes from the observation that TRPML1-deficient 
cells buildup Zn2+ inside lysosomes [393]. Eicheisdoerfer et al. showed that an RNA interference 
model of MLIV in HEK-293 cells leads to chelatable Zn2+ inside the lysosomes of TRPML1-
deficient cells [393]. They also showed that MLIV patient fibroblast cells had increased levels of 
Zn2+.  
In sum, TRPML1 is a lysosomal divalent metal transporter that seems to modulate key 
lysosomal functions. TRPML1 regulates the ionic environment within the lysosomal lumen and 
in doing so, affects lysosomal acidification and the delivery and activation of lysosomal 
enzymes. Due to its permeability, TRPML1 may also regulate membrane fusion events and key 
aspects of transition metal trafficking from lysosomes into the cytoplasm. The latter has gained a 
lot of attention in the recent years.  
Transition metal toxicity has been linked to lysosomal storage phenotypes [394, 395] and 
LMP [396]. Transition metals such as Zn2+, Ni2+, Cu2+, Co2+, Fe2+, and Fe3+ can be delivered to 
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lysosomes either from the cytoplasm through lysosomal transporters, or as byproducts through 
the endocytic pathway. During endocytosis, cells engulf extracellular content as well as 
transition metal-bound proteins that are degraded along the way to the lysosome, releasing the 
potentially toxic metals. Some transition metals such as Fe3+ can undergo Fenton-like reactions 
and produce free radicals that can lead to LMP [397, 398]. It is tempting to hypothesize that 
TRPML1 might have a role in dissipating transition metal buildup in lysosomes. There are 
several well-known transporters with this activity. SLC11A1 (NRAMP1) and SLC11A2 
(NRAMP2, also known as DMT-1) are divalent cation transporters implicated in lysosomal 
metal trafficking [399, 400] (Figure 5). However, based on the recent findings by Eicheisdoerfer 
et al. and Dong et al., it is likely that there are other metal export mechanisms and unidentified 
channels maintaining lysosomal ion homeostasis. As intriguing as this possibility is, it still leaves 
many questions to be answered. The role of TRPML1 in transition metal toxicity will need to be 
further dissected, and it would be interesting to see the relative contribution of TRPML1 
compared to the known metal transporters such as DMT-1 and TPCs. How are their localization 
and/or activation affected by TRPML1 loss? What activates the TRPML1 transport activity and 
what structural determinants are important for this activity? Is there a TRPML1 dependent 
correlation between inclusion bodies and transition metal toxicity? Addressing these and other 
questions will greatly expand the current knowledge of lysosomal function and lysosomal ion 
transport pathways.  
1.5.3 Lysosomal dysfunction and neurodegenerative diseases.   
Many of the pathologies associated with LSDs, such as defects in autophagy, intracellular 
substrate aggregation and inflammation, also occur in neurodegenerative diseases such as 
 47 
Alzheimer’s, Parkinson’s and Huntington’s [401]. In fact, recent evidence shows that 
neurodegeneration is often associated with lysosomal dysfunction [402, 403]. Neurons in 
particular, are especially sensitive to perturbations in lysosomal function or autophagy, and it has 
been shown that suppression of basal autophagy in mice leads to neurodegeneration [404, 405].  
 Alzheimer’s disease (AD) is one of the most common forms of dementia. Sadly, it is 
progressive with age, results in death, and there is currently no cure. Recent observations have 
implicated lysosomal function in this disease [406]. In AD, amyloid-β peptides aggregate in and 
affect the function of neurons [407]. Recent work by Li et al., showed that endocytic trafficking 
of amyloid-β to lysosomes for degradation is a major clearance pathway [408]. Furthermore, 
presenilin 1 (PS1), the transmembrane protein mutated in AD, has been shown to be essential for 
v-ATPase delivery to lysosomes, and consequently, essential for lysosomal acidification and 
proteolysis during autophagy [409]. PS1 was found to be required for N-glycosylation of the 
V0a1 subunit of the v-ATPase. Mutations in PS1 lead to defective lysosomal and autophagic 
degradation, and early-onset AD [410, 411]. However, another study recently showed that PS1 
mutations affect lysosomal function not by changing lysosomal acidification per se, but rather by 
disrupting Ca2+ homeostasis, and thereby lysosomal fusion [412]. Lastly, cystatin B is an 
endogenous inhibitor of lysosomal cystein proteases, and cystatin B knockout mice rescue 
amyloid-β aggregation, accumulation of ubiquitinated proteins and other autophagic substrates, 
and reverse the learning and memory defects seen in AD [413], further supporting the role of 
lysosomal function in neurodegeneration.   
 Lysosomal dysfunction is also associated with Parkinson’s disease (PD) where 
dopaminergic cell death and autophagosome accumulation are prevalent. One of the earliest 
insults in PD is a drastic decrease in the expression of the lysosomal proteins LAMP1 and 
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LAMP2 and lysosomes [414, 415]. This results in lysosomal membrane permabilization, likely 
induced by the accumulation of ROS generated by mitochondria, and results in the accumulation 
of autophagosomes, as well as cell death due to the release of lysosomal proteases into the 
cytoplasm [414]. Strikingly, both genetic, and pharmacological induction of lysosomal 
biogenesis through TFEB activation attenuates cell death by increasing lysosomal function and 
autophagic clearance [414]. Another characteristic feature of PD is the accumulation of α–
synuclein. α–synuclein is normally degraded by chaperone-mediated autophagy [416], but 
accumulates in PD. It was recently found that reduced expression and activity of 
glucocerebrosidase (the enzyme mutated in Gaucher’s disease), lead to α–synuclein 
accumulation [417], providing a link between LSDs and PD. These findings further emphasize 
the key role of lysosomal enzymes in the pathology of neurodegenerative disorders.  
1.5.4 Therapeutic strategies for lysosomal dysfunctions.   
There is currently no treatment for MLIV. Individuals are diagnosed by a blood test to confirm 
elevated gastrin levels (the cause of which still remains unknown) and mutations in MCOLN1 
[334]. Some symptoms may be alleviated through iron supplements to treat anemia, or corneal 
transplants to temporarily correct corneal clouding. Intensive physical therapy as well as 
occupational, speech and vision therapies are recommended to help with life skills and ataxia.  
 The search for therapies for lysosomal storage disorders is ongoing, disease specific, and 
difficult given that the biochemical and molecular basis for the diseases are still being 
discovered. Several attempts were made to treat animal models of LSD and neurodegenerative 
diseases by enhancing lysosomal and autophagic function [413, 414, 418, 419]. An exciting and 
promising recent therapeutic avenue became available with the discovery of TFEB. The 
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possibility to enhance cellular clearance by inducing TFEB function is very appealing. Indeed, 
TFEB overexpression has been shown to effectively clear storage material in cell models of 
Pompe’s, Batten, MSD, and MLIV disease [273]. TFEB also cleared storage material in in vivo 
mouse models of MSD and Pompe’s disease [273, 420] and has been used to promote clearance 
in neurodegenerative diseases such as Parkinson’s [414] and Huntington’s disease [421]. It is not 
exactly clear how TFEB is able to do this. TFEB mediated rescue of LSDs occurs even with 
lysosomal enzyme deficiency. The current evidence indicates that TFEB activates lysosomal 
exocytosis [273], thereby secreting the stored material out of the cells. It is likely that TFEB 
rescue is achieved through a combination of lysosomal biogenesis, autophagy and lysosomal 
excoytosis. As enticing as pharmacological manipulation of TFEB seems for therapeutics, long-
term studies will need to be done to fully understand the effects of TFEB overexpression. 
Furthermore, since the stored material is secreted out of the cell, its toxicity within circulating 
blood and their effects on the brain will clearly need to be addressed. A greater understanding of 
the molecular details in disease pathogenesis will lead to better diagnostic and therapeutic tools. 
As such, lysosomes are attractive targets because of their emerging roles in nutrient sensing, 
signaling, metabolism, and transition metal toxicity. 
1.6 DISSERTATION AIMS 
In the above sections, I have described the current state-of-knowledge of lysosomal and cellular 
zinc homeostasis. From these descriptions, it is clear that several questions have been raised but 
remain unanswered. For example, what is the function of TRPML1 and what does its zinc-
permeability have to do with lysosomal function or MLIV pathogenesis? Is the zinc 
 50 
dyshomeostasis a secondary defect due to endocytosis and autophagy, or is it directly related to 
TRPML1 function? Could this zinc dyshomeostasis be related to MLIV pathogenesis? What 
signals modulate TRPML1 function? Furthermore, if lysosomes are the main degradative 
compartment of the cell, then why and how do they regulate cellular metal ion homeostasis? My 
research has provided insights into these questions and a broader understanding of TRPML1 and 
lysosomal function. 
The first aim of my research was to determine the role of TRPML1 in zinc homeostasis. 
To this end, I have used the now well-established model system from our lab of siRNA-mediated 
knockdown of TRPML1 to address this question. These studies revealed that in the absence of 
TRPML1, lysosomes expand in size and accumulate zinc. The source of this zinc appears 
cytoplasmic and not endocytic or autophagic, since the zinc accumulation and lysosomal 
enlargement are dependent on the lysosomal zinc transporter ZnT4. Furthermore, TRPML1 
appears to be a zinc leak pathway, transporting zinc from the lysosome into the cytoplasm. 
Reassuringly, the zinc dyshomeostasis observed in TRPML1 knockdown cells also occurs in 
MLIV patient fibroblasts, and these studies have begun to establish the zinc-binding protein, 
metallothionein 2A, as a biomarker for MLIV.  
 The second aim of my research was to understand why zinc accumulates in lysosomes. 
Many published studies have shown Zn2+ buildup in lysosomes and some have even identified 
the molecular machinery that transports zinc in and out of lysosomes. But, given the 
susceptibility of lysosomal damage and the grave consequences that this would ensue for cells, it 
was unclear why lysosomal zinc accumulation occurred in cells. I was able to address this 
question through the use of pharmacological and siRNA-mediated knockdown of the molecular 
machinery regulating these processes. These studies provided not only a novel zinc 
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detoxification pathway, as well as a toolbox for zinc secretion research, but also uncovered a 
deeper understanding and a new role for lysosomal exocytosis. Specifically, my analysis 
revealed that under moderate zinc exposure, lysosomes function as zinc sinks, temporarily 
sequestering higher zinc levels from the cytoplasm in order to avoid apoptosis. This zinc is then 
expelled out of the lysosomes through an excocytosis mechanism that is dependent on the 
lysosomal SNAREs VAMP7 and SYT7. However, under higher zinc loads, lysosomal zinc 
sequestration is overloaded, leading to lysosomal membrane permeabilization and cell death. 
Cumulatively, my thesis research has provided a detailed characterization of a number of factors 
involved in lysosomal zinc homeostasis. 
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2.0  ZINC-DEPENDENT LYSOSOMAL ENLARGEMENT IN TRPML1-DEFICIENT 
CELLS INVOLVES THE MTF-1 TRANSCRIPTION FACTOR AND ZNT4 (SLC30A4) 
TRANSPORTER  
The work discussed in this Chapter has been adapted from published material and is reprinted, 
with alterations, by permission from the Biochemical Journal.: 
Ira Kukic, Jeffrey K. Lee, Jessica Coblentz, Shannon L. Kelleher, and Kirill Kiselyov, “Zinc-
dependent lysosomal enlargement in TRPML1-deficient cells involves the MTF-1 transcription 
factor and ZnT4 (Slc30a4) transporter.” Biochemical Journal. 2013; 451: 155-163 © the 
Biochemical Society. 
2.1 INTRODUCTION 
Transition metals, including Zn2+, are widely recognized for their toxic effects caused by acute 
and chronic exposures, albeit most of the transition metals are indispensable for proper cell 
function. Zn2+ has the widest repertoire of known biological roles, which include a cofactor in 
several enzymes and DNA-interacting proteins [12, 422]. Zn2+ deficiency, as well as excess, has 
been shown to be deleterious for cells [423, 424], prompting the need for tight regulation of its 
cellular levels. Such regulation is carried out by a system of transporters, chelating proteins and 
Zn2+ -sensitive transcriptional responses [91, 425, 426].  
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Zn2+ enters the body through enterocytes, primarily through Zip4, a member of the Zip 
(Slc39a) family of Zn2+ transporters [427, 428]. From the enterocyte cytoplasm, Zn2+ moves into 
the bloodstream through a series of transporters including those belonging to the ZnT (Slc30a) 
family [91, 429]. In general, Zip transporters are responsible for influx of Zn2+ into the 
cytoplasm, while ZnT transporters for its efflux. In the bloodstream, Zn2+ is taken up by cells via 
Zip transporters, and by the endocytosis of Zn2+ bound to plasma proteins. After entering the 
cytoplasm, Zn2+ is chelated by cytoplasmic proteins, such as metallothioneins (MTs) [430], and 
extracted into organelles or across the cell membrane by ZnT transporters. For example, ZnT2 
and ZnT4 transporters are localized in intracellular vesicular compartments, including 
lysosomes. They play important roles in vesicular Zn2+ accumulation [431-433]. The reason for 
Zn2+ chelation and extraction is twofold. First, high levels of Zn2+ are damaging to cells [423, 
424]. Second, a number of biological processes requiring Zn2+ take place inside organelles, 
necessitating Zn2+ transport across the organellar membranes [91, 434]. MTs also serve as Zn2+ 
reservoirs, releasing chelated Zn2+ under low- Zn2+ conditions [425].  
The balance between ZnTs, Zips and MTs is responsible for the net Zn2+ flux and for the 
free cytoplasmic Zn2+ concentration in the given cell type. Zn2+ spikes, driven by variations in 
dietary Zn2+ uptake, are read by Zn2+-responsive transcription factors including MTF-1, which 
binds cytoplasmic Zn2+ through its Zn2+-finger motifs leading to its nuclear translocation [435]. 
Upon activation by cytoplasmic Zn2+, MTF-1 induces the transcription of genes coding for MTs 
and some ZnTs, such as ZnT1 and ZnT2 [88, 436]. This feedback system allows cells to rapidly 
quench spikes in free cytoplasmic Zn2+. The combined activity of Zn2+ transporters and chelators 
keeps free Zn2+ concentration in the nanomolar range.  
 54 
The recent identification of Zn2+ permeability through the lysosomal ion channel 
TRPML1 [376] raised the possibility that this ion channel is involved in Zn2+ transport. This 
notion was later supported by the finding that Zn2+ builds up in the lysosomes of TRPML1-
knockdown (KD) cells [393]. TRPML1 is an ion channel residing in the later portions of the 
endocytic pathway due to the presence of lysosomal localization signals on its C- and N- 
terminals [437, 438]. TRPML1 is encoded by the MCOLN1 gene, which was identified as the 
gene mutated in the lysosomal storage disease mucolipidosis type IV (MLIV) [439, 440]. MLIV 
is associated with the buildup of cytoplasmic storage bodies, motor dysfunction and 
developmental delays [355, 441, 442]. The recent characterization of TRPML1 activation by 
PI(3,5)P2 [388] suggested its activation by delivery to the PI(3,5)P2-rich lysosomes and late 
endosomes [440]. The discussion of TRPML1 function has been focused on its role in the fusion 
of vesicles in the endocytic pathway (reviewed in [440]), and, recently, lysosomal secretion 
[273]. At the same time, the evidence of Fe2+ and Zn2+ permeability through TRPML1 [376] 
raises an interesting possibility that it plays a role in regulating cellular transition metal levels.  
Here, we sought to delineate the mechanism through which TRPML1 participates in 
cellular Zn2+ homeostasis. We based our search on the assumption that if TRPML1 is directly 
involved in the regulation of Zn2+ transport, then, cellular Zn2+ trafficking and Zn2+ dependent 
processes should change as a function of TRPML1 status. Our assays show that both of these 
assumptions are true, strongly suggesting that TRPML1 is involved in the regulation of cellular 
Zn2+ homeostasis. We found that the effects of Zn2+ in TRPML1 KD cells included a 
characteristic lysosomal enlargement. The Zn2+-sensing cytoplasmic transcription factor MTF-1 
plays a key role in this process, as MTF-1 KD reversed Zn2+-dependent lysosomal enlargement 
in TRPML1 KD cells. Suppressing the expression of the vesicular Zn2+ transporter ZnT4 
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eliminated the Zn-induced lysosomal enlargement and Zn2+ retention in TRPML1-deficient cells. 
Pulse-chase experiments with extracellular Zn2+ show that Zn2+ clearing from vesicular 
structures including lysosomes is delayed in TRPML1 KD cell. However, Zn2+ secretion was not 
decreased in these cells; instead, it was somewhat increased. We conclude that TRPML1 works 
in concert with ZnT4, to regulate lysosomal Zn2+ trafficking, perhaps by providing a lysosomal 
Zn2+ leak pathway. This is supporting evidence of the novel role of TRPML1 in regulating 
cellular transition metals and TRPML1 as a new target in transition metals toxicity.  
2.2 EXPERIMENTAL METHODS 
2.2.1 Cell Culture 
HeLa cells were maintained in DMEM (Sigma-Aldrich, St Louis, MO) supplemented with 7% 
FBS, 100 µg/ml penicillin/streptomycin, and 5 µg/ml Plasmocin prophylactic (Invivogen, San 
Diego, CA). For siRNA and cDNA transfection, antibiotic free media was used. Metals were 
added directly to the DMEM. Zn2+ (100 µM) was added to antibiotic free medium, containing 
serum, 24 hrs after transfection, for 48 hrs.  
2.2.2 siRNA-mediated KD and plasmid transfection 
ON-TARGET plus siRNA were designed as described previously [387, 443] and synthesized by 
Dharmacon (Lafayette, CO). The TRPML1 siRNA probe targeting the sequence 5'-
CCCACATCCAGGAGTGTAA-3' in MCOLN1 was used for all TRPML1 KDs. The MTF-1 
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siRNA (Cat number SASI_Hs01_00177112), ZnT2 siRNA (Cat number 
SASI_Hs01_00055662), and ZnT4 siRNA (Cat number SASI_Hs00225995) were from Sigma. 
Non-targeting control siRNA#1 (Sigma) was used as a negative control. Cells were transfected 
using Lipofectamine 2000 (Invitrogen, Carlsbag, CA) as described by manufacturer’s protocol 
using 600 nM siRNA per 35 mm well. All KDs were confirmed using SYBR-green based qPCR. 
For DNA transfections, 2 µg of HA-tagged human ZnT2 or ZnT4 were used in parallel with 1 µg 
of GFP tagged TRPML1 constructs.  
2.2.3 Reverse Transcriptase and Quantitative qPCR 
RNA was isolated from cells using Trizol (Invitrogen) according to the manufacturer’s protocol. 
cDNA was synthesized using the GeneAmp RNA PCR system (Applied Biosystems, Carlsbad, 
CA) with oligo dT priming. qPCR was performed SYBR green (Fermentas, Glen Burnie, MD). 
The amount of cDNA loaded was normalized to starting RNA concentrations, with a final 
concentration of 9 ng (40 ng in ZnT experiments) of RNA loaded per experimental well. Six-
point standard curves were generated for each primer using 1:2 dilutions of cDNA. cDNA for the 
following genes were amplified using the indicated primers (IDT, Coralville, IA).  
MCOLN1: forward:  5’-TCTTCCAGCACGGAGACAAC-3’,  
reverse: 5’-AACTCGTTCTGCAGCAGGAAGC-3’.  
MT2a: forward: 5’-AAGTCCCAGCGAACCCGCGT-3’,  
reverse: 5’-CAGCAGCTGCACTTGTCCGACGC-3’.  
MTF-1: forward: 5’-GCCATTTCGGTGCGATCACGAT-3’,  
reverse: 5’-TTTCACCAGTATGTGTACGAACGTGAGT-3’.  
ZnT2 (SLC30A2): forward: 5’-GCAATCCGGTCATACACGGGAT-3’,  
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reverse: 5’- CAGCTCAATGGCCTGCAAGT-3’.  
ZnT4 (SLC30A4): forward: 5’- CACATACAGCTAATTCCTGGAAGTTCATCT-3’,  
reverse: 5’- GCCTGTAACTCTGAAGCTGAATAGTACAT-3’.  
 All primers were designed to span exons and negative RT controls were tested to ensure 
amplification of cDNA only. qPCR was performed using the Standard Curve method on the 
7300 Real Time System (Applied Biosystems). Reactions were run on the following parameters: 
2 min at 50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 sec followed by 60°C for 1 min. All 
experimental samples were run in triplicate and normalized to a β-actin endogenous control.  
2.2.4 Microscopy 
Cells were seeded on glass coverslips and loaded with dyes for 15 min at 37ºC in buffer 
containing, in mM: 150 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4, 1 g/L glucose. The 
loading was followed by 15 min washout in all cases except TSQ. Lysotracker Red DND-99, 
FluoZin-3,AM, TSQ (Sigma) were used at 0.1, 0.1, and 150 µM respectively. Confocal 
microscopy was performed using Leica TCS SP5 and BioRad 3000 confocal microscopes. Live 
cells were treated as above. For colocalization experiments, cells were fixed for 5 min in 4% 
paraformaldehyde at room temperature and permeabilized using 0.1% Triton X100 for 5 min on 
ice. Following washout and blocking in BSA and goat serum, cells were treated with primary 
anti-HA antibody (Roche, 12CA5) overnight. Cells were then incubated in fluorescent-tagged 
secondary antibodies for 1 hr. Images were analyzed using ImageJ (Bethesda, MD). 
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2.2.5 β-Hexosamindase activity assay 
Untreated control and TRPML1 siRNA-transfected cells were washed with 37ºC PBS and 1 mL 
37ºC serum-free DMEM was added to each 35mm dish. For each sample, 100 µl of the 
supernatant was incubated with 400 µl 1mM 4-nitrophenyl N-acetyl-β-D-glucosaminide (Sigma, 
N9376) for 1 hour at 37ºC in 0.1M citrate buffer (pH 4.5) (Sigma, C2488). This volume was 
replaced with fresh 37ºC 100 µl of DMEM to the dish. Samples were collected every hour for 4 
hours. Reactions were stopped by adding 500 µl borate buffer (100 mM boric acid, 75 mM NaCl, 
25 mM sodium borate, pH 9.8) and the absorbance was measured in a spectrophotometer at 405 
nm. To determine total cellular content of β-hexosamindase, cells were lysed with 1mL 1% 
Triton X-100 and after a 10000g spin for 5 minutes at 4ºC, 100 µl of the cell extracts were used 
for the enzyme activity reaction. Enzyme activity was determined as the amount of 4-nitrophenol 
produced per mg of protein (Bradford method). Absorbance was calibrated with different 
amounts of 4-nitrophenol (Sigma, N7660) in 0.1 M citrate buffer. 
2.2.6 Zinc secretion assay 
Control, TRPML1 and MTF1 siRNA-transfected cells were plated on a 12 well plate and after 48 
hours, pulsed with 100 µM Zn for 3 hours, washed twice with warm PBS, and chased in 1mL 
DMEM per well. Duplicate time-points were collected for 0, 5, 15, 30 or 60 minutes. For each 
sample, 50 µl of supernatant was placed in a 96-well plate. Zn content was measured by 
incubating the supernatants with 10 µM cell-impermeant FluoZin-3 tetrapotassium salt 
(Molecular Probes, Invitrogen F-24194) for 15 minutes at 37oC. The 96-well plate was read via a 
FujiFilm FLA-5100 fluorescent image analyzer. After the last time point, cells were washed with 
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PBS, 200 µl detergent solution was added to lyse the cells and fluorescence was normalized to 
total protein in each sample. 
Statistical significance was calculated using a one-tailed, unpaired t-test with p≤0.05 
considered significant. Data are presented as mean±S.E.M. 
2.3 RESULTS 
2.3.1 Zinc-dependent lysosomal enlargement in TRPML1 KD cells 
Since Zn2+ dyshomeostasis has been reported in TRPML1-KD cells [393], we sought to delineate 
mechanisms linking TRPML1 loss, Zn2+ dysregulation, and vacuolar enlargement in TRPML1-
KD cells. In order to test how TRPML1 loss affects cells exposed to Zn2+, we used TRPML1-
specific siRNA described before [387, 443]. The siRNA-mediated KD resulted in more than 
85% KD of TRPML1 mRNA, as confirmed by qPCR with TRPML1 specific primers (Figure 7). 
In the previous studies utilizing the same system, the same siRNA resulted in almost complete 
elimination of TRPML1 protein, within the same time scale [387, 443].  
TRPML1 KD cells were previously reported to contain enlarged Zn2+-positive organelles 
[393]. We performed live-cell confocal analysis of control and TRPML1-KD HeLa cells stained 
with the Zn2+ selective dyes TSQ and FluoZin-3,AM, in conjunction with the lysosomal dye 
Lysotracker. Figure 8 A shows that, while Zn2+ is barely detectable in Lysotracker-positive 
compartments in untreated control cells, such compartments displayed TSQ fluorescence in cells 
treated with 100 µM Zn2+ for 48 hrs. We did not consistently detect enlarged Lysotracker-
positive compartments in TRPML1-KD cells until these cells were treated with Zn2+. Following 
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Zn2+ treatment, large compartments positive for Zn2+ (TSQ) and Lysotracker were abundant in 
TRPML1 KD cells (Figure 8A). Figure 8B shows similar analysis of Zn2+ in control and 
TRPML1-KD cells, performed using Lysotracker and another Zn dye, FluoZin-3,AM. The 
enlarged Lysotracker-positive vesicles in Zn2+ treated TRPML1-KD cells also displayed bright 
FluoZin-3 fluorescence, consistent with high concentrations of Zn2+. Interestingly, FluoZin-3 
signal was also detected in Lysotracker-negative vesicles, consistent with our previous 
observations of non-lysosomal Zn2+ pools in mammary cells [444, 445], which was more 
commonly observed in Zn2+-treated TRPML1-KD cells than in Zn2+-treated control cells (Figure 
7B). The lysosomal enlargement trend in Zn2+-treated TRPML1-KD cells persisted over 96-hr 
period (not shown).  
The fact that TRPML1-KD cells treated with Zn2+ and stained with TSQ show 
cytoplasmic fluorescence (Figure 8A), while FluoZin-3,AM-stained cells do not (Figure 8B), can 
be explained by the nature of these dyes’ fluorescence and interaction with Zn2+. In the 
cytoplasm, Zn2+ is bound to proteins such as MTs and very little Zn2+ is present in free ion form. 
MTs bind large amounts of Zn2+ (up to 7 ions per molecule), with very high affinity (pM range) 
[446]. Both TSQ and FluoZin-3 are sensitive to Zn2+ in mid- to high-nanomolar range. However, 
unlike FluoZin-3, which only fluoresces when bound to more labile Zn2+, TSQ fluoresces even 
when in a complex with metalloproteins such as MT-Zn [447, 448]. Therefore, the difference 
between TSQ and FluoZin-3 stains may reflect large amounts of Zn2+ ions bound in Zn2+-treated 
TRPML1-KD cells to cytoplasmic proteins such as metallothionein 2a (MT2a).  
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Figure 7. siRNA-mediated TRPML1 KD.  
qPCR results demonstrating TRPML1 KD. mRNA levels are expressed as percentile of control levels. Represents 6 
experiments. * represents p<0.05. 
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Figure 8. Zn2+ accumulation and enlargement of Lysotracker positive compartments in TRPML1-deficient 
Zn2+ treated cells. 
Confocal images of HeLa cells stained with Lysotracker and with TSQ (A) or FluoZin-3,AM (B). A. Cells costained 
with Lysotracker and TSQ. Control cells were transfected with scrambled siRNA. TRPML1 KD cells (ML1-) were 
transfected with TRPML1 siRNA, and treated with Zn2+ 24 hrs later. Zn2+ treatment took place over 48-hr period. N 
indicates nuclei; arrows point to enlarged Lysotracker and TSQ-positive compartments. Note enlargement of 
Lysotracker-positive compartments and presence of bright TSQ fluorescence inside them. B. Similarly treated cells 
costained with Lysotracker and FluoZin-3,AM. Each panel represents 3-5 individual experiments. Arrows point to 
Lysotracker positive compartments showing bright FluoZin-3 fluorescence. Scale bars are 20 µm. 
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Using Lysotracker fluorescence images, we calculated the average gain in the lysosomal 
size in Zn2+-treated TRPML1-KD cells. The same Lysotracker concentration, laser intensity, 
pinhole and gain values were used throughout the experiments. The grey-scale Lysotracker 
images were filtered using 50% intensity threshold yielding binary black-and-white images, 
which were then treated using Watershed segmentation algorithm implemented as an ImageJ 
plugin (Figure 9A). Large clusters of signal not resolved using this algorithm were manually 
eliminated (Figure 9B). Next, the ImageJ “Analyze particles” algorithm was used, which yielded 
numbers and sizes of Lysotracker-positive particles in each image (Figure 9C). For particle 
counting the following options were used: minimal size 0.09 µm2, minimal circularity was 0.5. 
The same algorithm was used in all subsequent analysis in this paper.  
Zn2+-treated TRPML1-KD cells showed a tendency towards increasing the number of larger 
Lysotracker-positive particles (Figure 10). In Zn2+-exposed TRPML1-KD cells, lysosomes were 
approximately 80% larger than in Zn2+-exposed control cells or in untreated TRPML1-KD cells 
(Figure 11). Lysotracker-positive particles in Zn2+-treated TRPML1-KD cells averaged 
176.15±12.50% (8 independent experiments, 3-5 images each, 1-3 cells on each image, 214 to 
573 Lysotracker-positive particles in each experiment, p<0.05 relative to control) of the average 
size of individual lysosomal areas in Zn2+-treated control siRNA-transfected cells (100±4%, 8 
independent experiments, 3-5 images each, 1-3 cells on each image, 99 to 1100 Lysotracker-
positive particles in each experiment). The use of threshold preserves the relative sizes of 
compartments, but makes evaluation of their absolute sizes unreliable. With this reservation in 
mind, the average size of Lysotracker-positive compartment in Zn2+-treated control cells was 
2.09±0.30 µm2 (statistics as above; two experiments were omitted from this analysis due to 
different microscope settings). In TRPML1-KD Zn2+-treated cell it was 3.56±0.51 µm2. Beyond  
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Figure 9.  Analysis of lysosomal enlargement in TRPML-KD cells exposed to Zn2+. 
Image analysis of lysosomal sizes. A. Confocal images of Lysostracker-stained cells from Fig 7B were subjected to 
50% maximal integrity threshold in ImageJ yielding black-and-white binary images. Next, the ImageJ watershed 
function was used. B. The binary images were compared to the original images and areas containing unresolved 
clumps of lysosomes were eliminated. C. The images were analyzed using “Analyze particles” function with 0.09 
µm2 minimal area threshold and the minimal circularity threshold of 0.5. Red characters represent numbering of the 
individual particles. 
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Figure 10.  An example of lysosomal enlargement in Zn2+-treated TRPML1-KD cells.  
Confocal images of HeLa cells stained with Lysotracker and analyzed as in Fig 8. Particle area sizes (in µm2) were 
calculated, sorted in descending order and plotted against number corresponding to each particle. Note an increase in 
number of larger particles in TRPML1-KD cells exposed to Zn2+. 
 
 
 
 
 
 
 
 
Figure 11.  Statistical analysis of lysosomal enlargement in TRPML1-deficient, Zn2+-treated cells. 
Average lysosomal particle area in control, MTF-1 siRNA-transfected and TRPML1 siRNA-transfected cells under 
untreated (hollow) and 48 hr Zn2+-treated (shaded) conditions. Lysotracker confocal images of Fluozin-3,AM 
experiments were thresholded at 50% and particle size area calculated for each experiment using ImageJ. Represents 
3-5 separate experiments. See main text for details of analysis and statistics. * represents p<0.05 relative to control 
sample. MTF-1+TRPML1 siRNA denotes cells transfected with mixture of MTF-1 and TRPML1 siRNA.  
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agreeing with the previous report on Zn2+ buildup in TRPML1-KD cells [393], these data 
suggest that in the absence of TRPML1, a Zn2+-dependent process leads to the enlargement of 
Lysotracker-positive (ostensibly lysosomal) compartments. Ni2+, used at the same concentration, 
did not induce lysosomal enlargement (Figure 12), suggesting that this aspect of TRPML1 KD 
phenotype is Zn2+-specific.  
These data confirm, in a different system, the previous findings on lysosomal 
enlargement and Zn2+ retention in TRPML1-KD cells [393]. A logical question following 
observation of this phenomenon is the source and means of Zn2+ buildup in the lysosomes of 
TRPML1-KD cells. Since Zn2+ is retained by the lysosomes in TRPML1-KD cells, TRPML1 
must be involved in the clearance of Zn2+ from the lysosomes. Where does the Zn2+ retained in 
TRPML1-KD cells come from? Zn2+ retained by the lysosomes 1) may come through 
endocytosis, or 2) may be taken up by cells through cell membrane transporters and then 
exported into lysosomes across their membranes. In both cases TRPML1 dissipates Zn2+ 
accumulation. The difference between the two scenarios is that the latter entails 1) a lysosomal 
Zn2+ transporter that works in concert with TRPML1 to regulate Zn2+ traffic between cytoplasm 
and lysosomes, and 2) dependence of the lysosomal Zn2+ accumulation in TRPML1-KD cells on 
a cytoplasmic step. 
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Figure 12.  Lysosomal enlargement is Zn2+- and MTF-1–specific.  
Confocal images of HeLa cells stained with Lysotracker, thresholded at 70% of maximal pixel intensity value. Cells 
not completely present within the field of view were removed from the image. Each image represents 3 experiments, 
3-5 images per experiment per condition. A. Lysosomes in control and TRPML1 siRNA-transfected cells under 
untreated (left) and 48 hr Zn2+ treated (right) conditions. B. TRPML1 siRNA transfected cells treated with 100 µM 
Ni2+ for 48 hrs. C. TRPML1 and MTF1 siRNA transfected cells treated with Zn2+. 
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2.3.2 The role of MTF-1 in lysosomal enlargement 
Cytoplasmic Zn2+ is tightly regulated, and therefore, the expression of proteins involved 
in Zn2+ maintenance is managed by Zn2+-dependent transcription factors such as MTF-1. Zn2+ 
binding to MTF-1, followed by MTF-1 nuclear import leads to the expression of proteins 
involved in Zn2+ handling, such as MTs. Their mRNA levels can thus be used to monitor 
cytoplasmic Zn2+ levels.  
Figure 13A shows a successful siRNA mediated knockdown of over 90% of MTF-1 
mRNA in untreated cells. This effect had a clear physiological significance, as MTF-1 KD 
severely suppressed mRNA levels of MT2a, which is the most ubiquitous and best described 
MT, well known to be regulated by MTF-1 (Figure 13B). In unstimulated cells, MTF-1 siRNA 
decreased MT2a mRNA levels to 19.12±5.71% of control levels (n=3, p<0.05). This established 
a toolkit for testing the role of MTF-1 in TRPML1-dependent effects of Zn2+.  
MTF-1 suppression eliminated the buildup of enlarged vacuoles in TRPML1 KD cells 
(Figures 11, 12, and 13C). In the double TRPML1/MTF-1–KD Zn2+-treated cells, the average 
lysosomal area was 101.78±7.06% (3 independent experiments, 3-4 images each, 1-3 cells on 
each image, 127 to 1035 Lysotracker-positive particles in each experiment) of its value in Zn2+-
treated control cells, a statistically indistinguishable value. These data suggest that these 
TRPML1-dependent aspects of Zn2+ phenotype in HeLa cells are mediated by MTF-1. The fact 
that suppression of a Zn2+-dependent step in the cytoplasm eliminates lysosomal enlargement 
and Zn2+ retention in TRPML1-KD cells strongly suggests that the source of Zn2+ retained in 
TRPML1-deficient lysosomes is not mediated through endocytosis, but is derived directly from a 
cytoplasmic route. This route is discussed below. We asked whether dysregulation of this route 
affects cytoplasmic Zn2+ and which Zn2+ transporters are involved in this process. 
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Figure 13. MTF-1 is involved in the enlargement of Lysotracker positive compartments in Zn2+-treated 
TRPML1 deficient cells.  
A. qPCR results demonstrating MTF-1 KD by siRNA. B. qPCR results showing MT2a suppression in cells treated 
with MTF-1 siRNA. Data points in Panels A and B represent 3 individual experiments, each performed in triplicate. 
* represents p<0.05. C. Confocal images of cells costained with Lysotracker and TSQ (top panels) or FluoZin-3 
showing that Lysotracker positive compartments are no longer enlarged in Zn2+-treated cells when MTF-1 is 
suppressed alongside TRPML1. Represents 3 experiments. Scale bars are 20 µm.  
 
2.3.3 The MT2a mRNA response in TRPML1 KD cells 
As discussed above, the presence of a cytoplasmic Zn2+- and TRPML1-dependent process 
suggests that the expression of Zn2+-dependent genes in cells exposed to Zn2+ is also affected by 
TRPML1 activity. In this regard, MTF-1/ Zn2+–dependent genes can be used as cytoplasmic Zn2+ 
reporters. In order to test this idea, we first screened mRNA levels of a well-known MTF-1- 
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Figure 14. MTF-1 is involved in the enlargement of Lysotracker positive compartments in Zn2+-treated 
TRPML1 deficient cells.  
MT2a response to Zn2+ changes is amplified in TRPML1-deficient cells. qPCR results showing augmented MT2a 
mRNA response to 48-hr long treatment with Zn2+ in TRPML1 KD HeLa cells, compared to HeLa cells transfected 
with scrambled siRNA. Represents 3 individual experiments, each performed in triplicate. * represents p<0.05. 
 
dependent gene product, MT2a. Figure 14 shows that upregulation of MT2a mRNA in response 
to Zn2+ is significantly augmented in TRPML1-KD cells, compared to cells transfected with 
control siRNA. In control cells, 48-h stimulation with Zn2+ increased MT2a mRNA levels to 
676.8±152.3% of control levels (n=3, p<0.05), while in TRPML1-KD cells, the response to Zn2+ 
was significantly greater (2992.7±678.5% of control levels; n=3, p<0.05). We conclude that a 
Zn2+ handling deficit in TRPML1-KD cells leads to a persistent dysregulation of Zn2+ 
management.  
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It should be noted that, in our system, the difference in MT2a mRNA response is only 
seen under Zn2+ exposure (Figure 14) and not under the basal conditions. Therefore, the 
upregulation of MT2a mRNA is a reaction to the change in cytoplasmic Zn2+ buffering in the 
absence of TRPML1. Together with the MTF-1 KD assays, these experiments established that 
the lysosomal Zn buildup and enlargement in TRPML1-KD cells depend on a cytoplasmic step, 
and that TRPML1 loss increases cytoplasmic Zn2+ (also consistent with the data shown in Figure 
8). We propose that TRPML1 works in concert with a lysosomal Zn2+ transporter to maintain 
normal Zn2+ levels in the cytoplasm and in the lysosomes. The loss of such concerted activity 
leads to cytoplasmic and lysosomal Zn2+ buildup. Next, we set out to identify such a transporter.  
2.3.4 ZnT4 KD rescues zinc-dependent lysosomal enlargement in TRPML1 KD cells 
Of the Slc30 (ZnT) family, ZnT2, ZnT3, ZnT4 and ZnT8 have been implicated in Zn2+ loading 
within endocytic compartments [449-451]. However, ZnT3 and ZnT8 expression seems to be 
restricted to brain and pancreas [104, 452]. For this reason, ZnT2 and ZnT4 became the first 
target of our investigation. Recombinant ZnT2 and ZnT4 both partially colocalized with 
TRPML1 (Figure 15), indicating that they might work in concert with TRPML1. If either ZnT2 
or ZnT4 are necessary for the TRPML1-dependent aspect of Zn2+ homeostasis, then KD should 
affect the Zn2+ phenotype in TRPML1-KD cells. The predicted direction of Zn2+ transport 
through ZnT transporters is into the lysosomes. Therefore, a ZnT KD should negate the effects of 
TRPML1 KD. We chose to modulate ZnT levels using siRNA. 
Figure 16A shows a qPCR confirmation of ZnT2 and ZnT4 KD (over 70% and 95% 
control mRNA levels in untreated cells, respectively). ZnT2 siRNA decreased ZnT2 mRNA  
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Figure 15.  ZnT2 and ZnT4 colocalize with TRPML1 
Confocal images of HeLa cells transfected with HA-tagged ZnT2 or ZnT4 constructs (in red) in parallel with a GFP-
tagged TRPML1 construct (in green). Panel represents 3 separate experiments, 3 images per experiment, per 
condition. Merged images showing colocalization (yellow) of the HA- and GFP-tagged constructs. Cells were 
transfected for 24 hrs and not treated with Zn2+.  
 
 
 
 
 
 
 
 
 
Figure 16.  ZnT4 knockdown rescues enlarged lysosomes under TRPML1 suppression.  
A. qPCR results showing ZnT2 and ZnT4 KD by siRNA. Data points represent 3 individual experiments, each 
performed in triplicate. * represents p<0.05. B. Confocal images of HeLa cells treated with 100 µM Zn2+ for 48 hrs, 
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and stained with Lysotracker (red) and FluoZin-3,AM (green). Cells were transfected with different siRNA 
constructs and treated with Zn2+ 24 hrs later. Merged confocal images show localization of Zn2+ and lysosomes in 
cells transfected with control siRNA, TRPML1 siRNA (ML1-), TRPML1 and ZnT2 siRNA, or TRPML1 and ZnT4 
siRNA. Represents 3 individual experiments, 3 images per experiment, per condition. Note enlarged lysosomes 
present in Zn2+ treated TRPML1-deficient cells with and without ZnT2. Note the marked reduced size of lysosomes 
in ZnT4 KD cells, even under TRPML1 suppression. Scale bars are 20 µm. 
 
levels to 29.88±21.31% of control levels (n=3, p<0.05), while ZnT4 siRNA decreased ZnT4 
mRNA levels to 4.36±3.73% of control levels (n=3, p<0.05). siRNA-mediated KD of ZnT4, but 
not ZnT2 rescued lysosomal swelling and lysosomal Zn2+ buildup in Zn2+-treated TRPML1 KD 
cells (Figure 16 B,C). In the double TRPML1/ZnT4–KD cells exposed to Zn2+, the average 
lysosomal area fell to about 50% of the value reported in TRPML1-KD cells. It averaged 
89.06±7.08% of the lysosomal size in control, untreated cells (4 independent experiments). In 
double TRPML1/ZnT2–KD cells, it remained largely the same as in TRPML1-KD cells exposed 
to Zn2+ (167.22±15.71% of control cells, 4 independent experiments, p<0.05). The fact that 
ZnT4 KD abolished lysosomal enlargement under TRPML1 suppression has a clear 
physiological significance because it identifies the lysosomal Zn2+ transporter that, in concert 
with TRPML1, forms a lysosomal “Zn2+ sink,” which absorbs the cytoplasmic Zn2+ (Figure 17). 
In direct agreement with this, Zn2+-treated TRPML1- and ZnT4-KD cells have large amounts of 
Zn2+ within the cytoplasm compared to ZnT2 KD (Figure 16B). Whether or not this phenomenon 
is specific to HeLa cells remains to be established, but this is consistent with Zn2+ accumulation 
in lysosomes in ZnT4-overexpressing mammary cells [444]. We would like to note that the triple 
TRPML1/ZnT2/ZnT4 KD was extremely cytotoxic even at the control conditions, which 
precluded its analysis.  
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Figure 17.  A model of “Zn2+ sink”. 
A. Under the normal conditions, Zn2+ entering the cytoplasm is sequestered into lysosomes by ZnT4 (and perhaps 
ZnT2 in some tissues). Lysosomal Zn2+ is released or secreted via a TRPML1-dependent process. TRPML1 may 
also regulate ZnT activity (denoted by “?”). B. The loss of “Zn2+ sink” function leads to lysosomal and cytoplasmic 
Zn2+ buildup.  
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2.3.5 Zinc secretion and lysosomal zinc leak in TRPML1 KD cells 
The data described above suggest that ZnT4 loads lysosomes with Zn2+ and that in the absence of 
TRPML1, Zn2+ is trapped in the lysosomes. Furthermore, clearance of Zn2+ from the lysosomes 
in TRPML1-KD cells was delayed, compared to control cells (Figure 18). The reason for Zn2+ 
retention in TRPML1-deficient lysosomes was the subject of our next set of experiments. 
TRPML1 has been implicated in lysosomal secretion. Therefore, it is possible that 
suppression of the lysosomal secretion due to TRPML1 loss traps Zn2+ in the lysosomes. 
Alternatively, it is possible that TRPML1 is lysosomal Zn2+ channel, responsible for the Zn2+ 
leak from lysosomes into the cytoplasm. The role of TRPML1 in Zn2+ secretion was analyzed 
using two assays. The premise of this experiment was: if Zn2+ retention in the TRPML1-KD cells 
is due to retarded secretion, then Zn2+ secretion in TRPML1-KD cell will be significantly lower 
than in control cells. This is directly addressed in Figure 19A. We measured Zn2+ release from 
Zn2+-preloaded control and TRPML1 KD-cells using FluoZin-3 tetrapotassium salt. Cells, grown 
on 12-well plates, were incubated in culture medium with 100 µM Zn2+ for 3 hr (pulse). Next 
they were washed in PBS and placed into fresh culture medium (chase), whose samples were 
taken 0, 5, 15 and 60 min later. Samples were analyzed using FluoZin-3 (cell impermeable salt) 
fluorescence, which was normalized to the total protein content of the well containing the given 
sample of cells. Figure 19A shows that Zn2+ content of the medium during the chase phase was 
not lower, but indeed higher in TRPML1-KD than in control cells.  
Next, total constitutive lysosomal secretion was recorded using ß-hexosaminidase release 
over four-hour time interval. The previously described protocol was used [453]. Figure 19B 
shows that there was no detectable difference in constitutive exocytosis of ß- hexosaminidase  
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Figure 18.  Delayed clearance of Zn2+ from lysosomes in TRPML1-KD cells.  
HeLa cells stained with Lysotracker and FluZin-3,AM. To test whether TRPML1 is involved in Zn2+ we performed 
confocal analysis of intracellular Zn2+ using Zn2+ pulse and chase. Control and TRPML1-deficient HeLa cells were 
incubated with Zn2+ for 3 hours (pulse) and then exposed to Zn2+-free medium for 0 to 60 min (chase) before 
confocal analysis. Cells were stained with Lysotracker and with FluoZin-3, AM as discussed before. Note that 
during the chase, Zn2+ persisted in the cytoplasmic vesicles in TRPML1-KD cells for longer period of time than it 
did in control cells. Scale bar is 20 µM.  
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Figure 19.  Zn2+ clearance and secretion in TRPML1-KD cells.  
A. Zn2+ secretion in control and TRPML1-KD cells. Cells were loaded in 100 µM Zn2+ for 3 hours, washed and Zn2+ 
secretion was analyzed as described in the text. FluoZin-3 fluorescence was expressed in arbitrary units per 
illumination/light collection area and normalized to the values in control cells exposed to Zn2+, which were taken as 
1. Data represent 3 individual experiments, performed in duplicate. B. ß-hexosaminidase secretion.  
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between TRPML1-KD and control cells. These data are consistent with similar secretion rates, 
but higher lysosomal Zn2+ content in TRPML1-KD cells. They argue against difference in 
secretion being the main cause of Zn2+ retention in the lysosomes of TRPML1-KD cells. 
2.4 DISCUSSION 
In the course of these studies, we found that, in agreement with the previously published report 
[393], there is a significant dysregulation of Zn2+ handling in TRPML1-KD cells. Our findings 
provide further insight into this process by showing that TRPML1 loss affects processes beyond 
lysosomes, and by identifying some of the components of the lysosomal “Zn2+ sink” responsible 
for export of the cytoplasmic Zn2+ into the lysosomes.  
We show that the lysosomal enlargement and Zn2+ buildup are alleviated by the 
suppression of cytoplasmic transcription factor MTF-1. These data clearly establish that a 
cytoplasmic step is involved in the loading of lysosomes with Zn2+ and their enlargement in 
TRPML1 KD cells exposed to Zn2+. They largely rule out endocytosis as the other source of 
lysosomal Zn2+ retention. What is this step and what is the role of MTF-1 in this process?  
We found that the loss of ZnT4 abolishes Zn2+ buildup and lysosomal enlargement in 
TRPML1-KD cells exposed to Zn2+. The fact that ZnT2 does not appear to have an effect in our 
system is puzzling. It likely reflects the specifics of Zn2+ handling by HeLa cells. ZnT2 
expression requires several factors [88]. It is possible that ZnT2 expression, or its response to 
Zn2+, is defective in HeLa cells. Furthermore, it is possible that ZnT2 and TRPML1 do not work 
in the same functional space. A more exciting possibility is that TRPML1 regulates localization, 
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or activity of ZnTs, specifically ZnT2 (Fig 16). Accordingly, a dependence of ZnT2 activity and 
structural integrity on lysosomal pH was recently shown [454].   
Finally, we demonstrate that Zn2+ leak from the lysosomes into the cytoplasm is delayed 
in TRPML1-KD cells. It is unlikely and that such delay is due to problems with Zn2+ secretion in 
TRPML1-KD cells, since there was no reduction in Zn2+ secretion in these cells, compared with 
control cells (Fig 18). The lack of TRPML1 effect on ß-hexosaminidase secretion in our system 
does not refute TRPML1’s role in secretion. It is possible that TRPML1 is involved in another 
aspect of secretion, such as regulated secretion, which was beyond the scope of the present work.  
Although MTF-1 was shown to regulate ZnT1 expression, no evidence of ZnT4 
regulation by MTF-1 has been presented so far. It is important to remember that MTF-1 regulates 
MT expression and that MTs are indispensable for Zn2+ transport. Several lines of evidence show 
that MTs deliver and load Zn2+ on the transporters and that in the absence of MTs, Zn2+ transport 
is severely compromised [455, 456]. Based on this, we suggest that, in our system, MTF-1 KD 
affected Zn2+ transport into lysosomes due to the loss of MT2a, and possibly other MTs. This 
likely affected the loading of lysosomal Zn2+ transporters with Zn2+. We hypothesize that, as 
previously suggested [457] MT2a transfers cytoplasmic Zn2+ onto ZnTs, such as ZnT4, 
promoting its export into lysosomes. Such a lysosomal “Zn2+ sink” may be a defense mechanism 
against deleterious Zn2+ spikes during toxic levels of Zn2+ exposure.  
At the same time, MT2a mRNA response to Zn2+ in TRPML1-KD cells is dramatically 
increased. This is consistent with increased cytoplasmic Zn2+ levels in TRPML1 KD cells 
exposed to Zn2+. What is the role of TRPML1 in this process? The fact that TRPML1 loss leads 
to lysosomal Zn2+ retention indicates that TRPML1 dissipates lysosomal Zn2+. TRPML1 may 
transport Zn2+ from the lysosomes into the cytoplasm, as suggested by our data in Figure 18. It is 
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important to remember that the upregulation of Zn2+ chelation and extraction from cells 
persistently exposed to Zn2+ is likely to lead to a drop in cytoplasmic Zn2+ concentration after the 
initial spike induced by the addition of Zn2+. It is possible that TRPML1 function is to dissipate 
Zn2+ accumulated in the lysosomes due to ZnT4 activity during Zn2+ spike. TRPML1 loss would 
result in weak, but prolonged Zn2+ leak through other transporters leading to low, but chronic 
Zn2+ elevation, perhaps sufficient to chronically activate MTF-1.  
The central finding of these studies are the identification of the source of Zn2+ buildup in 
TRPML1-KD cells as cytoplasmic as well as the identification of components that are necessary 
for the TRPML1-deficient “Zn2+ sink” to function properly: ZnT4 and cytoplasmic proteins, 
such as the transcription factor MTF-1. These components are involved in the cellular response 
to exposure to Zn2+ against the background of the loss of a lysosomal ion channel whose function 
to date remains unknown. Our findings shed light on TRPML1 function and its importance for 
proper cell function and health. Since the loss of TRPML1 is the cause of MLIV, further studies 
will show whether or not dysregulation of cytoplasmic Zn2+ in TRPML1-KD cells is a 
contributing factor in the key aspects of MLIV pathogenesis, such as the buildup of storage 
bodies or cell death. Beyond MLIV, the fact that TRPML1 is involved in Zn2+ trafficking 
potentially impacts other neurodegenerative diseases. Zn2+ is an essential transition metal that 
needs to be highly regulated and Zn2+ dysregulation has been linked to neuronal death following 
a seizure or ischemic episode [126, 458], formation of β–amyloid plaques associated with 
Alzheimer’s [459], and pancreatic β–cell degeneration [460]. It would be interesting to see the 
role of TRPML1 in those processes.  
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3.0  ZINC EFFLUX THROUGH LYSOSOMAL EXOCYTOSIS PREVENTS ZINC-
INDUCED TOXICITY  
The work discussed in this Chapter has been adapted from material that as of this dissertation, is 
in final review stages and is reprinted, with alterations, by permission from the Journal of Cell 
Science:  
Ira Kukic, Shannon L. Kelleher, and Kirill Kiselyov, “Zinc efflux through lysosomal exocytosis 
prevents zinc-induced toxicity.” Journal of Cell Science. 2014 © the Company of Biologists.  
3.1 INTRODUCTION 
Cellular Zn2+ dyshomeostasis has been linked to a number of human pathologies including 
growth defects [461], impaired immune function [462], diabetes [463], and neurodegenerative 
diseases [464-467]. Regulation of cellular Zn2+ levels involves controlling its influx, export and 
chelation. In general, Zn2+ transport is regulated by ZnT and ZIP transporters, and it is chelated 
by Zn2+ binding metallothioneins (MTs).  
In addition to Zn2+ evacuation across the plasma membrane (PM) by the Zn2+ transporter 
ZnT1 [15], Zn2+ is exported from the cytoplasm into the organelles by the dedicated ZnT 
transporters such as ZnT6 for the Golgi [468], and ZnT2 and ZnT4 for the lysosome [431, 444, 
449, 451]. This organellar Zn2+ export lowers potentially toxic cytoplasmic Zn2+ concentrations 
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in pathophysiological conditions such as neurodegeneration [469] and breast cancer [470]. 
Moreover, it provides Zn2+ to organellar processes that require it, such as the maturation of 
enzymes like the lysosomal acid sphingomyelinase [471], and the secretion of Zn2+ under normal 
physiological conditions such as synaptic transmission [115] and lactation [472]. 
The upregulation of Zn2+ chelation and transport machinery following the activation of 
the transcription factor MTF-1 by Zn2+ binding [435] requires time for transcription, translation 
and protein processing. It is tempting to speculate that Zn2+ export into organelles serves as a first 
line of defense to provide temporary Zn2+ storage, giving cells time to upregulate Zn2+ chelators 
and transporters. Our recent data on the role of lysosomes in Zn2+ handling, as well as some 
recently published results suggest that lysosomes play a role of such Zn2+ sinks, temporarily 
storing Zn2+ [304, 473]. In this paper, we sought to delineate the role of lysosomes in protection 
against Zn2+-induced toxicity. 
Zn2+ is transported from the cytoplasm into lysosomes by ZnT2 and ZnT4 [431, 449, 
451]. Zn2+ can also be delivered to the lysosomes through endocytosis or autophagy [474, 475]. 
What happens to Zn2+ absorbed by the lysosomes? A recent series of work from several labs 
indicate that Zn2+ buildup in the lysosomes is toxic. It leads to lysosomal membrane 
permeabilization (LMP), to the release of the lysosomal enzymes such as Cathepsins and to cell 
death [476-479]. As such, the lysosomal Zn2+ accumulation may constitute a cell death 
mechanism during normal remodeling of Zn2+-rich tissues, such as the mammary gland [480], as 
well as in pathological conditions. With this in mind, we sought to answer whether or not the 
accumulation of Zn2+ in the lysosome is the terminal depot for cellular Zn2+.  
Alternatively, it is possible that lysosomal Zn2+ dissipates and lysosomes constitute only a 
temporary Zn2+ storage site. Our recently published data suggest that the lysosomal ion channel 
 84 
transient receptor potential mucolipin 1 (TRPML1) is at least partly responsible for dissipating 
the lysosomal Zn2+ into the cytoplasm [473]. It should be noted that lysosomes fuse with the PM 
via a process involving a specific SNARE complex, which includes the VAMP7 protein and 
Synaptotagmin VII (SYT7) [239, 240, 268, 481, 482]. Such secretion was recently proposed to 
contribute to excretion of undigested/indigestible products inside lysosomes [273]. In the course 
of the present studies, we used VAMP7 and SYT7 KD to suppress lysosomal secretion and 
assess its role in Zn2+ clearance from the cells.  
Here we aimed to establish the functional context of the lysosomal Zn2+ accumulation. 
Our findings indicate that lysosomes actively absorb Zn2+ and secrete it across the PM, since 
suppressing the lysosomal Zn2+ absorption or secretion causes Zn2+ buildup in the cytoplasm, 
Golgi apparatus and mitochondria, leading to apoptosis.  
3.2 EXPERIMENTAL METHODS 
3.2.1 Cell Culture 
HeLa cells were maintained in DMEM (Sigma-Aldrich, St Louis, MO) supplemented with 10% 
FBS. For siRNA and cDNA transfection, media was changed after 24 hours. 100 μM ZnCl2 was 
added directly to the medium, containing serum, 24 hrs after transfection, for the indicated times. 
Bafilomycin A1 (#196000, EMD MIllipore, Darmstadt, Germany) was used at 1 μM for the 
indicated amount of time.  
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3.2.2 SiRNA-mediated KD and plasmid transfection 
The VAMP7 siRNA (Cat number SASI_Hs01_00197188), SYT7 (Cat number 
SASI_Hs01_0047888), ZnT2 siRNA (Cat number SASI_Hs01_00055662), ZnT4 siRNA (Cat 
number SASI_Hs00225995), and MTF-1 siRNA (Cat number SASI_Hs01_00177112)  were 
from Sigma (Sigma-Aldrich, St Louis, MO). Non-targeting control siRNA#1 (Sigma) was used 
as a negative control. Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbag, 
CA) as described by manufacturer’s protocol using 600 nM siRNA per 35 mm well (1200 nM 
siRNA per 35 mm well for efficient VAMP7 and SYT7 KD). All KDs were confirmed using 
SYBR-green based qPCR. For DNA transfections, 2 μg of GalT-mCherry and TFEB was 
transfected per 35mm dish. 
3.2.3 Microscopy 
Cells were seeded on glass coverslips and loaded with dyes for 15 min at 37ºC in buffer 
containing, in mM: 150 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4, 1 g/L glucose. The 
loading was followed by 15 min washout in all cases. Lysotracker Red DND-99, FluoZin-3,AM 
(F-24195, Invitrogen, Carlsbag, CA), were used at 0.1 μM. Confocal microscopy was performed 
using Leica TCS SP5 and BioRad 3000 confocal microscopes. Live cells were treated as above. 
Images were analyzed using ImageJ (Bethesda, MD). 
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3.2.4 Reverse Transcriptase and Quantitative qPCR 
RNA was isolated from cells using Trizol (Invitrogen, Carlsbag, CA) according to the 
manufacturer’s protocol. cDNA was synthesized using the GeneAmp RNA PCR system 
(Applied Biosystems, Carlsbad, CA) with oligo dT priming. qPCR was performed SYBR green 
(Fermentas, Glen Burnie, MD). The amount of cDNA loaded was normalized to starting RNA 
concentrations, with a final concentration of 9 ng (40 ng in ZnT experiments) of RNA loaded per 
experimental well. Six-point standard curves were generated for each primer using 1:2 dilutions 
of cDNA. cDNA for the following genes were amplified using the indicated primers (IDT, 
Coralville, IA). MT2a: forward: 5’AAGTCCCAGCGAACCCGCGT-3’, reverse: 5’-
CAGCAGCTGCACTTGTCCGACGC-3’. VAMP7: forward: 5’-
CCGGACAGACTGAAGCCAT-3’, reverse: 5’-ATCTGCTCTGTCACCTCCAG-3’. SYT7: 
forward: 5’-AAGCGGGTGGAGAAGAAGAA-3’, reverse: 5’-
CGAAGGCGAAGGACTCATTG-3’. ZnT1 (SLC30A1): forward: 5’-
GGGAGCAGCGACATCAACGT-3’, reverse: 5’-GGGTCTGCGGGGTCCAATT-3’. ZnT2 
(SLC30A2): forward: 5’-GCAATCCGGTCATACACGGGAT-3’, reverse: 5’-
CAGCTCAATGGCCTGCAAGT-3’. ZnT4 (SLC30A4): forward: 5’-
CACATACAGCTAATTCCTGGAAGTTCATCT-3’, reverse: 5’-
GCCTGTAACTCTGAAGCTGAATAGTACAT-3’. LAMP1: forward: 5’-
GGACAACACGACGGTGACAAG-3’, reverse: 5’-GAACTTGCATTCATCCCGAACTGGA -
3’. All primers were designed to span exons and negative RT controls were tested to ensure 
amplification of cDNA only. qPCR was performed using the Standard Curve method on the 
7300 Real Time System (Applied Biosystems, Carlsbad, CA). Reactions were run on the 
following parameters: 2 min at 50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 sec followed 
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by 60°C for 1 min. All experimental samples were run in triplicate and normalized to an RPL32 
endogenous control.  
3.2.5 β-Hexosamindase activity assay 
Untreated control and transfected cells were washed with 37ºC PBS and 300 μl 37ºC PBS with 1 
mM CaCl2 was added to each 35mm dish. For each sample, 100 μl of the supernatant was 
incubated with 300 μl 3 mM 4-nitrophenyl N-acetyl-β-D-glucosaminide (N9376, Sigma-Aldrich, 
St Louis, MO) for 30 minutes at 37ºC in 0.1 M citrate buffer (pH 4.5) (C2488, Sigma-Aldrich, St 
Louis, MO). This volume was replaced with fresh 100 μl of 37ºC of PBS with 1 mM CaCl2 to 
the culture dish. Samples were collected every after 0, 10 and 30 minutes. Reactions were 
stopped by adding 650 μl borate buffer (100 mM boric acid, 75 mM NaCl, 25 mM sodium 
borate, pH 9.8) and the absorbance was measured in a spectrophotometer at 405 nm. To 
determine total cellular content of β-hexosamindase, cells were lysed with 300 μl 1% Triton X-
100 in PBS and after a 10,000g spin for 5 minutes at 4ºC, 10 μl of the cell extracts were used for 
the enzyme activity reaction. Enzyme activity was determined as the amount of 4-nitrophenol 
produced per mg of protein (Bradford method). Absorbance was calibrated with different 
amounts of 4-nitrophenol (N7660, Sigma-Aldrich, St Louis, MO) in 0.1 M citrate buffer. 
3.2.6 Zinc secretion assay 
Cells were plated on a 12 well plate and 48 hours after, transfection pulsed with 100 μM ZnCl2 
for 3 hours, washed twice with warm PBS, and chased in 1mL DMEM per well. Duplicate time-
points were collected for 0, 5, 15, 30 or 60 minutes and replaced with new 50 μl of DMEM. For 
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each sample, 50 μl of supernatant was placed in a 96-well plate. Zn2+ content was measured by 
incubating the supernatants with 10 μM cell-impermeant FluoZin-3 tetrapotassium salt (F-24194, 
Molecular Probes, Invitrogen, Carlsbag, CA) for 15 minutes at 37oC. The 96-well plate was read 
via a FujiFilm FLA-5100 fluorescent image analyzer. After the last time point, cells were washed 
with PBS, 200 μl detergent solution was added to lyse the cells and fluorescence was normalized 
to total protein in each sample. 
3.2.7 Caspase 3 activity assay 
Cells were prepared and measured using the EnzChek Caspase-3 Assay Kit #1 (E13183, 
Invitrogen, Carlsbag, CA) following the manufacturer’s instructions. AMC substrate 
fluorescence was measured using a fluorometer at an excitation wavelength of 342 nm and an 
emission wavelength of 441 nm. 
3.2.8 Western Blot Analysis 
Cells were solubilized for 10 min at room temperature in either a 1X detergent solution (0.5 M 
EDTA, pH 8.0, 1 M Tris, pH 8.0, 0.4% deoxycholate, 1% Nonidet P-40 substitute) for (LAMP1) 
or a 1% CHAPS in PBS solution (for VAMP7) containing protease inhibitor mixture III 
(Calbiochem, Gibbstown, NJ) and centrifuged at 16,000 g for 5 min. The supernatant was 
collected and protein concentrations were determined using a Bradford assay. Protein was 
incubated at 100 °C for 5 min in sample buffer containing 14% β -mercaptoethanol. Equal 
amounts of protein were loaded on a 10% precast Tris-HCl polyacrylamide gel (Bio-Rad) for 
each experimental sample. Proteins were transferred to PVDF membrane (EMD MIllipore, 
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Darmstadt, Germany) and blocked in 10% nonfat dry milk for 1 hour. The following primary 
antibodies were used: monoclonal LAMP1 (sc-20011, Santa Cruz, Santa Cruz, CA) at 1:1,000 
dilution, monoclonal VAMP7 (ab36195, Abcam, Cambridge, US) at 1:500, and monoclonal β-
actin (ab6276, Abcam, Cambridge, US) at 1:5,000 dilution. HRP-conjugated goat anti-mouse 
secondary antibodies (Amersham Biosciences) were used at 1:20,000 dilutions. 
Immunodetection was performed with the Luminata Forte HRP substrate (EMD MIllipore, 
Darmstadt, Germany). Band densities were measured using ImageJ (Bethesda, MD). 
3.2.9 Flow Cytometry 
HeLa Transfected HeLa cells were treated with either 100 μM ZnCl2 for 48 hours for Baf and 
VAMP7 experiments, or 200 μM ZnCl2 for 12 hours for TFEB experiments. Cells were then 
washed with PBS, trypsinized, and counted. 2X106 cells were pelleted for each sample, washed 
with PBS and then resuspended in Annexin Binding Buffer from the Vybrant Apoptosis Assay 
Kit #3 (V.13242, Molecular Probes). Cells were then loaded with 1 μl propidium iodide and 2 μl 
Annexin V 488 and sorted on the Accuri (BD) C6 at the University of Pittsburgh Cancer Institute 
Cytometry Facility. Cell sorting was gated to include healthy and apoptotic cells while excluding 
debris.  
Statistical significance was calculated using a one-tailed, unpaired t-test with p ≤ 0.05 
considered significant. Data are presented as mean ± S.E.M. 
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3.3 RESULTS 
3.3.1 Inhibition of lysosomal function through Bafilomycin increases cellular zinc 
Towards testing the role of lysosomal Zn2+ sink in the cellular Zn2+ handling, we blocked the 
lysosomal H+ pump in HeLa cells using 1 μM Baf and exposed cells to 100 μM ZnCl2 for 3 
hours. The resulting cytoplasmic Zn2+ spikes were measured using live-cell confocal microscopy 
and FluoZin-3,AM as described before [473]. Figure 20 A shows that the exposure of Baf-treated 
cells to Zn2+ caused significantly higher FlouZin-3,AM response than the exposure of untreated 
cells to Zn2+. Although Baf has been shown to decrease cytoplasmic pH, potentially affecting 
Zn2+ binding to cytoplasmic proteins, or FlouZin-3,AM fluorescence, the magnitudes of the 
observed effects appear to be incompatible with the quantitative estimates of changes induced by 
Baf. Thus, Baf’s effect on cytoplasmic pH appears to be small, within only tenths of pH units 
[483]. The degree of pH change necessary to cause an effect on Zn2+ handling, on the other hand, 
significantly exceeds that reported to be caused by Baf. A pH drop below 6.7 is required to 
trigger an increase in intracellular Zn2+ according to one set of studies [484], while another set 
showed that metallothioneins release Zn2+ only after cytoplasmic pH drops below 5.0 [485]. 
Thus, the increase in cytoplasmic Zn2+ caused by Baf likely correlates with the loss of lysosomal 
function, rather than cytosolic pH changes. 
We have previously shown that Zn2+ transporters ZnT2 and ZnT4 colocalize with the 
lysosomal ion channel TRPML1 in HeLa cells [473]. We suggested that these transporters play a 
role in loading of the lysosomes with Zn2+. In order to test this assumption, we KD ZnT2 and 
ZnT4 using siRNA as described before and tested the resulting changes in Zn2+ handling using  
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Figure 20. Inhibition of lysosomal Zn2+ sink function by Baf increases cytoplasmic Zn2+ levels. 
A) Confocal images of HeLa cells treated with 100 μM Zn2+ and/or 1 μM Baf for 3 hours then loaded with FluoZin-
3,AM and LysoTracker. Note disappearance of LysoTracker staining, indicative of lysosomal deacidification, and an 
increase in FluoZin-3,AM staining intensity, indicative of increased Zn2+. B) Confocal images of control or ZnT 
siRNA transfected HeLa cells (48 hours post-transfection) treated with 100 μM Zn2+ for 3 hours then loaded with 
FluoZin-3,AM. Images represent at least 3 separate experiments, at least 3 images per condition in each experiment. 
Scale bars are 20 microns. 
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FluoZin-3,AM. Figure 20 B shows that ZnT2 and ZnT4 KD increased cytoplasmic Zn2+ levels 
observed in these cells after 3 hour long treatment with 100 μM Zn2+. These results are in 
agreement with the previously published data on the dependence of ZnTs activity on the acidic 
environment of the lysosomes [24, 25] for Zn2+ binding and transporting activity.  
3.3.2 Inhibition of lysosomal function through Bafilomycin increases the transcriptional 
response of zinc genes 
The upregulation of MTF-1–dependent, Zn2+-responsive genes such as MT2a and ZnT1 [486] 
indicates elevated cytoplasmic Zn2+. MT2a mRNA was used previously in our studies of the role 
of TRPML1 in Zn2+ handling. We measured the expression of the mRNA of these genes using 
qRT-PCR (Figure 21). An increase in MT2a and ZnT1 mRNA responses to Zn2+ in cells treated 
with Baf is evident. With MT2a mRNA levels in DMSO-treated (no Zn2+) cells taken for 100%, 
MT2a mRNA levels were 816.39±73.61% in cells treated with DMSO+Zn2+ (n=4; p<0.001), and 
1174.61±94.20% (n=4; p<0.05 relative to DMSO-only and DMSO+Zn2+ controls) in cell treated 
with Baf+Zn2+ (Figure 21 A). ZnT1 mRNA increased to 323.43±23.32% (n=4; p<0.001) in 
DMSO+Zn2+–treated cells, and to 552.09±40.46% (n=4; p<0.05 relative to DMSO-only and 
DMSO+Zn2+ controls) of control values in Baf+Zn2+–treated cells (Figure 21 B). In addition to 
confirming the elevated cytoplasmic Zn2+ levels seen by FluoZin-3,AM in Figure 20 A due to 
Baf, these data also corroborate MTF-1 activation due to cytoplasmic Zn2+ buildup.  
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Figure 21. Inhibition of lysosomal Zn2+ sink function by Baf increases the transcriptional response of Zn2+ 
genes.  
qRT-PCR results of MT2a (A) and ZnT1 (B) mRNA, shown as percent of DMSO-only-treated (no Zn2+) cells. RNA 
was isolated from HeLa cells treated for 3 hours with either DMSO or 1 µM Baf alone or with 100 µM Zn2+. * 
Represents p<0.05. ** Represents p<0.001. 
 
3.3.3 Inhibition of the lysosomal zinc sink through Bafilomycin redistributes cellular zinc 
pools to the Golgi and the mitochondria 
In addition to increasing cytoplasmic Zn2+, suppression of the lysosomal function caused 
redistribution of Zn2+ storage pools. Concentration of FluoZin-3 fluorescence in intracellular 
inclusions was noted in Baf-treated cells exposed to Zn2+. At least some of these inclusions were 
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positive for Golgi marker GalT-mCherry (Figure 22 A). Under these conditions, Zn2+ also 
accumulated in the mitochondria as well, which was shown using the mitochondrial Zn2+ dye 
RhodZin-3,AM, whose signal was brighter in Baf-treated than in control Zn2+-treated cells 
(Figure 22 B). Therefore, suppression of the lysosomal function leads to the loss of Zn2+ 
buffering capacity and to a spike in cytoplasmic Zn2+ when cells are exposed to Zn2+. In the 
absence of Zn2+ buffering by the lysosomes, Zn2+ is redirected to other organelles.  
3.3.4 Inhibition of the lysosomal function and zinc exposure leads to increased cell death 
As previously shown, high Zn2+ is toxic to the cells due to its buildup in the cytoplasm and in the 
organelles [487]. If the lysosomes are a Zn2+-buffering sink, then inhibiting that function should 
result in cell death. Our findings in Figure 23 A support this: while HeLa cells were fairly 
resistant to the effects of 100 μM Zn2+ or 1 μM Baf alone, their combination caused pronounced 
increased Cas3 activity by 43.90± 14.25% (n=3, p<0.05) and exposure to 1 μM Baf increased 
caspase-3 (Cas3) activation, indicative of apoptosis. An exposure of cells to 100 μM Zn2+ for 48 
hours Cas3 activity by 179.5±68.04% (n=3, p<0.05). A combination of Zn2+- and Baf-exposure 
increased Cas3 activity by 387.87±36.70% (n=3, p<0.001 relative to untreated control), 
suggesting that Baf enhances the pro-apoptotic effects of Zn2+. Since Baf is conventionally used 
to block the lysosomal H+ pump, we think that the simplest interpretation of these data is as 
diminished cytoprotective capacity of the lysosomal Zn2+ sink in Baf-treated cells.  
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Figure 22.  Inhibition of lysosomal Zn2+ sink function by Baf redistributes cellular Zn2+ pools to the Golgi and 
the mitochondria.  
A) Confocal images of GalT-mCherry–transfected HeLa cells treated with 100 µM Zn2+ and/or 1 µM Baf for 3 
hours, then loaded with FluoZin-3,AM. The black-and-white panes show overlap between the green and the red 
channels, obtained using the RG2B function of ImageJ. B) Confocal images of HeLa cells treated with 100 µM Zn2+ 
and/or 1 µM Baf for 3 hours, then loaded with RhodZin-3,AM. Plot profiles on the right show intensity profiles of 
RhodZin-3,AM fluorescence recorded along the lines indicated in the corresponding image. Note increased 
RhodZin-3,AM florescence with Baf-treated cells. Images represent at least 3 separate experiments, at least 3 
images per condition in each experiment. Scale bars are 20 microns. 
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As a complimentary cell death assay, Annexin V (AnnV) and propidium iodide (PI) 
staining were analyzed using flow cytometry. Figures 23 B and 24 show an increase in the 
number of AnnV-positive, apoptotic cells when cells are treated for 48 hours with Zn2++Baf. 
Taken together, these data show that suppression of the lysosomal Zn2+ sink facilitates apoptotic 
cell death caused by Zn2+ exposure. They suggest that lysosomes play a crucial role in buffering 
cytoplasmic Zn2+ and in its detoxification. A loss of such a role exposes cells to the pro-apoptotic 
effects of Zn2+.  
3.3.5 A model of lysosomal zinc sink and its role in zinc detoxification 
Zn2+ toxicity was linked to LMP resulting in cell death under some conditions [304, 477-479]. 
Why is the lysosomal Zn2+ sink cytoprotective under some, but not other conditions of Zn2+ 
exposure? We propose that the switch between pro- and anti-apoptotic effects of the Zn2+ sink is 
dictated by the rate of Zn2+ absorption by the lysosomes and/or the rate of its clearance from the 
lysosomes. If the rate of Zn2+ clearance exceeds the rate of its sequestration into the lysosomes, 
then the Zn2+ sink is cytoprotective. A rate of sequestration exceeding the rate of clearance leads 
to LMP and cell death (see Model in Figure 25). Zn2+ clearance may occur through a Zn2+ leak 
into the cytoplasm (as suggested by our recent publication [473]), or through its secretion via  
lysosomal fusion with the PM. The latter has recently gained a lot of attention as detoxification 
mechanism in the lysosomal storage diseases [164, 273, 488-490]. The next set of experiments 
tested the role of lysosomes in Zn2+ secretion.  
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Figure 23. Inhibition of lysosomal function leads to increased cell death upon high Zn2+ exposure. 
A) Caspase 3 activity assay showing increased Cas3 activation upon 48 hour 100 µM Zn2+ and 1 µM Baf treatment 
in HeLa cells. Three hour long exposure to 1 µM Staurosporine was used as a positive control, which increased Cas3 
activity by 796.72±109.06% (n=3, p<0.001). Cas3 activity is shown as AMC fluorescence and a percentage of 
untreated controls. * p <0.05. B) Flow cytometry data showing increased AnnV staining of cells treated with 100 
µM Zn2+ and/or 1 µM Baf for 48 hours. Data represent 3 experiments.  
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Figure 24.  Baf and VAMP7 KD facilitate Zn2+-dependent apoptosis.  
Representative (of 3) flow cytometry experiments performed on cells stained with PI and AnnV. Note a decrease in 
numbers of cells with low AnnV/PI stain (“healthy” cells) and an increase in numbers of AnnV/PI-positive cells 
(early and late apoptotic cells) treated with Baf and Zn2+, (middle panels) indicating cell death in these cells. Cells 
were treated with Baf and Zn2+ for 48 hours. Right panels show a decrease in numbers of cells with low AnnV/PI 
stain (“healthy” cells) and an increase in numbers of AnnV/PI-positive cells (early and late apoptotic cells) in 
VAMP7-KD sample, indicating cell death in these cells. Note a decrease in numbers of cells with low AnnV/PI stain 
(“healthy cells”) and an increase in numbers of AnnV/PI-positive cells in VAMP7-KD cells (“dead or dying cells”) 
treated with Zn2+, indicating cell death in these cells. 
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Figure 25.  A model of lysosomal Zn2+ sink and its role in Zn2+ detoxification.  
A) Under normal conditions, Zn2+ enters the cells through ion channels and ZIPs and is (1) recognized by the Zn2+-
sensitive transcription factor MTF-1 which once Zn2+-bound, will translocate to the nucleus to upregulate ZnT1 and 
MT2a mRNA expression and (2), transported out of the cytoplasm and into the lysosome through ZnT2 and ZnT4. 
Zn2+ that builds up in the lysosomal Zn2+ sink is then secreted across the plasma membrane (3) via a VAMP7-
dependent mechanism. This prevents toxic Zn2+ buildup in the cytoplasm and other organelles (4). B) Suppression of 
Zn2+ absorption by the lysosomal Zn2+ sink (5), leads to toxic levels of Zn2+ buildup in the cytoplasm as well as 
other organelles (6) such as the Golgi and mitochondria.  
 
 
 
 100 
3.3.6 Inhibition of lysosomal exocytosis through VAMP7 and SYT7 KD inhibits zinc 
secretion 
We suppressed lysosomal secretion by using siRNAs against two lysosomal SNARE 
components:  VAMP7 and SYT7 [239, 240, 268, 481, 482, 491]. Figure 26 A shows that 
VAMP7 siRNA reduced VAMP7 mRNA to 27.76±3.99% of control siRNA levels (n=4, 
p<0.001) while Figure 27 A shows that SYT7 siRNA reduced SYT7 mRNA to 30.12±4.11% of 
control siRNA levels (n=3, p<0.001). VAMP7 mRNA levels were not altered by either 3 or 48 
hour exposure to 100 μM Zn2+ (I.K., unpublished observation; SYT7 dependence on Zn2+ was 
not tested). VAMP7 KD was confirmed by examining protein levels through Western blot 
confirming that VAMP7 siRNA reduced VAMP7 protein expression to 30.21±6.82% of control 
siRNA levels (n=5, p<0.001)   (Figure 26 B). VAMP7 and SYT7 KD were associated with 
changes in the lysosomal numbers and organization. There was an increase in the total lysosomal 
numbers in VAMP-7 KD cells (Figure 28), although there was a high degree of cell-to-cell 
variation with that metric. Both VAMP7 and SYT7 KD also caused clustering of lysosomes in 
large structures, which is compatible with the role of these SNARE proteins in membrane traffic. 
Examples of such clustering and its statistical analysis are shown in Figures 27 and 28.  
VAMP7 and SYT7 KD were functionally significant as they caused a loss of secreted 
activity of the lysosomal enzyme β-hexosaminidase (β-hex), a common marker of lysosomal 
exocytosis. In these experiments, lysosomal secretion was initiated by treatment with 1 μM of 
the Ca2+ ionophore ionomycin (Ion) (Figures 26C and 27 B). After 30 minutes, control KD cells 
secreted 18.80±0.66% of their total β-hex content without stimulation, while VAMP7 KD cells 
secreted 14.09±1.60% of their total β-hex content (Figure 26C). Once stimulated with 
ionomycin,  however, control KD cells secreted 32.57±2.36% of their total β-hex content, while  
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Figure 26.  Inhibition of lysosomal exocytosis through VAMP7 KD inhibits Zn2+ secretion.  
A) qRT-PCR results confirming VAMP7 KD by siRNA. B) Quantification of western blot results confirming 
VAMP7 KD. Insert shows representative blot (of 5) of endogenous VAMP7 and actin levels under with either 
control or VAMP7 siRNA. C) ß-hexosaminidase activity assay for lysosomal exocytosis. Results are shown as 
percent of total ß-hexosaminidase secreted after either 10 or 30 minutes. One µM ionomycin was used to stimulate 
lysosomal exocytosis. D) Zn2+ secretion assay using cell-impermeant FluoZin-3 tetrapotassium salt. Results are 
shown as percent of the maximum fluorescence value recorded in the Control+ Zn2+ samples, which were taken as 
100%. * Represents p<0.05. ** Represents p<0.001. 
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VAMP7 KD cells only secreted 18.87±1.57% of their total β-hex content (n=3, p<0.001) (Figure 
26 C). Similarly, SYT7 KD was also functionally significant, decreasing lysosomal exocytosis 
compared to control KD. Figure 27 B shows that after 30 minutes, ionomycin-treated control KD 
cells secreted 35.57±1.36% of their total β-hex content, while SYT7 KD cells secreted 
20.29±1.65% of their total β-hex content (n=3, p<0.001).  
To measure the effect of suppressing lysosomal exocytosis on Zn2+ secretion, we 
incubated control and VAMP7, or SYT7 KD cells with 100 μM Zn2+ for 3 hours. Next, cells 
were placed in normal medium (no Zn2+) and Zn2+ secretion was analyzed using FluoZin-3 
fluorescence as described before [492]. Both VAMP7 (Figure 26 D) and SYT7 (Figure 27 C) KD 
significantly reduced Zn2+ secretion. Within 30 minutes of secretion, VAMP7 KD cells were 
only able to secrete 51.79±19.26% (n=3, p<0.05) of the amount of Zn2+ secreted by the control 
KD cells (100%) (Figure 26 D), indicating that VAMP7 is necessary for Zn2+ secretion. 
Similarly, SYT7 KD cells were only able to secrete 58.90±2.87% (n=3, p<0.05) of the amount 
of Zn2+ secreted by the control KD cells, which was taken as 100% (Figure 27 C). This inhibition 
of Zn2+ secretion in VAMP7 and SYT7 KD cells was also corroborated by the elevated cellular 
Zn2+ levels seen by FluoZin-3,AM staining via confocal microscopy (Figure 27 D). 
 
 
 
 
 
 
 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Inhibition of lysosomal exocytosis through SYT7 KD inhibits Zn2+ secretion.  
A) qRT-PCR results confirming SYT7 KD by siRNA. B) ß-hexosaminidase activity assay for lysosomal exocytosis. 
Results are shown as percent of total ß-hexosaminidase secreted over 10 or 30 minutes. One µM ionomycin was 
used to stimulate lysosomal exocytosis. C) Zn2+ secretion assay using cell-impermeant FluoZin-3 tetrapotassium 
salt. Results are shown as percent of the maximum fluorescence value recorded in the Control+ Zn2+ samples, which 
were taken as 100%. * Represents p<0.05. ** Represents p<0.001. D) Confocal images of control, VAMP7 and 
SYT7 KD cells untreated or treated for 3 hours with 100 µM Zn2+ and loaded with FluoZin-3,AM (green) and 
LysoTracker (red). Scale bars are 20 microns. 
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Figure 28. VAMP7 and SYT7 KD increase lysosomal numbers and aggregation. 
A) Average number of lysosomes and lysosomal aggregates per image under each condition. Represents an average 
of 2 separate experiments, with 3 images per condition per experiment. Lysosomes were visualized using confocal 
microscopy with Lysotracker channel and analyzed using ImageJ. To calculate lysosomal aggregates, the same 
method was used, but the lower limit of particle size was set at 10 µm. * Represents p<0.05. B) Intermediate steps of 
calculating lysosomal sizes. Each image was thresholded at 100/255 of the maximal pixel intensity value so that 
most lysosomes were visible. Lysosomal size and number were then quantified using the “Analyze particle” 
function within ImageJ. 
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3.3.7 Inhibition of lysosomal exocytosis through VAMP7 KD increases cell death in zinc 
treated cells 
The effects of suppressing lysosomal secretion on Zn2+-induced cell death were analyzed using 
the AnnV/PI assay described above. This assay revealed significant upregulation of Zn2+-induced 
cell death in VAMP7 KD cells treated with 100 μM Zn2+ for 48 hours, compared to control KD 
cells undergoing the same treatment (Figures 29 and 24). In summary, the data described here 
show that the Zn2+ sink integrates Zn2+ absorption from the cytoplasm with its secretion through 
lysosomal exocytosis. Both aspects of the Zn2+ sink function are novel and necessary for Zn2+ 
detoxification.  
 
 
 
 
 
 
 
 
 
 
Figure 29. Inhibition of lysosomal exocytosis through VAMP7 KD increases cell death in Zn2+-treated cells.  
Flow cytometry data of AnnV- and PI-stained control and VAMP7-KD cells treated for 48 hours with 100 µM Zn2+, 
showing increased Annexin V fluorescence in VAMP7- Zn2+ treated cells (grey solid line) compared to control- 
Zn2+ treated cells (solid black line).  
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3.3.8 Enhancing lysosomal exocytosis through TFEB overexpression increases zinc 
secretion 
Since lysosomal biogenesis and exocytosis are regulated by TFEB and related factors [163, 167], 
TFEB should have an impact on lysosomal Zn2+ clearance. Indeed, Figure 30 shows that TFEB 
overexpression, a common protocol used to study its function, increases both lysosomal 
exocytosis as well as Zn2+ secretion. Figure 30 A shows that after 30 minutes, mock-(empty 
vector)-transfected cells secreted 13.95±0.67% of their total β-hex content, while TFEB-
transfected cells secreted 23.11±3.75% (n=3, p<0.05) of their total β-hex content. Once 
stimulated with ionomycin, mock-transfected cells secreted 20.30±1.47% (n=3, p<0.01) of their 
total β-hex content, while TFEB-transfected cells secreted 38.65±1.98% (n=3, p<0.001) of their 
total β-hex content. TFEB also increased Zn2+ clearance. Figure 30 B shows that after 15 
minutes, control KD cells were able to secrete 76.70±1.37% of secretable Zn2+ in our assay, 
while TFEB-transfected cells were able to secrete 104.52±10.12% (n=3, p<0.05) of secretable 
Zn2+. This increase in Zn2+ secretion was dependent on the lysosomal fusion machinery as TFEB 
cDNA and SYT7 siRNA transfected cells had similar levels to control (71.70±3.09%). To our 
knowledge, this is the first evidence linking increased Zn2+ secretion by TFEB and lysosomal 
exocytosis. 
3.3.9 Overloading the lysosomal zinc sink with 200 µM zinc leads to LMP. 
Although no measureable apoptosis was detected at 100 µM Zn2+ alone in our system, exposure 
to 200 µM Zn2+ induced activation of the apoptosis executioner caspase 3 (Cas3), which 
developed between 8 and 12 hours after Zn2+ application (Figure 31 A). The exposure of cells to  
 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Enhancing lysosomal exocytosis though TFEB overexpression increases Zn2+ secretion. 
A) ß-hexosaminidase activity assay for lysosomal exocytosis. Results are shown as percent of total ß-
hexosaminidase secreted over 10 or 30 minutes. One µM ionomycin was used to stimulate lysosomal exocytosis. B) 
Zn2+ secretion assay using cell-impermeant FluoZin-3 tetrapotassium salt. Results are shown as percent of the 
maximum fluorescence value recorded in the Control+ Zn2+ samples at 30 minutes, which were taken as 100%. The 
results shown above are at 15’ of secretion time. * Represents p<0.05. ** Represents p<0.001.  
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Figure 31. Exposure to 200 µM Zn2+ induces LMP and activates Caspase 3 activity.  
A) Caspase 3 activity assay. Exposure to 200 µM Zn2+ over 8 hours induced Caspase 3 activation and apoptosis. B) 
Confocal images of control, ZnT2 or ZnT4 siRNA transfected cells, transduced with LAMP1-RFP (red) and stained 
with Hoechst dye (blue) and LysoTracker (green). Scale bars are 20 microns. The exposure of cells to 200 µM Zn2+ 
for up to 12 hours caused the LMP as indicated by the loss of Lysotracker stain. The Zn2+-induced LMP was 
inhibited by ZnT2/ZnT4 KD.  (C) qRT-PCR of LAMP1 mRNA levels. (D) Western blot of LAMP1 or actin levels. 
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200 µM Zn2+ for up to 12 hours caused the LMP as indicated by the loss of Lysotracker stain 
(Figure 31 B). The Zn2+-induced LMP was inhibited by either ZnT2 or ZnT4 KD, which 
suggests that ZnT2 and ZnT4-mediated influx of Zn2+ into the lysosomes causes LMP and cell 
death. We suggest that normally, under the conditions of high Zn2+ exposure, the ZnT2- and 
ZnT4-dependent overload of the lysosomes with Zn2+ leads to LMP. The ZnT2 and ZnT4 
involvement is in line with the previously published data implicating lysosomal Zn2+ buildup in 
cell death. In this system, ZnT-KD did not seem to affect lysosomal biogenesis, as neither 
mRNA (Figure 31C) or protein (Figure 31D) levels of the lysosomal membrane protein LAMP1, 
nor the levels of Lysotracker stain (Figure 31B) were significantly affected by ZnT2/ZnT4 KD 
under the normal conditions. 
3.4 DISCUSSION 
Although lysosomes are most commonly discussed in terms of their role in endocytic digestion 
and absorption, mounting evidence points towards their role in cell death and in signaling [493]. 
Recent evidence indicates that under oxidative stress conditions, Zn2+ accumulates in the 
lysosomes and can lead to LMP [304]. Furthermore, this Zn2+ dysregulation is mechanistically 
linked to autophagy [475, 478, 494]. Considering that autophagy and oxidative stress play a 
critical role in cell death and neurodegenerative pathologies, it is likely that Zn2+ represents a 
new target for modulating diseases and a key step in understanding neuronal cell death. The 
recent developments emphasize the role of lysosomes in metal toxicity. Thus, the accumulation 
of Zn2+ and other metals in lysosomes was shown to lead to LMP, to the release of lysosomal 
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enzymes into the cytoplasm, and to cell death. While pathological aspects of Zn2+ buildup in the 
lysosomes are undisputable, its physiological role is unclear.  
Our recent data suggest that lysosomes play a role of a “Zn2+ sink,” working in parallel 
with the transcriptional regulation of Zn2+ chelation and transport proteins. Cytoplasmic Zn2+ is 
gauged by the transcription factor MTF-1, which, upon Zn2+ binding, induces transcription of 
Zn2+ chelators such as metallothioneins and Zn2+ transporters such as ZnT (Slc30a). The ability to 
absorb Zn2+ via active transport involving ZnT transporters makes lysosomes a good candidate 
for absorbing rapid cytoplasmic Zn2+ spikes. The recently published data on the lysosomal 
absorption of Zn2+ released from metallothioneins by H2O2 highlight such a function of 
lysosomes [304, 478, 495, 496].  
Although ZIP (Slc39) transporters such as ZIP8 were shown to exist in the lysosomes 
[497], their impact on the function of the lysosomal Zn2+ sink has not been shown. At the same 
time, the ion channel TRPML1, whose dysfunction causes the lysosomal storage disease MLIV 
[366], was shown to be a component of the lysosomal Zn2+ transport machinery. Its loss was 
shown to cause Zn2+ buildup in the lysosomes in studies by two groups [393, 473] and its 
permeability to Zn2+ by another group [376]. It seems reasonable to conclude that TRPML1 is 
involved in trafficking Zn2+ from lysosomes into the cytoplasm. We proposed that upon entering 
the cell, Zn2+ is registered by MTF-1, which leads to an eventual increase in transcription and 
translation of Zn2+ chelators and exporters. However, Zn2+ must be rapidly eliminated from the 
cytoplasm in order to protect against toxicity. Thus, in parallel, Zn2+ is scavenged by the 
lysosomes, to be later released through a TRPML1-dependent mechanism.  
The data in Fig 25D, 26C and 29B show that lysosomal secretion is also involved in Zn2+ 
clearance from the cell. What is the relationship between the two mechanisms of Zn2+ clearance? 
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We think that their function reflects their ability to respond to changes in Zn2+ flow. Such 
changes can be caused by increased autophagy of Zn2+-rich organelles such as mitochondria or 
proteins. Interestingly, TRPML1 is upregulated in response to increased endocytic load in a 
manner that requires the transcription factor TFEB, while VAMP7 remains unchanged (I.K., 
unpublished observation). Based on this, we propose that TRPML1-driven Zn2+ release is a 
dynamic response to increased Zn2+ load, while VAMP7- and SYT7-dependent secretion is a 
constitutive mechanism. We believe that our data clearly show Zn2+ absorption into the 
lysosomes followed by its secretion as an important detoxification mechanism. Furthermore, the 
fact that suppression of the lysosomal function caused Zn2+ redistribution into Golgi and 
mitochondria shows that the lysosomal Zn2+ sink has a major impact on the cellular Zn2+ 
handling.  
LMP following Zn2+ exposure was clearly shown to be a cell death pathway [304, 477-
479]. Why would cells employ a Zn2+ detoxification mechanism that effectively kills them? We 
think that the answer to this question lies in the relation between the lysosomal Zn2+ absorption 
rates and the rate of its secretion/release. Such a ratio may depend on the tissue, developmental 
stage and on other factors. We propose that under the normal conditions, or moderate Zn2+ 
exposure, the Zn2+ sink limits cytoplasmic Zn2+ by absorbing it (Model in Figure 25). Zn2+ is later 
released into the cytoplasm (as discussed above), or secreted across the PM. However, during the 
exposure to high (200 μM) levels of Zn2+, Zn2+ extraction lags, leading to LMP and cell death 
(Figure 31). Our data show a role of lysosomes in transition metal toxicity and identify a novel 
detoxification mechanism.   
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4.0  THE LYSOSOMAL ZINC SINK IS PHYSIOLOGICALY RELEVANT IN 
REMODELLING OF THE MAMMARY GLAND 
The work discussed in this Chapter is unpublished data of which I performed all the experiments, 
except for the cytochrome C immunofluorescence and some of the original Mitotracker 
experiments, which were performed by Dr. Kirill Kiselyov and three undergraduates from our 
lab: Neel Andharia, Yi Wang, and Ly Li. Much of this work stems from a collaborative effort 
with Dr. Shannon Kelleher at Penn State.  
4.1 INTRODUCTION 
Zinc (Zn2+) plays a critical role in many cellular functions including gene expression, cell 
proliferation, differentiation and apoptosis. One of the important physiological requirements for 
Zn2+ is in the mammary gland. The mammary gland depends on the coordination of processes 
such as cell proliferation, differentiation and apoptosis for proper development and function. For 
example, during lactation, the mammary gland needs to provide adequate Zn2+ content for 
cellular processes, as well as secrete substantial amounts of Zn2+ into milk necessary for the 
development of the baby. At the same time, the mammary gland undergoes one of the most 
profound examples of cell death as a result of apoptotic and lysosomal-mediated pathways. It has 
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been shown that Zn2+ transport plays a key role in several aspects of mammary gland 
development and function [498, 499]. 
However, Zn2+ dysregulation has been associated with a vast number of human diseases 
and pathological conditions, including impaired breast function [500] and breast cancer [501, 
502]. As such, cytoplasmic Zn2+ levels must be carefully modulated. In fact, failure to regulate 
Zn2+ sequestration into organelles leads to defects in cell proliferation, autophagy, transcription, 
and apoptosis. For example, elevated cytoplasmic Zn2+ levels activate the mitogen-activated 
protein kinases (MAPKs) responsible for mediating various cellular responses to extracellular 
stimuli, including growth, proliferation and cell survival [503, 504]. Elevated cytoplasmic Zn2+ 
levels also activate protein kinase C (PKC), and thereby affect signal transduction pathways 
involved in cell growth and transcription [505, 506]. At the same time, Zn2+ can be cytotoxic if 
high levels cause Zn2+ buildup in the mitochondria, where it has been shown to decrease ATP 
production and induce apoptosis [423, 424, 507]. Thus, cytoplasmic Zn2+ levels are carefully 
modulated by two families of Zn2+–specific transporters: members of the ZIP family import Zn2+ 
into the cytoplasm from the extracellular environment or from subcellular organelles, while 
members of the ZnT family export Zn2+ from the cytoplasm into organelles or out of the cell.  
Lysosomes are emerging as key players in regulating cytoplasmic and organelle Zn2+ 
pools [393, 473]. Although lysosomes are critical for degradation of macromolecules, recent 
compelling evidence indicates that lysosomes have a much broader function and are involved in 
many other processes ranging from plasma membrane repair, to intracellular signaling, and 
secretion.  Recently, the lysosomal ion channel transient receptor potential mucolipin 1 
(TRPML1) has also been implicated in Zn2+ transport. Mutations in TRPML1 lead to 
mucolipidosis type IV (MLIV) [366], a disease with a neurodegenerative profile characterized by 
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severe mental and psychomotor delays and retinal degeneration. TRPML1 has been shown to 
conduct Zn2+ [376] and regulate the efflux of Zn2+ from lysosomes [393, 473]. Interestingly, 
while TRPML1 levels are below detection in virgin and lactating mammary glands and mouse 
mammary epithelial  HC11 cells, TPRML1 becomes highly upregulated in the involuting 
mammary gland, a process associated with increased autophagy and cell death [499]. This 
implicates TRPML1-mediated processes in mammary gland remodeling. The other proteins 
implicated in lysosomal Zn2+ transport are ZnT2 and ZnT4. We and others have found that ZnT2 
and ZnT4 import Zn2+ into lysosomes [431, 444, 449, 451]. Together with TRPML1, ZnT2 and 
ZnT4 are key elements of the lysosomal Zn2+ sink, which is a dynamically regulated Zn2+ pool 
that absorbs and releases cytoplasmic Zn2+ in response to cellular needs. Curiously, both ZnT2 
and ZnT4 are required for Zn2+ secretion into milk [451, 508] and were found to colocalize with 
TRPML1 in HeLa cells [473], suggesting that ZnT2 and/or ZnT4 work with TRPML1 to 
regulate lysosomal Zn2+ pools in mammary epithelial cells. Furthermore, both ZnT2 and ZnT4 
knockout mice have significant defects in mammary gland involution, while ZnT2 
overexpression prematurely activates autophagic cell death (Shannon Kelleher, unpublished 
data).  
Overall, lysosomal Zn2+ accumulation has not only been observed in the involuting 
mammary gland [499], but has also been shown to cause lysosomal membrane permeabilization 
(LMP) leading to cell death in neurons [304, 478], retinal pigment epithelial and photoreceptor 
cells [475] and breast cancer cells [477]. However, the role of Zn2+ and LMP in lysosomal-
mediated cell death is unclear and very little information is available on lysosomal Zn2+ 
transport. Also, it is not clear what signaling pathways regulate the localization of Zn2+ 
transporters to lysosomes. Neither ZnT2 [433], nor ZnT4 [445], or TRPML1 [499] are expressed 
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in lysosomes of mammary epithelial cells under basal conditions. It is likely that local stimuli 
such as LIF, TGF-β, or TNFα produced by the mammary gland initiate involution [509] and 
modulate signaling pathways responsible for trafficking ZnT2 and ZnT4 to the lysosome. 
Here we sought to address whether the lysosomal Zn2+ sink and TRPML1 are involved in 
mammary gland function. Our findings indicate that TRPML1 expression is regulated by 
involution signals such as TNFα and likely plays a vital role in mammary gland involution by 
dissipating lysosomal Zn2+ buildup. Given the vast number of Zn2+–dependent processes, our 
findings are likely to have implications beyond lactation and MLIV pathogenesis. 
4.2 EXPERIMENTAL METHODS 
4.2.1 Cell Culture 
HeLa cells were maintained in DMEM (Sigma-Aldrich, St Louis, MO) supplemented with 7% 
FBS, 100 µg/ml penicillin/streptomycin, and 5 µg/ml Plasmocin prophylactic (Invivogen, San 
Diego, CA) and grown at 37oC in 5% CO2. For siRNA and cDNA transfection, antibiotic free 
media was used. Zn2+ (100 µM) was added to antibiotic free medium, containing serum, 24 hrs 
after transfection, for 48 hrs. 
Retinal pigmented epithelial 1 (RPE1) cells were maintained in DMEM/ Ham F12 
(DMEM/F12), 1:1 mix (HyClone, Logan, UT) supplemented with 10% FBS and grown at 37oC 
in 5% CO2. TNFα was added to media containing serum, 24 hrs after transfection, for 24 hrs at a 
concentration of 40 ng/ml. 100 mM sucrose was pre-dissolved in media containing serum, and 
added to cells 24 hrs after transfection, for 48 hrs at a concentration of 100mM.  
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4.2.2 siRNA-mediated TRPML1 knockdown and TFEB overexpression 
ON-TARGET plus siRNA were designed as described previously [387, 443] and synthesized by 
Dharmacon (Lafayette, CO). The TRPML1 siRNA probe targeting the sequence 5'-
CCCACATCCAGGAGTGTAA-3' in MCOLN1 was used for all TRPML1 KDs. Non-targeting 
control siRNA#1 (Sigma) was used as a negative control. Cells were transfected using 
Lipofectamine 2000 (Invitrogen, Carlsbag, CA) as described by manufacturer’s protocol using 
600 nM siRNA per 35 mm well. All KDs were confirmed using SYBR-green based qPCR. . For 
DNA transfections, 2 μg of TFEB-Flag was transfected per 35mm dish. 
4.2.3 Microscopy 
HeLa cells were seeded on glass coverslips and loaded with dyes for 15 min at 37ºC in buffer 
containing, in mM: 150 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, pH 7.4, 1 g/L glucose. The 
loading was followed by 15 min washout in all cases. Mitotracker Red CMXRos, DAPI 
(Invitrogen), and propidium iodide (Calbiochem) were used at 0.1, 1, 0.05 µM respectively. 
Confocal microscopy was performed using the BioRad 3000 confocal and Nikon microscopes.  
Live cells were treated as above. For Cytochrome C (CytC) experiments, cells were fixed for 5 
min in 4% paraformaldehyde at room temperature and permeabilized using 0.1% Triton X100 
for 5 min on ice. Following washout and blocking in BSA and goat serum, cells were treated 
with primary antibody overnight: CytC (Abcam, ab13575). Cells were then incubated in 
fluorescent-tagged secondary antibodies for 1 hr. No permeabilization or blocking was 
performed in DAPI experiments. Images were analyzed using ImageJ (Bethesda, MD).  
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4.2.4 Western Blot Analysis 
For CytC experiments, cells were homogenized using a Dounce homogenizer in a buffer 
containing protease inhibitor cocktail mix III (Calbiochem, Gibbstown, NJ). The cytoplasmic 
fraction was isolated by centrifugation at 60,000 g for 20 min at 4ºC and collecting supernatant. 
Proteins were concentrated using Millipore 10K Ambion filters. Protein concentrations were 
determined using a Bradford assay. Proteins were incubated at 100°C for 5 minutes in sample 
buffer containing 14% β-Mercaptoethanol. Equal amounts (60 µg) of protein were loaded on a 
12.5% precast Tris-HCl polyacrylamide gel (BioRad, Hercules, CA) for each experimental 
sample. Proteins were transferred to PVDF membrane (Millipore, Billerica MA) and blocked in 
10% NFDM for 1 hr. Membranes were incubated overnight at 4ºC in primary antibody for CytC 
(Abcam, Cambridge MA, ab13575) or caspase 9 (Cell Signaling, #9502). HRP conjugated anti-
mouse secondary antibodies (Amersham, Piscataway, NJ) were used at 1:20,000 dilution. 
Immunodetection was performed with the Luminata Forte HRP substrate (Millipore).  
4.2.5 Seahorse assay for mitochondrial function 
An XF24 Analyzer (Seahorse Biosciences, North Billerica MA) was used to determine 
mitochondrial function in untreated cell, cells treated with 100 µM Zn2+ for 48 hrs, or with 1 µM 
staurosporine for 4 hrs. Cells were seeded on specialized microplates so that oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) or proton production rate 
(PPR) are monitored in real time by the XF24. Then, oligomycin (1 µg/ml), FCCP (1 µM) and 
antimycin A (10 µM) were injected by the cartridges in order to determine basal levels of oxygen 
consumption, the amount of oxygen consumption linked to ATP production, proton leak, 
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maximal respiration capacity and non-mitochondrial oxygen consumption. OCR and ECAR were 
then normalized to protein levels per well using a Bradford-based assay. Five replicates per 
group were analyzed.  
4.2.6 Reverse Transcriptase and Quantitative qPCR 
RNA was isolated from cells using Trizol (Invitrogen, Carlsbag, CA) according to the 
manufacturer’s protocol. cDNA was synthesized using the GeneAmp RNA PCR system 
(Applied Biosystems, Carlsbad, CA) with oligo dT priming. qPCR was performed SYBR green 
(Fermentas, Glen Burnie, MD). The amount of cDNA loaded was normalized to starting RNA 
concentrations, with a final concentration of 9 ng of RNA loaded per experimental well. Six-
point standard curves were generated for each primer using 1:2 dilutions of cDNA. cDNA for the 
following genes were amplified using the indicated primers (IDT, Coralville, IA). Mouse 
TRPML1: forward: 5’ -GGCATTGAGGCAAAGAACCT-3’, reverse: 5’- 
GAATGACACCGACCCAGACT-3’. Mouse LAMP1: forward: 5’ -
GCGAATGGTTCTCAGATCGT-3’, reverse: 5’- AGGCTGGGGTCAGAAACATT-3’. Mouse 
Cathepsin D: forward: 5’ - TACTCAAGGTATCGCAGGGTG-3’, reverse: 5’- 
CCAATGAAGACATCGCCCAG-3’. Mouse beta Actin: forward: 5’ -
GCTCCGGCATGTGCAAAG-3’, reverse: 5’- CATCACACCCTGGTGCCTA-3’. Human 
LAMP1: forward: 5’-GGACAACACGACGGTGACAAG-3’, reverse: 5’-
GAACTTGCATTCATCCCGAACTGGA -3’. Human TRPML1: forward: 5’- CAC GGT GCA 
GCT CAT CCT GTT T-3’, reverse: 5’- CGC CAA GTT CTT GGC CTC GAT-3’. Human 
RPL32: forward: 5’- CAACATTGGTTATGGAAGCAACA-3’, reverse: 5’- 
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TGACGTTGTGGACCAGGAACT-3’. Human MT2a: forward: 
5’AAGTCCCAGCGAACCCGCGT-3’, reverse: 5’-CAGCAGCTGCACTTGTCCGACGC-3’. 
All primers were designed to span exons and negative RT controls were tested to ensure 
amplification of cDNA only. qPCR was performed using the Standard Curve method on the 
7300 Real Time System (Applied Biosystems, Carlsbad, CA). Reactions were run on the 
following parameters: 2 min at 50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 sec followed 
by 60°C for 1 min. All experimental samples were run in triplicate and normalized to a β–actin 
endogenous control.  
Statistical significance was calculated using a one-tailed, unpaired t-test with p≤0.05 
considered significant. Data are presented as mean±S.E.M. 
4.3 RESULTS 
4.3.1 TRPML1 is a component of the lysosomal zinc sink. 
Since TRPML1 has been shown to modulate Zn2+ efflux from the lysosomes [393], we sought to 
first verify that TRPML1 indeed retains Zn2+ in the lysosome. The upregulation of MTF-1–
dependent, Zn2+-responsive genes such as MT2a and ZnT1 [486] indicates elevated cytoplasmic 
Zn2+. MT2a mRNA was used previously in our studies of the role of TRPML1 in Zn2+ handling. 
We measured the expression of the mRNA of these genes using qRT-PCR in HeLa cells (Figure 
32). MT2a expression does not seem to be more sensitive to Zn2+ stimulation in TRPML1-
deficient cells than in control cells as 2-hr long stimulation of control and TRPML1 KD cells 
with Zn2+ resulted in significant MT2a mRNA spikes, but the spikes were of similar magnitudes 
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in control and TRPML1 KD cells (Figure 32). When 2-hr long exposure to 100 µM Zn2+ was 
followed by a return to normal Zn2+ levels for 24 hours, MT2a levels in control cells fell back to 
pre-stimulation levels. By contrast, MT2a mRNA remained significantly higher (512±189% of 
control levels, n=3, p<0.05) in TRPML1 KD cells. These data can be explained by the protracted 
release of Zn2+ from the lysosomes into the cytoplasm in TRPML1 KD cells.  
Next, we sought to explore the possible effects of TRPML1 on cell function, and to 
delineate mechanisms linking TRPML1 loss, Zn2+ dysregulation, and vacuolar enlargement in 
TRPML1 KD cells. MLIV is a neurodegenerative disease [441, 442, 510-513], ostensibly linked 
to neuronal cell death. Mitochondrial dysfunctions play a prominent role in cell death and in 
storage diseases [514-518]. Since mitochondrial architecture and function are directly affected by 
cytoplasmic ions, we first focused on the mitochondrial structure as a readout of TRPML1 
effects at the cellular level. The integrity of the mitochondrial membrane and the mitochondrial  
network architecture are critically important determinants, as well as indicators, of cell health 
[519]. A number of toxic events, genetic diseases and degenerative conditions are associated 
with the loss of mitochondrial architecture and integrity [519]. A key step in the apoptosis 
program is the destabilization of the mitochondrial membrane followed by the release of 
cytochrome (CytC), which can be a passive outcome of chemical modification of mitochondrial 
lipids [520], or an active event, mediated by the pro-apoptotic Bcl-2 family members [521, 522].  
Figure 33 shows that exposure of HeLa cells to 100 µM ZnCl2 for 48 hours induced 
dramatic changes in mitochondrial structure. Cells stained with Mitotracker suggest that in Zn2+ 
treated cells mitochondrial morphology changed from a well-pronounced network of thread-like 
organelles to a highly fragmented punctate pattern (Figure 33A). In order to test how TRPML1 
affects cells exposed to Zn2+, we used siRNA to modulate TRPML1 levels. Interestingly, Figures  
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Figure 32. MT2a mRNA response to Zn in TRPML1-deficient cells persists after Zn2+ removal. 
Pulse-chase experiments showing chronic upregulation of MT2a mRNA in TRPML1 KD cells stimulated with Zn2+ 
for 2 hours (pulse), followed by 24-hr long exposure to normal Zn2+  levels (chase). MT2a mRNA was measured 
using qPCR. Data represent 3-5 experiments. * represents p<0.05.  
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Figure 33. Mitochondrial phenotype in Zn2+ treated cells.  
HeLa cells transfected with control and TRPML1 siRNA analyzed using confocal microscopy. A. Mitotracker stain. 
Zn2+ treated cells were incubated with 100 µM Zn2+ for 48 hrs. Panel represents 3-5 separate experiments, 5 images 
per experiment, per condition. B. Frequency of punctate mitochondrial phenotype occurrence is compared in 
untreated and Zn2+ treated control and TRPML1 KD cells. Control cells were transfected with scrambled siRNA. 
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Data were calculated from confocal images represented by Panel A. Images containing 3 or more cells were used. 
Only the cells that were completely present in the field of view were taken into account. Each column represents 3 
or more experiments, 3-5 images per experiment, per condition. * represents p<0.05. C. Confocal images 
representing Cytochrome C stain. Zn2+ treated cells were incubated with 100 µM Zn2+ for 48 hrs. Panel represents 3-
5 separate experiments, 5 images per experiment, per condition. D. Western blot analysis of cytoplasmic fractions 
from untreated and Zn2+ treated (48 hrs) HeLa cells probed with actin and Cytochrome C antibodies. Staurosporine 
(1µM) was used as positive control for Cytochrome C release into cytoplasm.  
 
33A and B show that TRPML1 KD reversed the mitochondrial punctate phenotype induced by 
Zn2+.  
This trend persisted when mitochondrial morphology was tested using immunostaining 
with antibodies against CytC. This mitochondrial protein is released into the cytoplasm during 
apoptosis [523]. Therefore, CytC assays enabled us to monitor mitochondrial fragmentation as 
well as cell death as a function of TRPML1 status and Zn2+ exposure. Figure 33 C shows that a 
48-hr treatment with Zn2+ induced consolidation of CytC into puncta, similar to the Mitotracker 
stain in cells exposed to Zn2+. As with Mitotracker, TRPML1 KD reversed the punctate 
phenotype of CytC (Figure 33 C).  
The observed effects were not directly caused by, or associated with, measureable 
deterioration of the mitochondrial functional status. No CytC release into the cytoplasm was 
observed using confocal microscopy (Figure 33 C) or Western blot (Figure 33 D) with cells 
treated with Zn2+. Cell death assays utilizing 4',6-diamidino-2-phenylindole (DAPI) or propidium 
iodide did not result in a statistically significant increase in nuclear fragmentation or loss of 
membrane integrity (Figure 34). Experiments utilizing mitochondrial dye MitoSOX did not  
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Figure 34. DAPI- and Propidium iodide-based apoptosis assays in Zn2+-treated cells.  
A. DAPI stain. Images were obtained using compound microscope fitted with fluorescent attachment. Arrows 
indicate misshapen nuclei. HeLa cells were treated with Zn2+ for 48 hrs, and with Staurosporine (Sta) – for 4 hours. 
B. Cells treated with various concentrations of Zn2+ for 48 hrs and stained with PI. No measureable PI uptake is seen 
in cells treated with 100 µM Zn2+.  
 
 
 
 
 
 
 
Figure 35. Mitochondrial assays in Zn2+-treated cells.  
Top panels show brightfield images of cells. Bottom panels - MitoSOX signal. Images were obtained using 
compound microscope fitted with fluorescent attachment. Zn2+ was applied for 48 hrs, at 100 µM concentration in 
HeLa cells. Antimycin A (30 min treatment at 1 µM) was used as positive control. Arrows point to cells with 
MitoSOX signal.  
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Figure 36. Functional mitochondrial health (Seahorse) assays in Zn2+-treated HeLa cells.  
A. Oxygen consumption rates (OCR) are shown for the basal respiration rate of untreated (solid black), Zn2+ treated 
(dashed grey), or staurosporine treated (dashed black) HeLa cells. After the basal measurements, cells were treated 
with oligomycin (a complex V inhibitor) at the 12 minute mark, FCCP (an uncoupler of ATP synthesis) at the 24 
minute mark and Antimycin A (to disrupt the proton gradient) at the 37 minute mark. Zn2+ treated cells did not have 
a significantly reduced basal mitochondrial OCR (left side), nor a reduced ATP-linked OCR (12-24 mins). B. ATP-
linked OCR rates were compared between untreated, Zn2+ treated and Sta treated cells by averaging the drop in OCR 
following oligomycin treatment.  
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reveal measurable production of reactive oxygen compound superoxide under our experimental 
conditions (Figure 35). Finally, the Seahorse assay did not show a statistically significant loss of 
basal or ATP-linked oxygen consumption in cells treated with Zn2+ within the time frame used in 
these experiments (Figure 36). Mitochondrial respiration was significantly affected and apoptosis 
was activated upon a 4-hr long treatment with 1 µM staurosporine, which was used as a positive 
control (Figure 36). These data show that prolonged Zn2+ treatment results in a mitochondrial 
punctate phenotype, which is likely an effect of Zn2+ and not a result of cell death. TRPML1 KD 
prevents mitochondrial punctate phenotype induced by Zn2+.  
Taken together, the data described above suggest that although TRPML1 is localized in 
lysosomes, its effects extend beyond lysosomes and affect other compartments. We have 
previously shown that TRPML1 loss affects mitochondria function and autophagy [515, 516]. 
This is another evidence indication that TRPML1 plays a role outside the late endocytic 
pathway.  
4.3.2 TFEB rescues Zn2+–induced LMP. 
LMP following lysosomal Zn2+ accumulation was clearly shown to be a cell death pathway in 
many different cell types [304, 477-479]. We propose that the relation between the lysosomal 
Zn2+ absorption rates and the rate of its secretion/release determine whether lysosomal Zn2+ 
accumulation is protective or destructive. We have not observed a significant amount of cell 
death following moderate (100 μM) Zn2+ exposure. However, we did observe LMP with high 
(200 μM) Zn2+ (Figure 31) and show that knockdown of either ZnT2 or ZnT4 prevents LMP. 
Furthermore, since lysosomal biogenesis and exocytosis are regulated by TFEB and related 
factors [163, 167], we showed that TFEB overexpression increased lysosomal Zn2+ clearance and  
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Figure 37. TFEB ameliorates cell death induced by 200 µM Zn2+ and LMP.  
A) Flow cytometry analysis of HeLa cells stained with PI and AnnV. Mock- or TFEB-transfected cells were either 
untreated or treated with 200 µM ZnCl2 for 12 hours. Note a decrease in number (7.0%) of cells with positive PI, 
negative AnnV stain (“necrotic cells”) in TFEB cells treated with Zn2+ (lower right panel) compared to control Zn2+ 
treated cells (11.1%, lower left panel). B and C) qRT-PCR results of MT2a (B) and ZnT1 (C) mRNA, shown as 
percent of control untreated (no Zn2+) cells. RNA was isolated from HeLa cells either untreated (no Zn), or cells 
treated for 3 hours with 100 µM ZnCl2. * Represents p<0.05. ** Represents p<0.001. 
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secretion (Figure 30). If lysosomes function as Zn2+ sinks, then increasing lysosomal numbers 
through TFEB overexpression, should prevent LMP by providing additional Zn2+ storage sites. 
Indeed, Figure 37 A shows that TFEB overexpression decreased propidium iodide staining in 
LMP-inducing conditions compared to control cells (200 µM Zn for 12 hrs). However, TFEB 
overexpression, leads to increased expression of at least two genes, whose products are known to 
play a key role in Zn2+ handling. First, Figure 37 B shows that expression of the gene coding for 
Zn2+ chelating protein MT2a is increased as well. MT2a mRNA increased to 305.62±15.93% 
(n=3, p<0.001 compared to untreated control) in Zn2+ treated control cells, TFEB overexpression 
increased MT2a expression to 697.82±42.85% (n=3, p<0.001, compared to Zn2+ treated control 
cells). Increased MT2a expression will decrease cytoplasmic Zn2+ as well. It should be noted that 
Zn2+ secretion experiments in which TFEB was overexpressed in VAMP7 or SYT7 knockdown 
cells showed an increased fraction of Zn2+ export that is unaffected by VAMP7 and SYT7 
knockdown (Figure 30 B). This could indicate increased ZnT1-dependent Zn2+ export through 
the plasma membrane in TFEB-overexpressing cells.  Interestingly, this increase does not seem 
to be directly controlled by TFEB transcriptionally, as knockdown of the transcription factor 
MTF-1 partially reduces ZnT1 and MT2a expression (Figures 37 B and C). TFEB-cDNA and 
MTF-1-siRNA-transfected cells had an attenuated response where MT2a mRNA increased only 
to 360.94±36.86% (n=3, MTF-1 knockdown was confirmed in our previous studies [473]). 
Second, Figure 37 C shows that the mRNA expression of ZnT1 is increased in Zn2+-treated, 
TFEB-overexpressing cells. ZnT1 exports Zn2+ from the cytoplasm across the plasma membrane. 
Increased ZnT1 expression itself will decrease cytoplasmic Zn2+. TFEB-overexpressing cells had 
an elevated ZnT1 mRNA response where ZnT1 mRNA increased to 280.30±6.74% (n=3, 
p<0.001, compared to untreated control cells) in Zn2+ treated control cells and 589.00±27.80% 
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(n=3, p<0.001, compared to Zn2+ treated control cells) in TFEB-overexpressing cells. Again, this 
response in Zn2+ treated TFEB-overexpressing cells was attenuated by MTF-1 KD to 
254.41±28.23%.  
4.3.3 TRPML1 expression is regulated by TNFα. 
The mammary gland is a highly complex and specialized tissue designed to provide nutrition for 
offspring. Consequently, mammary gland involution is an essential and natural process that 
eliminates milk-producing epithelial cells when they are no longer needed at weaning. This two-
step process first involves removing the secretory epithelium through autophagic cell death and 
then replacing it with adipocytes [509]. For some time now, it has been recognized that certain 
hormones and cytokines drive the molecular mechanisms in the involution process.  For 
example, it has been shown that weaning signals and milk stasis induce LIF, TGF-β, and TNFα 
signaling pathways [499, 524, 525]. However, what is not well understood are factors that 
modulate these processes and how they affect mammary gland remodeling and secretion. 
Interestingly, lysosomal Zn2+ accumulation has been observed in the involuting mammary gland 
and ZnT2 and ZnT4 have been found necessary for involution [499]. Considering that ZnT2-, 
ZnT4- and TRPML1-deficient cells have autophagic defects, we hypothesize that the lysosomal 
Zn2+ sink plays an important role in autophagice cell death and mammary gland remodeling. To 
that end, we sought to determine if TRPML1 expression can be modulated by involution signals 
such as TNFα. Figure 38 shows that TRPML1 expression is significantly upregulated in TNFα-
treated mammary epithelial HC11 and RPE cells. Figure 38 A and B show that TNFα increased 
TRPML1 mRNA expression by 66.39±31.74% (n=3, p<0.05, compared to untreated control 
cells) in HC11 cells and by 38.80±7.59% (n=3, p<0.05, compared to untreated control cells) in 
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RPE cells. TNFα also increased the mRNA expression of LAMP1, a lysosomal membrane 
protein, by 51.84±22.27% (n=3, p<0.01, compared to untreated control cells) in HC11 cells and 
by 31.09±15.55% (n=3, p<0.05, compared to untreated control cells) in RPE cells (Figure 38 A 
and B). To our knowledge, except for TFEB, this is the only other factor shown to regulate 
TRPML1 expression. As expected, TFEB overexpression increased TRPML1 mRNA expression 
by 134.99±28.81% (n=3, p<0.001) in untreated RPE cells and by 326.67±47.04% (n=3, 
p<0.001, compared to TNFα–treated mock cells) in TNFα-treated RPE cells. 100mM sucrose 
was used for 48 hours as a positive control for TFEB as it has been shown to activate and 
translocate TFEB to the nucleus. 3 hour starvation was also used as a control for the activation of 
autophagy, another TFEB dependent process. These data support our hypothesis that TRPML1 is 
upregulated during involution and plays an important role in the autophagic and lysosomal-
mediated cell death pathways involved in remodeling of the mammary gland.  
4.4 DISCUSSION 
While the channel properties of TRPML1 are only now beginning to be understood, the 
functional impact of TRPML1 activity on cellular processes is unclear. TRPML1 function has 
been implicated in Ca2+–sensitive membrane fusion events within the endocytic pathway [370, 
379, 380], as well as transition metal homeostasis [376, 393, 473]. These data for the first time, 
have implicated TRPML1 in processes outside of the lysosome. In the course of these studies, 
we found that, in agreement with the previously published studies, TRPML1 is a vital component 
of the lysosomal Zn2+ sink. Our findings provide further insight into this process by showing that  
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Figure 38. TRPML1 expression is regulated by mammary gland involution signals such as TNFα. 
A) qRT-PCR data showing the mRNA expression of mouse TRPML1, LAMP1 and Cathepsin D in mouse 
mammary epithelial HC11 cells treated with 15 ng/ml TNFα. B) qRT-PCR of human TRPML1 (bottom, left) and 
LAMP1 (bottom, right) mRNA expression in RPE cells. Mock (empty vector) or TFEB overexpressing RPE cells 
were either untreated (untr), or 24 hours post transfection, treated with 40 ng/ml TNFα for 24 hours, 3 hour 
starvation, or 48 hour 100mM sucrose. RNA was isolated 48 hours post transfection. Data represents 3 independent 
experiments per treatment. * Represents p<0.05. ** Represents p<0.001. 
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TRPML1 loss affects processes beyond lysosomes, and by identifying some of the signaling 
pathways that regulate TRPML1 expression.  
The impact of TRPML1 on Zn2+ regulation seems to involve the mitochondria and 
cytoplasmic proteins. Augmentation of the MT2a mRNA response to Zn2+, as well as 
mitochondrial involvement strongly suggest that the effects of TRPML1 loss do not involve only 
lysosomal compartments; indeed such effects involve the entire cell. Although the exact 
mechanism and full list of components of TRPML1’s mitochondrial involvement is presently 
unclear, these data illustrate the cell-wide role of TRPML1, beyond the lysosomal context. A 
role for TRPML1 in regulating cellular ionic balance may be important for understanding the 
mechanisms of cell death in MLIV. Overall, these data are consistent with TRPML1 as a 
lysosomal divalent cation channel whose function is to regulate the distribution of transition 
metals between the cytoplasm and lysosomes. This hypothesis is supported by previously 
published data on Zn2+ and Fe2+ buildup in the lysosomes of TRPML1 deficient cells [376, 393]. 
We have also shown that the lysosomal Zn2+ sink can be modulated by TFEB 
overexpression. TFEB overexpression rescued Zn2+–induced LMP. However, even though this is 
a fascinating topic, it is very complicated at the moment. Our data on secretion in TFEB-
overexpressing cells are in line with our main model of the lysosomal Zn2+ sink. However, the 
complexity of regulatory networks converging on, and regulated by TFEB, means that other 
interpretations cannot be ruled out within the context of our limited knowledge of TFEB. Our 
data suggest that the use of TFEB to highlight the importance of the lysosomal secretion in Zn2+ 
toxicity may be misleading since TFEB overexpression increased the mRNA expression of ZnT1 
and MT2a as well. In accordance with increased ZnT1 expression, the fraction of Zn2+ efflux that 
is insensitive to VAMP7 or SYT7 KD in our assays (Figure 30) indicates that both pathways 
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involved in Zn2+ clearance under these conditions. The relative contribution of each respective 
pathway warrants further exploration, but has the potential to provide insights for many 
lysosomal, neurodegenerative and Zn2+ related diseases. We do not know how TFEB stimulates 
expression of these genes, since they do not contain CLEAR sequences required for TFEB 
binding. It is, however, clear that TFEB over-expression significantly changes Zn2+ handling by 
cells, and thus all interpretations of the TFEB effect on Zn2+ toxicity that are based on our current 
understanding of TFEB and Zn2+ regulation will have this uncertainty. At this time, we do not 
know any way to specifically prevent TFEB-induced ZnT1 and MT2a expression, without 
dramatically affecting the entire Zn2+ handling landscape.  
More importantly, we have not only implicated TRPML1 in mammary gland remodeling, 
but have also identified a new signaling pathway that modulates TRPML1 expression. These 
data suggest that TRPML1 expression might be regulated by pro-inflammatory signals and that 
TRPML1 might be regulating inflammatory processes in other tissues such as the brain and eyes, 
which would provide novel insights into MLIV. To our knowledge, before these studies, TFEB 
is the only factor shown to regulate TRPML1 expression [273]. From these and our previous 
studies we conclude that TRPML1 releases Zn2+ from lysosomes into the cytoplasm. It is 
possible that TRPML1 also releases autophagy-derived Zn2+ buildup in lysosomes.  For example, 
in lung epithelial cells, TNFα induces ZIP8 translocation to the mitochondria, and is associated 
with increased mitochondrial Zn2+ content [526]. Although ZIP8 transport activity into or out of 
the mitochondria has not been characterized, increased mitochondrial Zn2+ content has been 
associated with apoptosis. Yet, another study suggests that ZnT2 localizes to the mitochondria 
and ZnT2 overexpression leads to increased apoptosis [507]. Indeed, Zn2+ accumulation in the 
mitochondria has been demonstrated to play a major role in neuronal death [1, 527] by 
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decreasing mitochondrial membrane potential (Δψm), and increasing the production of reactive 
oxygen species (ROS) [528-530]. Even though we did not observe a significant ROS signal in 
our experiments, cell type-specific tolerances for Zn2+ concentrations, and cell type-specific ZnT 
and ZIP expression have been shown [480]. Another possibility is that increased Zn2+ 
concentrations lead to decreased Δψm and it has been shown that TRPML1 modulates Δψm [336, 
531]. It is possible that the regulation of mitochondrial Zn2+ pools plays a pivotal role in 
mammary gland involution since the mitochondria regulate cell death mechanisms leading to 
cytochrome C release. During autophagy, these mitochondria with high Zn2+ content likely 
accumulate in autolysosomes. We suggest that TRPML1 might be important for releasing this 
trapped Zn2+ in order to prevent LMP. In support of this hypothesis, a recent report from our lab 
has shown that TRPML1 loss increases the release of the lysosomal protease cathepsin B into the 
cytoplasm [443].  
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
Lysosomes have long been thought of as centers for macromolecular degradation in cells due to 
their highly acidic environment. However, a growing body of evidence has found that many 
metal transporters localize to lysosomes, and has demonstrated that lysosomes are involved in 
many cellular processes that are crucial for regulating cellular homeostasis. Over the course of 
these studies, I have discovered that lysosomes act as “zinc sinks” that dynamically take up, store 
and expel zinc based on cellular needs. These studies have provided insights into the lysosomal 
regulation of zinc homeostasis, TRPML1 function, MLIV pathogenesis, and have identified a 
new zinc detoxification pathway. Given that over 10% of all cellular proteins bind and depend on 
zinc for proper function, the implication of this research extend to a large number of cellular 
processes and are likely to have physiological significance in many human pathologies.  
5.1 TRPML1 IS A LYSOSOMAL ZINC LEAK PATHWAY 
In Chapter 2, I used an siRNA-mediated approach to knockdown TRPML1 in HeLa cells to 
establish that TRPML1 is involved in transporting Zn2+ out of the lysosome and into the 
cytoplasm. Moreover, I have found that the source of the lysosomal Zn2+ buildup is ZnT4 
dependent, and therefore, not autophagic or endocytic, but rather, cytoplasmic in origin.  
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Since very little is known about lysosomal Zn2+ transport mechanisms, I decided to 
examine whether lysosomal Zn2+ content was affected by TRPML1 function. It was previously 
shown that TRPML1 is permeable to Zn2+ [376], and that TRPML1 RNAi-treated HEK-293 cells 
have large lysosomes that accumulate chelatable Zn2+ [393]. The same study also showed that 
MLIV patient fibroblasts had increased Zn2+ content measured by TSQ fluorescence, and 
claimed (but did not show) that TRPML1 null mice had elevated levels of the 66Zn2+ isotope in 
brain tissue. However, it was unclear where this Zn2+ came from. I confirmed the enlarged 
lysosomes and the accumulation of chelatable Zn2+ in TRPML1-deficient HeLa cells with two 
different Zn2+-sensitive dyes (TSQ and FluoZin-3) and showed that knocking down either MTF-
1 or ZnT4 rescued the lysosomal enlargement. MTF-1 is a cytoplasmic Zn2+-sensing 
transcription factor that upregulates the expression of Zn2+-responsive genes such as MT2a and 
ZnT1, while ZnT4 is a lysosomal Zn2+ importer. Consequently, I concluded that the 
accumulation in TRPML1 was due to ZnT4 importing Zn2+ into the lysosomes, and not due to 
autophagic or membrane trafficking deficits. This suggested that TRPML1 is a Zn2+ leak 
pathway, regulating Zn2+ transport out of lysosomes (Figure 39). Considering that lysosomes can 
dissipate Zn2+ either directly through ion channels and transporters, or indirectly through 
lysosomal exocytosis, I wanted to determine which mode of action was impaired in TRPML1 
knockdown cells. I did not observe significant changes in lysosomal exocytosis in TRPML1 
knockdown cells, so I used FluoZin-3 fluorescence to measure extracellular Zn2+ content to be 
able to monitor Zn2+ secretion. Interestingly, Zn2+ secretion assays did not show a decrease in 
TRPML1 knockdown cells, but rather an increase in extracellular Zn2+ content, suggesting that 
TRPML1 directly influences lysosomal Zn2+ release into the cytoplasm. Satisfyingly, TRPML1  
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Figure 39. Loss of TRPML1 leads to zinc accumulation in and enlargement of lysosomes. 
A model for TRPML1 function. In normal cells (left side), Zn2+ enters the cells through ion channels or ZIP 
transporters and is imported into the lysosome through ZnT4. TRPML1 then transports Zn2+ out of the lysosome and 
into the cytoplasm, where it can either be transported out of the cell via ZnT1, or chelated in the cytoplasm by 
binding to metallothionein (MT). In MLIV cells, TRPML1 loss leads to Zn2+ buildup in lysosomes, leading to their 
enlargement and an augmented MT response.  
 
knockdown cells not only have delays in Zn2+ clearance, as judged by FluoZin-3 fluorescence 
persisting much longer than in control knockdown cells, but also have less mitochondrial 
fragmentation than control Zn2+ –treated cells (since the is Zn2+ trapped in lysosomes). 
One of the most interesting findings of my studies was that TRPML1 knockdown cells 
have significantly elevated metallothionein (MT2a) mRNA expression. In search for a different 
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read out in addition to FluoZin-3 or TSQ fluorescence, I monitored the mRNA expression of 
MT2a since it is upregulated in response to elevated Zn2+ levels. I found that both TRPML1 
knockdown in HeLa cells, as well as MLIV patient fibroblasts (Appendix A, Figure 43), have 
dramatically elevated MT2a mRNA levels compared to controls. This was interesting because it 
hints at the possibility of using MT2a mRNA expression as a biomarker for MLIV and possibly 
other lysosomal storage disorders, which would add a diagnostic tool for MLIV detection. Future 
studies will be needed to verify the sensitivity, specificity and induction level of MT2a in other 
cell types and in vivo.  
Even though these studies provided great insights into TRPML1 function, they still left a 
lot of unanswered questions. For example, how does TRPML1 affect lysosomal Zn2+ release? 
Does it do so directly, and if so, what is the structural basis for the transport function, or does it 
release Zn2+ by modulating the function of other transporters such as ZIP8? Except for TRPML1, 
ZIP8 is the only Zn2+ transporter identified to release Zn2+ from lysosomes. Interestingly, ZIP8 
has been shown to localize to the plasma membrane, lysosomes and mitochondria [497, 526], 
and to release Zn2+ in response to TNFα [532]. Future research will address whether TRPML1 
stimulates lysosomal Zn2+ release by affecting ZIP8 function or localization. The other 
possibility is that TRPML1 affects ZnT2 or ZnT4 function by regulating the ionic environment 
of lysosomes, and the low lysosomal pH has been shown to be necessary for Zn2+ binding and 
transport activity of ZnTs [24, 25]. Lastly, TRPML1 has been shown to be permeable to Zn2+ 
and could directly transport Zn2+ out of lysosomes. Although no structural elements have been 
identified for TRPML1 Zn2+ transport, I predict that the large loop between the first and second 
transmembrane of TRPML1 plays a critical role. In fact, a sequence alignment of TRPML1 and 
TRPML3 shows a fair amount of histidine residues that localize to the loop between the 1st and 
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2nd transmembrane, similar to the histidine-rich domains of ZnTs and ZIPs that confer their Zn2+ 
transport activity [16, 20-22]. To date, no current TRPML1 function has been assigned to that 
loop. 
Another area of future research is to further characterize the Zn2+ buildup in TRPML1 
knockdown cells. Figure 8 B shows FluoZin-3,AM fluorescence within both Lysotracker 
positive vesicles, as well as other non-lysosomal cytoplasmic punta. At this point, it is unclear if 
these punta are endosomes, Golgi vesicles, or simply lysosomes that are no longer acidic. Future 
experiments with FluoZin-3,AM along with lysosomal constructs, such as LAMP-RFP, instead 
of Lysotracker, could shed light on this discrepancy. Alternatively, it would not be surprising if 
these were endosomes since membrane trafficking defects have been observed with TRPML1-
deficient cells [218, 370, 377, 378]. Perhaps these puncta represent endocytosed Zn2+ trapped in 
endosomes en route to the lysosomes? This is actually a very interesting question within the 
field. Extracellular zinc ions have been shown to be taken up through the endocytic pathway and 
confined in vesicles termed “zincosomes’ in many cell types and yeasts [17, 533-536], however, 
what specific proteins or Zn2+ transporters localize to zincosomes has remained a mystery. One 
report suggests that ZnT2 and protein kinase C (PKC) localize to zincosomes along with actin 
and possibly caspases [537]. Also, these findings should be repeated using a different TRPML1-
specific siRNA to rule out any off target effects, and experiments should be done overexpressing 
an siRNA resistant TRPML1 construct in knockdown experiments to determine if lysosomal 
enlargement and Zn2+ buildup could be rescued.  
Additionally, another possible avenue is to use TRPML1 agonists and develop lysosome-
targeted genetically encoded Zn2+-indicators to determine the contribution of TRPML1 
lysosomal Zn2+ release. A genetically encoded Ca2+ indicator (GCaMP3) attached to TRPML1 
 141 
has been successfully used to study TRPML1 lysosomal Ca2+ release [538]. This method could 
be adapted to develop a Zn2+ indicator using MT, for example, similar to a method developed for 
studying nitric oxide signaling with FRET-MT [539, 540]. Then, a TRPML1 agonist could be 
used to increase Zn2+ levels. ML-SA1 was recently identified as a TRPML1 agonist and has been 
shown to activate TRPML1 currents [538], along with TRPML2 and TRPML3. One way to 
isolate TRPML1 function would be to either use the constitutively active TRPML1-Va mutant 
[541] (which unfortunately, has been associated with toxicity), or to use ML-SA1 in conjunction 
with TRPML1 mutants. Mutations could be introduced in TRPML1 to mutate the histidine 
residues, the pore region, or to delete the loop between the first and second transmembrane 
domains, for example. 
5.2 LYSOSOMES SECRETE ZINC THROUGH LYSOSOMAL EXOCYTOSIS 
My work in Chapter 3 has identified a new Zn2+ detoxification pathway, as well as a novel 
lysosomal function. It was shown that lysosomal Zn2+ accumulation is necessary for lysosomal 
enzymes [471], and many processes including mammary gland remodeling, but at the same time 
toxic by inducing lysosomal membrane permeabilization (LMP) and cell death due to the release 
of the lysosomal enzymes such as cathepsins [476-479]. Since very little is known about why 
and how Zn2+ accumulates in the lysosomes, I decided to examine the role of lysosomes in Zn2+ 
homeostasis.  
 To begin with, I pharmacologically inhibited lysosomal function with bafilomycin, a drug 
that increases the lysosomal pH by inhibiting the lysosomal H+ pump. I discovered that Zn2+-
exposed cells with impaired lysosomal function had elevated cytoplasmic Zn2+ levels, indicated 
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by brighter FluoZin-3 staining as well as increased mRNA expression of MT2a and ZnT1. 
Curiously, this elevated cytoplasmic Zn2+ increase correlated with a redistribution of Zn2+ pools 
to other organelles such as the Golgi and the mitochondria, as well as increased cell death. Thus, 
I concluded that the lysosomal “Zn2+ sink” was important in maintaining Zn2+ homeostasis 
(Figure 40). But this then prompted a series of other new questions: Are lysosomes the terminal 
depot for this Zn2+, or are they temporary storage sites? How much Zn2+ can lysosomes store 
before LMP ensues? Can we increase the volume of Zn2+ storage by manipulating lysosomal 
numbers? If lysosomes are not the terminal destination for this Zn2+, then where does it go and 
how does it get there? Lysosomes can dissipate Zn2+ through either lysosomal Zn2+ transporters, 
or through lysosomal exocytosis, a process where lysosomes fuse with the plasma membrane to 
expel their content. Considering that very limited information is available on lysosomal Zn2+ 
transporters, and that it is likely that their localization is dependent on yet unidentified signaling 
cascades, I decided to address these questions by inhibiting lysosomal exocytosis. Since 
lysosomal fusion with the plasma membrane is mediated by the vesicle SNARE (v-SNARE) TI-
VAMP/VAMP7, the Ca2+ sensor synaptotagmin VII (SYT7) on lysosomes, the target SNAREs 
(t-SNAREs) SNAP23 and syntaxin 4 on the plasma membrane [268], along with many Rab 
proteins on the lysosomal membrane [269-271], I decided to knockdown VAMP7 and SYT7. 
Notably, both VAMP7 and SYT7 knockdown decreased Zn2+ secretion compared to control 
cells. VAMP7 and SYT7 knockdown cells also had increased lysosomal and cellular Zn2+ levels 
when imaged with FluoZin-3. Based on this, I concluded that lysosomes secrete Zn2+ through 
lysosomal exocytosis and thereby, are not the terminal depot for Zn2+. Moreover, VAMP7 
knockdown Zn2+–treated cells had elevated levels of apoptosis, indicating that clearance of 
lysosomal Zn2+ content through lysosomal exocytosis was important for cell homeostasis  
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Figure 40. Inhibition of the lysosomal zinc sink leads to zinc accumulation in other organelles and cell death. 
A model for the lysosomal function as a zinc sink. Lysosomes are cytoprotective and temporarily store Zn2+, 
preventing its buildup in other organelles such as the Golgi and mitochondria. 
 
 
 
 
 
 
 
 
 
Figure 41. Inhibition of the lysosomal exocytosis in zinc treated cells leads to cell death. 
Lysosomes expel sequestered Zn2+, in a VAMP7 and SYT7 dependent manner through lysosomal exocytosis in 
order to prevent LMP and cell death.  
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(Figure 41). Next, I wanted to determine if this new detoxification pathway can be modulated by 
augmenting lysosomal biogenesis. Indeed, TFEB overexpression increased Zn2+ secretion, but it 
also unexpectedly increased ZnT1 mRNA expression as well. Consequently, without inhibiting 
ZnT1, it is difficult to conclude the lysosomal contribution to this observed increase in Zn2+ 
secretion. Perhaps future experiments can overexpress the recently identified transcription factor 
E3 (TFE3) [167] to increase lysosomal biogenesis without increasing ZnT1 expression. 
Nonetheless, I also wanted to determine whether LMP-inducing, higher lysosomal Zn2+ loads 
could be prevented. Indeed, I have shown that LMP can be induced in HeLa cells by increasing 
the Zn2+ concentration, and more importantly, can be prevented by ZnT2 and ZnT4 knockdown, 
as well as TFEB overexpression (Figure 42). These studies have identified components of the 
Zn2+ sink, shown that its function can be modulated, and transformed our perception of 
lysosomes into dynamic organelles that are essential for metal ion homeostasis.  
 Although this work has made significant progress toward understanding the role of 
lysosomes in Zn2+ trafficking, many important questions remain. For example, what is the 
relative contribution of lysosomal Zn2+ secretion to ZnT1? ZnT1 is the only Zn2+ detoxification 
pathway identified to date. This question is easily testable by performing the Zn2+ secretion assay 
with a ZnT1-specific siRNA and comparing the loss of Zn2+ secreted to VAMP7 or SYT7 
knockdown. Also, it is possible that some Zn2+ is secreted through the Golgi, and as such should 
be analyzed with a ZIP9 knockdown. However, I would expect that a ZnT1, VAMP7 double 
knockdown should completely ablate Zn2+ secretion.  
My work discussed in Chapters 3 and 4 has opened an exciting new avenue of research 
for the Kiselyov lab. As discussed before, while many metal transporters have been shown to 
localize to lysosomes, there is scarce information on lysosomal Zn2+ transporters, likely because  
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Figure 42. Inhibition of lysosomal zinc loading through ZnT2 or ZnT4 knockdown, or increasing lysosomal 
biogenesis through TFEB overexpression prevents LMP and cell death. 
High (200 µM) zinc concentrations lead to lysosomal membrane permeabilization (LMP), which results in cell death 
due to the release of lysosomal enzymes such as cathepsin B and D. LMP can be rescued by reducing lysosomal 
loading, increasing ZnT1 function, or augmenting lysosomal biogenesis and exocytosis.  
 
they are cell type specific and induced by yet unidentified signaling cascades. Towards that end, 
some Zn2+ transporters have been shown to be activated by transcription factors other than MTF-
1, such as signal transducers and activators of transcription 3 (STAT3), STAT5 and TNFα. For 
example, ZIP6 localizes to the plasma membrane and has been shown to be regulated by STAT3 
[87] and MAPK signaling [542]. ZIP14 also localizes to the plasma membrane and is 
upregulated by Interleukin-6 [96]. ZnT2 has been shown to localize to the mitochondria and 
lysosomes and to be regulated by STAT5 [88]. Meanwhile, ZIP8 localizes to the plasma 
membrane, mitochondria and lysosomes and is regulated by TNFα and NF-κB [497, 526, 532]. 
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In Chapter 4, I discussed a novel pathway for TRPML1 transcriptional activation through TNFα. 
Future experiments will dissect the signaling pathways that regulate the lysosomal localization of 
Zn2+ transporters. I expect that the pathways that regulate lysosomal Zn2+ content will correlate 
with the physiological requirements of lysosomal Zn2+, such as during development, lactation 
and an immune response.  In most cases, I predict that these Zn2+ transporters will have 
lysosomal sorting sequences such as dileucine motifs that are revealed by the activation of the 
signaling pathways to allow it to re-localize to lysosomes. There is some precedence for this with 
the lactogenic hormone prolactin, which has been shown to change the subcellular localization of 
ZIP3 and ZnT2 [93, 433]. Additionally, there are bound to be genetic, dietary or environmental 
factors that affect lysosomal Zn2+ sequestration. 
5.3 CLINICAL SIGNIFICANCE 
There is surprisingly little information on lysosomal storage disorders (LSDs) and metal 
homeostasis. On the one hand, altered expression of Zn2+ genes and reduced Zn2+ serum levels 
have been reported in Niemann-Pick type C (NPC) disease [543-545], as well as in 
aspartylglycosaminuria (AGU) patients [546]. AGU is a rare LDS caused by mutations in the 
lysosomal enzyme aspartylglucosaminidase. AGU symptoms begin at the age of 2 and range 
from spine and eye deformities, behavior problems and psychomotor and intellectual disability. 
While on the other hand, increased Zn2+ concentrations have been reported in neuronal ceroid 
lipofuscinosis (NCL) [469, 547], and as discussed in Chapter 1, altered Zn2+ homeostasis has 
been implicated in many neurological diseases including Alzheimer’s disease, amyotrophic 
lateral sclerosis (ALS), depression, epilepsy, ischemia, schizophrenia [14, 548], and most 
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recently, Parkinson’s disease [549]. For example, in Parkinson’s disease, ATP13A2 has been 
shown to maintain Zn2+ homeostasis and α-synuclein secretion through exosomes [550]. Thus, 
given the grave health consequences associated with Zn2+ dyshomeostasis, the implications for 
my research extend beyond lysosomal storage disorders and include many neuropathies.  
 MLIV diagnosis includes TRPML1 genetic mutations, anemia, and elevated gastrin 
levels [355]. There is some evidence that gastric secretion can be increased with Zn2+ 
supplementation [551, 552]. Thus, I hypothesize that some MLIV symptoms might be alleviated 
with Zn2+ chelators. Moreover, one study showed that gastrin induced the plasminogen activator 
inhibitor-2 (PAI-2), a protein associated with cell invasion and suppression of apoptosis, through 
p50 and p65 [553]. This is interesting, considering that the Kiselyov lab has found elevated p50 
levels in TRPML1 knockdown cells (unpublished data, Grace Colletti 2011 dissertation). Future 
experiments will determine the direct correlation between gastrin levels and Zn2+ status. 
Cumulatively, my thesis research has implicated lysosomes as “zinc sinks” that 
dynamically take up, store and expel zinc based on cellular needs. These studies have not only 
provided significant insights into TRPML1 function and MLIV pathogenesis, but have also 
identified a new zinc detoxification pathway. Considering the broad physiological roles of zinc, 
my work can be applied to study many cellular processes ranging from neurotoxicity to the 
immune response and wound repair. Thus, in summary, my progress on understanding the role of 
TRPML1 and lysosomes in zinc homeostasis will serve as a foundation for future studies to 
address many of the remaining unanswered questions.  
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APPENDIX A 
ZINC DYSHOMEOSTASIS IN MLIV PATIENT FIBROBLASTS  
 
 
 
 
 
 
 
 
 
Figure 43. Elevated cellular zinc levels in MLIV patient fibroblasts. 
A. Confocal images of control (WG0987) and MLIV (WG0909) patient fibroblast cells treated with 100 μM Zn2+ for 
3 hours and loaded with FluoZin-3,AM and LysoTracker. B. qRT-PCR results of MT2a mRNA, shown as percent of 
untreated control (WG0987) cells. RNA was isolated from control (WG0987) and MLIV (WG0909) patient 
fibroblasts treated for 3 hours with 100 µM Zn2+. * Represents p<0.05 compared to respective control cells.  
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APPENDIX B 
HOMER AS A MECHANISM FOR CALCIUM SIGNALING ADAPTATION 
The work discussed in this section is unpublished data of which I performed all the experiments. 
B.1 INTRODUCTION 
Many hormones, neurotransmitters and growth factors exert their effects on eukaryotic cells by 
initiating calcium (Ca2+) signaling: an increase in cytoplasmic Ca2+ levels in target cells. Ca2+ 
signaling has both short- and long-term effects. The short-term effects include muscle 
contraction, vesicle fusion, fluid and electrolyte secretion, and neurotransmitter release, while 
prolonged exposure to intracellular Ca2+ spikes can have long-term, or adaptive effects and 
include proliferation, and gene and protein expression profile changes [554]. 
The major means of regulating Ca2+ signaling is through the proximity of key signaling 
elements. Scaffold proteins modulate Ca2+ signaling by forming molecular interactions that 
tether components of a signaling pathway together, allowing for more efficient signaling. Homer 
is a product of an immediate early gene (IEG) that is unique among scaffolds involved in Ca2+ 
signaling because it is dynamically regulated. Homers play a central role in Ca2+ signaling by 
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increasing the proximity of Ca2+ signaling proteins [555, 556]. As a result of alternative splicing, 
there are multiple Homer variants that are classified primarily into long and short forms. The 
long Homer forms are constitutively expressed and form protein clusters with other target 
proteins in order to facilitate signal transduction [557]. In neurons, cells switch in an activity-
dependent manner to expressing short Homer forms that function as a natural dominant negative 
to long Homers, disrupting Homer clusters and Ca2+ signaling [556]. How this switch occurs is 
not known. Homer is expressed and functional in Ca2+ signaling in non-excitable cells [555], but 
the full implications of having two forms of a scaffold protein in non-neuronal cells are not fully 
understood. In the course of these studies, I sought to determine a) the mechanism that regulates 
the Homer switch and b) whether non-neuronal cells can switch Homer isoforms. 
B.1.1 Ca2+ and GPCR signaling 
When a neuron is stimulated, an influx of Ca2+ occurs through the activation of voltage-
dependent Ca2+ channels in the plasma membrane [558]. This increase in cytoplasmic Ca2+ levels 
regulates a range of cellular processes including transcription, cytoskeletal structural changes, 
and apoptosis. Ca2+ also exists within the cellular compartments of all cells such as in the 
endoplasmic reticulum (ER), and can be released upon cell stimulation. In both neuronal and 
non-neuronal cells, G protein-coupled receptors (GPCRs) are the major method by which an 
external stimulus is translated into an intracellular Ca2+ signal. Upon receptor activation, Gα (the 
G-protein subunit containing the guanine nucleotide binding site which is GDP-bound in the 
inactive state) can activate effector proteins. In Ca2+ signaling, the effector is phospholipase C 
(PLC), which when activated, hydrolyzes phosphoinositides (PIP2) to generate inositol 
triphosphate (IP3) and diacylglycerol (DAG).6 IP3 binds to IP3 receptors (IP3Rs) within the ER, 
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facilitating Ca2+ release from intracellular pools such as the ER. Prolonged stimulation of IP3Rs 
is associated with activation of the Ca2+ entry pathway [559]. 
GPCRs are signal interpretation, translation and amplification mechanisms for almost all 
hormones, growth factors and other important signaling proteins. Due to the inherent complexity 
of GPCR signaling, proximity of key interacting proteins is essential for efficient signaling. The 
major means of regulating proximity is through scaffold proteins. One of the first examples of a 
scaffold protein involved in Ca2+ signaling complex formation is the Drosophila photoreceptor 
scaffold protein INAD. INAD contains five PDZ domains that allow it to bind multiple proteins 
involved in visual signal transduction such as GPCRs, transient receptor potential (TRP) 
channels, protein kinase C (PKC) and PLC [560], bringing all of these proteins in close 
proximity. Mutating the PDZ domain that directly binds TRP disassembles the complex and 
severely handicaps signal transduction [561]. Other examples of Ca2+ signaling scaffold proteins 
include AHNAK1 [562] and IQGAP1 [563]. Thus, scaffolding proteins are well established in 
the formation and regulation of Ca2+ signaling complexes.  
B.1.2 Homer in neurons 
Homer is a unique scaffold protein because it is dynamically regulated. As a result of alternative 
splicing of the Homer 1 gene, there are multiple Homer variants primarily classified into long 
and short forms. The long form of Homer 1, Homer 1 b/c (h1b/c), contains two major domains; a 
coiled-coil (CC) domain and an Enabled/vasodilator-stimulated phosphoprotein Homology 1 
(EVH1) domain [557]. The EVH1 domain binds to proline rich sequences in target proteins such 
as glutamate receptors, TRP cation channel (TRPC1), or IP3Rs, while the CC domain contains 
leucine zippers and is responsible for Homer multimerization (Fig. 44) [557, 564-567]. Homer 
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multimers hold signaling molecules together by binding plasma membrane molecules and 
intracellular Ca2+ stores to facilitate and modulate signal transduction efficiently between them 
[557, 568]. The short form of Homer, Homer 1 a (h1a), does not have the CC domain and thus 
functions as a natural dominant negative to h1b/c by disrupting the complexes formed by h1b/c 
(Fig. 44). In neurons, several studies have shown that h1b/c is constitutively expressed, but that 
h1a expression is induced during memory establishment and following specific neural activity 
such as seizures, learning, dopaminergic stimulation, long-term potentiation, or drug use [568-
573]. Therefore, the expression of h1a might be a feedback mechanism to reduce glutamate-
induced release of Ca2+ from intracellular pools [556]. 
The Homer switch has been extensively shown to occur in neuronal tissue, but little is known 
about the regulatory mechanism that controls this switch. Based on Homer’s role in Ca2+ 
signaling and the current literature, our main hypothesis is that the Homer switch is regulated by 
Ca2+ signaling and can be modulated by other signaling pathways such as cyclic AMP (cAMP). 
In order to determine the regulatory mechanism that activates the Homer switch, we used a 
pheochromocytoma of the rat adrenal medulla (PC12) cell line to induce h1a upregulation in a 
cell culture system. Total RNA from treated cell culture samples was isolated and subjected to 
reverse transcription PCR (RT-PCR). Isoform specific primers were designed to span the unique 
last exon in rat Homer 1 a (GenBank: AJ276327.1) and to cover the unique additional exon in rat 
Homer 1 c (GenBank: AF093268.1). The amplified isoforms share a highly conserved sequence 
between the rat, mouse and human species.  
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Figure 44. Homer regulates mGluR signaling.  
(a) Constitutively expressed Homer proteins (CC-Homers) are localized to the postsynaptic compartment, where 
they bind the carboxyl terminus of group I mGluRs and IP3Rs. These receptors are physically coupled by CC-
Homers to form an efficient signaling complex that generates IP3 and releases Ca2+ from intracellular pools. (b) In 
response to specific forms of neural activity, Homer 1a is rapidly upregulated. Figure adapted from [556] . 
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B.2 RESULTS 
B.2.1 Regulation of Homer splicing 
When Ca2+ stimulation by depolarization via 50mM potassium chloride (KCl) generates a 
modest increase in h1a, increasing h1a levels over 20% (21.6±0.39%, n=3, p<0.001) compared 
to control conditions. H1a was also shown to be upregulated following dopaminergic stimulation 
with cocaine injections [574]. Dopaminergic stimulation increases intracellular cAMP levels. To 
mimic this effect in cell culture, PC12 cells were stimulated with forskolin (FSK), which 
activates the adenylyl cyclase, raising intracellular cAMP levels. Indeed, Figure 45 shows that 
we successfully induced the Homer switch in a cell culture model: 3 hour stimulation with 20µM 
FSK and 50mM KCl upregulates h1a RNA levels by over 70% (70.57±7.48%, n=3, p<0.001) 
compared to control. This result indicates a possible synergistic effect between the Ca2+ 
pathways and cAMP pathways. 
FSK alone increased h1a levels by over 50% (52.25± 12.61%, n=3, p<0.05). h1c levels 
are fairly constant across treatments with large variations, possibly reflecting the variation found 
in the constitutively expressed h1c levels across samples. However, because it is not known how 
the Homer switch occurs relative to long Homer levels, it is possible to explain these results as 
either a downregulation of h1c or as natural variation across samples. To answer this question, 
better statistical analysis with more samples is needed. In sum, we have shown that we can 
successfully induce the Homer switch by inducing the expression of h1a in neuronal cells.  
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Figure 45. Forskolin and KCl activate Homer switch in neuronal cells.  
Representative RT-PCR gel and quantifications of Homer levels in PC12 cells following forskolin (FSK) and KCl 
treatment. Short Homer increases significantly when PC12 cells are treated with both FSK and KCl, while long 
Homer levels do not change. * indicates p<0.05 and ** indicates p<0.001.   
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B.2.2 Homer in non-neuronal cells 
Interestingly, Homer was shown to be expressed and functional in non-excitable cells [555, 575, 
576]. A physical interaction via coimmunoprecipitation experiments between endogenous Homer 
1 and TRPC1, as well as TRPC1 and the IP3R in HEK293 cells [569] has been reported. 
Generally, there are two mechanisms for raising intracellular Ca2+ levels: receptor-activated Ca2+ 
release and store-operated Ca2+ entry that is activated by the depletion of intracellular Ca2+ stores 
[577]. Through their interaction with IP3 receptors, STIM and Orai proteins [578], TRPC 
channels have been implicated in capacitive Ca2+ entry which replenishes depleted intracellular 
Ca2+ stores [577, 579]. TRPC activation is not well understood. Yuan et al. have shown that 
Homer 1 not only interacts with TRPC1, 2 and 5 in HEK cells, but is also involved in their 
gating. Thus, Homer 1 could function in activating store-depletion mechanisms in non-neuronal 
cells. Overall, Homer proteins help to ensure high spatial and temporal fidelity of the Ca2+ signal. 
Homer proteins are important to study because Homer knockout mice show increased 
spontaneous Ca2+ influx [569], which most certainly affects cellular functions. If a Homer switch 
exists in non-neuronal cells, then this could be the first indication that the cells have Ca2+ 
signaling memory, or adaptation as a means to modulate and buffer their response to future 
environmental signals. This is a novel mechanism for non-neuronal cells. Why would a 
postsynaptic density protein be present where there are no synapses? Can non-excitable cells 
actively switch between h1b/c and h1a as well and if so, how is this switch regulated? Why 
would a non-excitable cell need two different forms of a scaffolding protein? To answer these 
questions, we sought to elucidate the role of Homers in non-excitable cells by performing RT-
PCR experiments in non-neuronal cell lines such as HEK293, HeLa and L cells.  
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Figure 46. H1a is upregulated in neurons but not in non-neuronal cells in response to Ca2+ and cAMP 
signaling.  
Representative RT-PCR of Homer levels in neuronal PC12 cells (top) and non-neuronal HEK 293 cells (bottom) 
following stimulation of cAMP with forskolin (FSK) and Ca2+ ionophore A23187 for 3 hours. H1a and the positive 
control gene HNRPH3 increase significantly compared to actin when PC12 cells are treated with both FSK and 
A23187, but do not change in HEK 293 cells. Graph indicates quantification of PC12 cell stimulations (n=3). 
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Figure 46 shows that H1a is upregulated in neurons (top panel, PC12 cells), but not in 
non-neuronal cells (bottom panels, HEK293 cells) in response to Ca2+ and cAMP signaling. H1a 
levels increase 3 fold under stimulated conditions compared to untreated cells when normalized 
to actin, indicating that we are successfully activating the Homer switch in neurons. Non-
neuronal cells may be activated through a different mechanism, for example to replenish Ca2+ 
stores upon depletion. Interestingly, Homer1 premRNA levels in PC12 cells also increase upon 
stimulation, indicating that control of the H1a transcript probably occurs at the transcriptional 
level, a process that is coupled with Ca2+ signaling pathways and the regulatory splicing 
machinery (Fig 47).  
 
 
 
 
 
 
 
 
Figure 47. Homer 1 premRNA increases as H1a is induced.  
RT-PCR of Homer 1 premRNA in PC12 cells. Note the sharp increase upon stimulation with A23187 and FSK for 3 
hours, peaking at 6 hours compared to control and DMSO treatments (in duplicate). 
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B.2.3 The Ca2+  -responsive splicing factor Tra2β  
Changes in splicing patterns are mediated by regulatory proteins that bind the pre-mRNA and 
enhance or silence splice sites. Some of the best characterized positive factors of splicing are 
serine-arginine-rich (SR) proteins.  SR proteins bind to exonic splicing enhancer elements and 
stimulate exon inclusion [580]. Transformer-2β (Tra2β) is an SR-like splice factor that has been 
shown to change in response to Ca2+ stimulation in neurons [581, 582]. Raising intracellular Ca2+ 
levels with thapsigargin causes hyperphosphorylation and an accumulation of Tra2β and other 
interacting SR proteins in the cytosol of primary neurons [582]. Once the regulatory splicing 
protein, Tra2β, accumulates in the cytoplasm, it changes the alternative splice-site of the ICH-1 
gene, increasing levels of the ICH-1S form [582]. Upon examining the Homer RNA sequence, 
we observed an enrichment in Tra2β binding sequences (GAA repeats or GHVVGANR, where 
R indicates A or G, V indicates A, C, or G, and H indicates A, C or U) [580] compared to other 
splicing regulators located around a putative long Homer switch within the RNA (11 Tra2β 
binding sites, 4 PTB  sites and 1 FOX site, Fig. 48). Moreover, a strong Tra2β exon splicing 
enhancer (ESE) motif (98.53% and 100% according to HSF) was identified within the Homer 
sequence. Known targets of Tra2β include clathrin LCB, survival of motor neuron 2 (SMN2), 
tau, and Tra2β itself [580].  The high enrichment of Tra2β binding sites, as well as the regulation 
of this splice factor by increased intracellular Ca2+, made this a strong candidate for the 
regulation of the Homer switch.  
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Figure 48. Tra2β  binding sites in Homer sequences. 
Tra2β binding sites (in brown) are enriched around putative splice switch in the Homer sequence. Homer pre-
mRNA sequence shown with known splice factor binding sites highlighted. 
 
Towards finding how the Homer switch is regulated, we identified a candidate splice 
factor, Transformer 2β, based on a search for Ca2+ dependent splice factors that have binding 
motifs within the Homer sequence. Tra2β is an SR-like splice factor that has been shown to 
respond to Ca2+ stimulation in neurons and regulate the alternative splice-site. Figure 49 shows 
Tra2β to be phoshorylated under DMSO and H1a stimulating conditions in PC12 cells. Lambda 
phosphatase was used to dephosphorylate Tra2β as a control. Thus, Tra2β protein expression and 
phosphorylation status does not seem to correlate with H1a induction, indicating that Tra2β may 
not regulate Homer levels. To confirm Tra2β’s involvement in the regulation of H1a, we 
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designed two siRNA constructs to knockdown Tra2β mRNA levels. Figure 50A shows 
successful knockdown of Tra2β with construct #2 in PC12 cells, which we used in following 
experiments. However, Tra2β knockdown does not deter H1a induction upon stimulation (Fig 
50B), further confirming that Tra2β is not the only splice factor that regulates H1a. Tra2β was 
also successfully knocked down in HeLa cells (Fig 50C), and did not lead to H1a induction, 
indicating that Tra2β does not block H1a induction in non-neuronal cell types.  
 
 
 
 
 
 
 
 
Figure 49. Tra2 Ca2+ and cAMP stimulation do not regulate Tra2β phosphorylation status.  
Tra2β phosphorylation analysis in PC12 cells via Western blot indicates that Tra2β is phosphorylated in DMSO and 
FSK and A23187 stimulated cells. Tra2β phosphorylation status does not seem to correlate with H1a induction. 
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Figure 50. Tra2β siRNA knockdown of Tra2β.   
Two Tra2β siRNA constructs were designed and construct #2 yielded better knockdown and was used for continued 
studies. Tra2β was successfully knocked down in PC12 cells as demonstrated by Western analysis (A) and HeLa 
cells (C). However, Tra2β knockdown does not have an effect on H1a or H1b/c levels upon stimulation in either 
neuronal (B, PC12) or non-neuronal cells (D, HeLa) as demonstrated by RT-PCR analysis. 
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B.3 DISCUSSION 
My work has shown that the Homer switch in neurons is dependent on the activation of both 
Ca2+ and cAMP signaling pathways that result in the upregulation of the alternative splice 
variant, H1a. Furthermore, H1a mRNA induction is correlated with an increase in Homer1 
premRNA levels, suggesting an interaction between the transcriptional activation component and 
the regulatory splicing machinery in order to regulate H1a expression. Current data indicate that 
non-neuronal cells lack the ability to switch Homer isoforms. The role of Homers in non-
neuronal cells remains unclear, but understanding how the Homer switch occurs in neuronal cells 
will provide valuable insight. It is likely that H1a functions to modulate the activity of TRPC 
channels in non-neurons. I have also shown through protein expression and siRNA knockout, 
that our putative splice factor, Tra2β, is not the definitive pathway to regulate H1a induction. 
However, given the poor resolution and the remaining troubleshooting associated with the 
experiments, we cannot confidently reach this conclusion yet.  
B.3.1 Future directions. 
Tra2β as a H1a regulatory factor: Confocal image analysis could be used to confirm Tra2β 
subcellular localization. DAPI nuclear staining could be used for controls. Additionally, 
subcellular fractionation can be done to determine if Tra2β accumulates in the cytoplasm. To 
ensure that we are not changing Tra2β’s normal function with our stimulations, we could use the 
clathrin light chain, LCB, as our positive control since it is alternatively spliced and one of 
Tra2β’s known targets. Alternatively, we could identify other splice factors by using published 
data and publicly available algorithmic tools (such as the Human Splicing Finder, 
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www.umd.be/HSF or SFmap, http://sfmap.technion.ac.il) to find other Ca2+ dependent splice 
factors that have binding motifs within the Homer sequence. If other Ca2+ dependent splice 
factors do not statistically correlate with h1a induction or do not have binding sites in the Homer 
sequence, then our alternative model might be supported; Homer may be directly activated by 
the cyclic AMP (cAMP) pathway, or by cAMP modulating the Ca2+ signal. If this is the case, 
then one such class of factors could potentially be PKA signaling factors.  
Non-neuronal H1a regulation: It is possible that the reason for not seeing a significant 
upregulation of short Homer forms in non-neuronal cells is due to insufficient or too short of a 
stimulation with these treatments. Ca2+ imaging by Fura-2 could be performed to optimize 
treatment strength and duration. Fura-2 is a dye-molecule that binds Ca2+ and can be used to as 
an indicator, or direct readout of cytoplasmic Ca2+ levels. As such, different concentrations of 
Ca2+ stimulants can be used in conjunction with other treatments, until a sustained Ca2+ response 
can be detected immediately following treatment. Additionally, there might be splice factor or 
site specific differences in H1a induction between species. In this study, we compared rat 
neuronal cells with mouse and human non-neuronal cells. In the future, we could compare 
neuronal and non-neuronal cells from the same species. Lastly, Homer 1 coimmunoprecipitates 
with TRPC1 and 5, which are thought to be activated by store depletion, thus Homer could have 
a role in replenishing depleted stores in non-neuronal cells. We could determine if store-
depletion activates the Homer switch by passively depleting Ca2+ stores with SERCA inhibitors 
such as Thapsigargin. 
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